Photosensitizing effects of chlorin e6 - Polyvinylpyrrolidone for fluorescence guided photodynamic therapy of cancer by WILLIAM CHIN WEI LIM
  
PHOTOSENSITIZING EFFECTS CHLORIN E6 – POLYVINYLPYRROLIDONE  
FOR FLUORESCENCE GUIDED PHOTODYNAMIC THERAPY OF CANCER 
 
 
WILLIAM CHIN WEI LIM 
BSc (Hons), University Malaysia Sabah 
 
A THESIS SUBMITTED 
 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
DEPARTMENT OF PHARMACY 
 
 




This study was conducted in the Tan Chin Tuan Laboratory of Optical Imaging 
and Photodynamic Therapy of Cancer, National Cancer Centre Singapore and 




Associate Professor Paul Heng Wan Sia  
Associate Professor, Department of Pharmacy, National University of Singapore; 
Principal Investigator, GEA-NUS Pharmaceutical Processing Research 
Laboratory  
 
Professor Malini Olivo 
Principle Investigator, Laboratory of Optical Imaging and Photodynamic Therapy 
of Cancer, National Cancer Centre Singapore 
Principle Investigator, Biophotonics Laboratory, Singhealth 
Adjunct Professor, Department of Pharmacy, National University of Singapore 








There is no feeling more comforting and consoling  
than knowing you are right next to me  




This thesis is the result of four years of work whereby I have been accompanied 
and supported by many wonderful people. I have now the opportunity to express 
my gratitude to all of them. 
 
First, I would like to thank my advisor, Prof. Malini Olivo, for giving me the 
opportunity to pursue a PhD and be a part of this challenging team. Her advice 
and constant motivation has kept me moving forward. She has also trained me in 
manuscript writing, grantsmanship and all other aspects of scientific research. 
Prof. Malini’s overall enthusiasm and integral view on research and her mission 
for providing only high-quality work have made a deep impression on me. I owe 
her lots of gratitude for having shown me this way of research. 
 
I would like to thank Associate Prof. Paul Heng WS who kept an eye on the 
progress of my work, and always was available when I needed an advice. If it 
were not for his willingness to give me the opportunity to pursue my PhD 
candidature in the Department of Pharmacy, this thesis would not exist. 
 
I would like to thank A/Prof Weber Lau from Dept of Urology, SGH and Prof Soo 
Khee Chee for providing valuable support from a clinician standpoint. 
 
My thanks are also to my labmate Ms Bhuvana Shridar, who has also embarked 
in the pursuit of PhD together with me. Throughout the six years of working 
together, she has become more than just a colleague. She has not only 
cheerfully participated in many experiments described in this thesis but she has 
 v 
also been a source of encouragement and unwavering support during my ups 
and downs. Your friendship is priceless and a blessing to me. 
 
I also would like to thank my current lab members and others who have left this 
lab for greener pastures: Thank you to Dr Patricia Thong for valuable scientific 
discussions and help with experimental setup and advice; Ms Lucky Sasidharan 
for helping out in lab administration work during my thesis writing; Mr Kho Kiang 
Wei for all the help on laser light sources, Ms Karen Yee and Ms Vanaja 
Manivasager whom initially mentored me in cell culture and animal work, Dr 
Praveen Thoniyot from Singapore Bioimaging Consortium for labeling PVP with 
FITC, Dr Sirajudeen from Nanyang Technological University for rendering help in 
some of the image analysis and Dr Constance Saw for her kind friendship.  
 
Thanks to the following students who have rendered their help throughout the 
course of my research work: Mr Fan Ming Wei, Mr Camillus, Ms Lim Pei Li, Ms 
Christine, Ms Maryam Jameelah and Mr Lin Yingbo. 
 
Special thanks to Dr Othmar Dill from Targetmed, GmbH, Germany for numerous 
stimulating discussions, and Dr Manfred Haupt from Haemato-science, GmbH, 
Germany who provided the photosensitizer that was investigated in this study.   
 
And last but not least, thank you to my mom, Mdm. Poomaney Chelladurai, and 
my dad, Mr. Chin Chee Keong for encouraging the pursuit of my education. 
     W illiam  Chin  
F ebruary 2009 
 
 vi 





LIST OF TABLES………………………………………………………………………………xii 
LIST OF FIGURES……………………………………………………………………………..xiii 
GLOSSARY OF ABBREVIATIONS………………………………………………………….xxi 
 
CHAPTER 1: Literature Review………………………………………………………………..1 
1.1 Historical perspective…………………………………………………………………….…1 
1.2 Photodynamic Therapy……………………………………………………………………..2 
1.3 Photosensitizer for fluorescence diagnosis of cancer…………………………………...5 
1.4 Photochemistry and photophysics of PDT and fluorescence imaging…………………7 
1.5 Current issues in PDT: Delivery of photosensitizer to mucosal tissue………………...8 
1.6 Chlorins as a promising photosensitizer…………………………………………………11 
1.7 Polyvinylpyrrolidone………………………………………………………………………..13 
1.8 Novel association of polyvinylpyrrolidone with chlorin e6……………………………..14 
1.9 Experimental purpose and hypothesis…………………………………………………..16 
 
 
CHAPTER 2: Biodistribution And Pharmacokinetic Profile Of Chlorin e6 – 
Polyvinylpyrrolidone In The Murine Model…………………………………………………..18 
2.1 Summary……………………………………………………………………………………18 
2.2 Introduction…………………………………………………………………………………20 
2.3 Materials and methodology……………………………………………………………….24 
2.3.1 Preparation of photosensitizers………………………………………………………...24 
2.3.2 Cell culture conditions and xenograft tumor model…………………………………..24  
2.3.3 Serum uptake of Ce6–PVP……………………………………………………………..25 
2.3.4 Fluorescence imaging…………………………………………………………………...26 
2.3.5 Spectroscopic measurement using fiber optics-based 
fluorescence spectrometer…………………………………………………………………….27 
2.3.6 Determination of Ce6-PVP concentrations in tissues in mice……………………....27 
2.3.7 Confocal fluorescence microscopy and image analysis……………………………..28 
2.3.8 Statistical analysis……………………………………………………………………….29 
2.3.9 Experimental design for PDT………………………………………………………….. 29 
2.3.10 Assessment of tumor response post PDT…………………………………………...30 
2.4 Results and discussions…………………………………………………………………..32 
2.4.1 Fluorescence distribution in serum…………………………………………………….32 
2.4.2 Qualitative assessment of Ce6-PVP accumulation in MGH tumor xenograft……..33 
2.4.3 Qualitative assessment of Ce6-PVP accumulation in CNE2 tumor xenograft…….36 
2.4.4 Fluorescence imaging in normal organs in mice……………………………………..38 
2.4.5 In vivo fiber optic spectrofluorometric measurement………………………………...42 
2.4.6 Quantitative assessment of Ce6-PVP accumulation in human nasopharyngeal 
tumor (CNE2) xenograft……………………………………………………………………….45 
2.4.7 A comparison of Ce6-PVP induced fluorescence quantification using image 
processing and tissue extraction method in human bladder tumor (MGH) 
xenograts………………………………………………………………………………………..49 
2.4.8 Comparision of fluorescence distribution of Ce6-PVP versus Ce6 only in 
MGH tumor and normal tissue………………………………………………………………..51 
2.4.9 Fluorescence monitoring in skin………………………………………………………..53 
 vii 
2.4.10 Tumor response post PDT…………………………………………………………….56 
2.4.11 Toxicity effects………………………………………………………………………….62 
2.4.12 Correlation of Ce6-PVP uptake in serum and percentage 
of tumor necrosis at post PDT………………………………………………………………...67 
2.5 Conclusion………………………………………………………………………………….69 
 
CHAPTER 3: New formulation of chlorin e6 – polyvinylpyrrolidone shows improved 
selectivity and specificity for fluorescence diagnostic imaging and photodynamic 
therapy of human cancer………………………………………………………………………71 
3.1 Summary……………………………………………………………………………………71 
3.2 Introduction…………………………………………………………………………………73 
3.3 Materials and methodology……………………………………………………………….75 
3.3.1 Photosensitizers and chemicals………………………………………………………..75 
3.3.2 In vitro photosensitizing efficacy……………………………………………………….75 
3.3.3 Bladder tumor model…………………………………………………………………….76 
3.3.4 Cell culture………………………………………………………………………………..77 
3.3.5 Chick chorioallantoic membrane (CAM) tumor xenograft…………………………...77 
3.3.6 Fluorescence imaging and image analysis……………………………………………78 
3.3.7 Nonlinear regression and statistical analysis of fluorescence intensity……………79 
3.3.8 Statistical analysis of fluorescence image………………………………………….…80 
3.3.9 Chemical extraction and spectrofluorimetry analysis………………………………..81 
3.3.10 PDT treatment on murine xenograft model……………………………………….…82 
3.3.11 Assessment of tumor response post PDT…………………………………………...83 
3.4 Results and discussions…………………………………………………………………..84 
3.4.1 HPLC chromatogram of two formulations of Ce6-PVP and Ce6…………………...84 
3.4.2 In vitro photosensitizing efficacy…………………………………………………….…85 
3.4.3 Biodistribution of Ce6 formulations………………………………………………….…88 
3.4.4 Sensitivity and specificity of Ce6 formulations………………………………………..92 
3.4.5 In vivo photodynamic therapy on tumor xenografts……………………………….…94 
3.4.6 Ce6-PVP induced fluorescence on human lung carcinoma………………………...99 
3.4.7 Ce6-PVP induced PDT on human lung carcinoma…………………………………106 
3.5 Conclusion………………………………………………………………………………...109 
 
CHAPTER 4: Membrane transport enhancement of chlorin e6 - polyvinylpyrrolidone and 
its photodynamic efficacy on the chick chorioallantoic model……………………………110 
4.1 Summary…………………………………………………………………………………..110 
4.2 Introduction. ………………………………………………………………………………111 
4.2.1 Theory: Fick’s Law of diffusion………………………………………………………..114 
4.3 Materials and methodology……………………………………………………………...117 
4.3.1 Photosensitizer preparation…………………………………………………………...117 
4.3.2 Preparation of chick chorioallantoic membrane (CAM) tumor model…………….117 
4.3.3 Administration of photosensitizer……………………………………………………..119 
4.3.4 Fluorescence intensity imaging on CAM tumor model……………………………..120 
4.3.5 Statistical analysis of fluorescence image…………………………………………...121 
4.3.6 Transport of photosensitizer across CAM…………………………………………...122 
4.3.7 Laser confocal fluorescence microscopy…………………………………………….122 
4.3.8 Photodynamic therapy of CAM model……………………………………………….123 
4.3.9 Flow cytometry analysis……………………………………………………………….123 
4.4 Results and discussions………………………………………………………………....125 
4.4.1 Multicellular spheroids on the CAM model…………………………………………..125 
4.4.2 Fluorescence imaging of Ce6-PVP in normal CAM………………………………...127 
 viii 
4.4.3 Fluorescence imaging of Ce6-PVP in CAM tumor xenografts……………………130 
4.4.4 Membrane transport study…………………………………………………………….138 
4.4.5 Fluorescence confocal microscopy imaging………………………………………...141 
4.4.6 Photodynamic therapy efficacy of Ce6-PVP………………………………………...143 
4.5 Conclusion………………………………………………………………………………...145 
 
CHAPTER 5: Effect of polyvinylpyrrolidone on the interaction of chlorin e6 with plasma 
proteins and its subcellular localization…………………………………………………….146 
5.1 Summary…………………………………………………………………………………..146 
5.2 Introduction………………………………………………………………………………..147 
5.3 Materials and methodology……………………………………………………………...149 
5.3.1 Photosensitizer and serum proteins………………………………………………….149 
5.3.2 Determination of photosensitizer stability using fluorescence spectrometry…….149 
5.3.3 Preparation of photosensitizer–protein complex and measurement……………...149 
5.3.4 Determination of partition coefficient…………………………………………………150 
5.3.5 Labelling of PVP with fluorescein isothiocyanate (FITC)…………………………..151 
5.3.6 Intracellular localization by confocal laser scanning microscopy………………….152 
5.4 Results and discussions…………………………………………………………………153 
5.4.1 Partition coefficient……………………………………………………………………..153 
5.4.2 Fluorescence properties of Ce6-PVP in various biological media………………..155 
5.4.3 Effect of different plasma lipoproteins on spectral properties of Ce6 and 
Ce6-PVP……………………………………………………………………………………….158 
5.4.4 Association binding measurement……………………………………………………162 
5.4.5 Subcellular localization………………………………………………………………...167 
5.7 Conclusion………………………………………………………………………………...170 
 
CHAPTER 6: Evaluation of clinical response of chlorin e6 – polyvinylpyrrolidone 
mediated photodynamic therapy of refractory bladder cancer…………………………...171 
6.1 Summary…………………………………………………………………………………..171 
6.2 Introduction………………………………………………………………………………..173 
6.3 Materials and methodology……………………………………………………………...174 
6.3.1 Angiosarcoma patients………………………………………………………………...174 
6.3.2 Bladder cancer patients………………………………………………………………..174 
6.3.2.1 Clinical history for patient received intravenous administration of Ce6-PVP….175 
6.3.3.2 Clinical history for patient received intravesical administration of Ce6-PVP…..176 
6.3.4 Light source and fiber positioning…………………………………………………….177 
6.3.5 Light irradiation…………………………………………………………………………178 
6.3.5.1 Intravenous drug administration……………………………………………………178 
6.3.5.2 Intravesical drug administration…………………………………………………… 178 
6.3.6 Laser confocal fluorescence microscopy studies…………………………………...181 
6.3.7 Analysis of serum and urine uptake………………………………………………….181 
6.3.8 ELISA detection of human inflammatory cytokines…………………………………182 
6.4 Result and discussion……………………………………………………………………183 
6.4.1 Fluorescence imaging of angiosarcoma lesions in patients……………………….183 
6.4.2 Ce6-PVP mediated PDT response for refractory bladder carcinoma patients…..186 
6.4.3 Analysis of serum and urine uptake of Ce6-PVP…………………………………...188 
6.4.4 Fluorescence imaging and laser confocal microscopy 
study of refractory bladder carcinoma patients…………………………………………….191 




CHAPTER 7: Conclusion and future direction …………………………………………….199 
7.1 Conclusion………………………………………………………………………………...199 
7.2 Future perspective………………………………………………………………………..203 
 
BIBLIOGRAPHY………………………………………………………………………………205 
APPENDIX A: LIST OF PUBLICATIONS…………………………………………………..218 





Photodynamic therapy and fluorescence diagnosis of cancers can realize their 
full clinical potential if photosensitizers could be delivered specifically to tumor 
tissue at optimal rates and concentrations. An improvement of photophysical and 
pharmacokinetic parameters of existing photosensitizers can be achieved by 
either chemical or non-covalent modifications of photosensitizing molecules with 
polymers. In particular, polyvinylpyrrolidone (PVP), a water soluble and nontoxic 
polymer, is widely used to modify water solubility and bioavailability of various 
biologically active compounds. Thus, the photosensitizer-polymer formulation of 
chlorin e6 – polyvinylpyrrolidone (Ce6-PVP) was developed with the rationale of 
providing a new photosensitizer with a high photochemical stability, good 
solubility both in aqueous and in biological fluids, high affinity to the target tissue, 
large depth of necrosis, efficient generation of the reactive oxygen species that 
cause destruction of the pathologically changed tissue, low phototoxicity in 
normal tissue as well as to provide a method of preparation of such 
photosensitizer. In this thesis, photodynamic therapy consists in systemic or 
topical administration of Ce6-PVP that selectively accumulates in the tumor 
tissue of a human or an animal. Following exposure to light of 665 nm 
wavelength, the photosensitizer produces cytotoxic species that destroy tissues. 
Destruction of cells by cytotoxic species, via necrosis or apoptosis leads to 
destruction of the tissue. Simultaneously, the irradiation at 400 nm wavelength 
induces fluorescence of the photosensitizer that is a sensitive diagnostic tool 
suitable for detecting the regions of the body which are abnormal in terms of their 
structural and functional condition or where intense biological processes occur, 
including formation of benign and malignant neoplasms. The scope of this study 
includes in vitro and in vivo evaluation of Ce6-PVP formulations human tumor 
 xi 
xenograft in murine and chick chorioallantoic membrane (CAM) tumor model. In 
addition, we have investigated on how the polymer PVP has affected the 
mechanisms of penetration of Ce6 and its binding distribution to various 
lipoproteins. Using CAM as a drug transport model, we have demonstrated that 
the presence of PVP facilitates the transport of Ce6 across a biological 
membrane. This formulation has also been tested in selected patients in a pilot 
clinical trial to determine depth of penetration, specificity and selectivity of the 
photosensitizer for angiosarcoma and bladder cancer. It is hope that this new 
association of PVP with Ce6 with enhanced penetration, selectivity and 
photosensitizing properties towards cancer tissue will be developed as a 
potential photosensitizer in photodynamic therapy and diagnostics in the area of 
oncology. 
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administration of drug normalized with images before drug administration. For 
tumor, each point represents a mean of 5 eggs whereas for normal (●), each 
point represents a mean of 10 eggs. Bars = standard error of the mean. Non-
linear regression analysis demonstrated that all the curves were statistically 
different with each other. The elimination rate constant for NSCLC, SCLC and 
normal CAM was in the following order: NSCLC < SCLC < normal CAM. 
 
Figure 3.10 Receiver operating characteristic curves illustrating the ability of 
Ce6-PVP to separate NSCLC (solid line) and SCLC (dotted line) from normal 
chorioallantoic membrane in the CAM model. The ROC curve of two 
indistinguishable populations (i.e. abnormal versus normal region), represented 
by the 45-degree line (area under the ROC curve = 0.5), is included for 
comparison. Area under the ROC curve was 082 ± 0.04 (p < 0.0001) and 0.70 ± 
0.05 (p = 0.0009118) for NSCLC and SCLC respectively. 
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Figure 3.11 A morphologic study of NSCLC and SCLC tumor damage efficiency 
using the method of vital staining with Evans blue at 48 h post Ce6-PVP 
mediated PDT. Strong homogeneous staining was observed in the untreated 
controls (Fig. 5A, B), whereas in the treated tumor at 3 h drug-light interval (DLI) 
(Fig 5C, D) and at 6 h DLI (Fig 5E, F). Tissues damage was clearly 
distinguishable as an unstained area in the tumor. Drug dose: 2.0 mg/kg; light 
dose: 150 J/cm2; 125 mW/cm2. Each data point is an average of at least 5 
animals, Bars = standard error of the mean. *The mean difference is significant at 
the 0.05 level compared to the NSCLC group. 
 
Figure 4.1 A diagrammatic representation of a photosensitizer transport model 
using CAM. The concentrations across the cells are represented in the top part of 
the figure. The concentration gradient across the membrane of thickness h is 
shown at steady state. Cg is not expected to equal C1 unless the partition 
coefficient of the drug into the membrane from the donor phase is unity. 
 
Figure 4.2 (A) Egg incubator and (B) Xenograft tumor on the CAM. 
Figure 4.3 Topical administration of photosensitizer on CAM. 
Figure 4.4 Xenografting of tumor spheroids on the CAM model. (A) MGH tumor 
(tu) was xenografted on the CAM. (B) Formation of neovasculature (arrow) 
surrounding the implanted cells after 2 days of xenografting. (C). Formation of 
spheroid like structure of the tumor on the CAM. 
 
Figure 4.5 Representative images of normal CAM before and after 
administration of the Ce6-PVP. CAM before administration of the photosensitizer 
under white light and blue light mode (A-B). CAM fluorescence at 0.5, 4 and 24 h 
after systemic (C-E) and topical (F-H) administration of the photosensitizer. 
 
Figure 4.6 The Ce6-PVP fluorescence kinetics on normal CAM examined up to 
24 h post drug systemic administration (■) and topical administration (▼). Values 
are expressed as fluorescence intensities after normalization with CAM before 
drug administration. Each point represents a mean of 5-measurements/6 
eggs/time point. Bars = SE. 
 
Figure 4.7 Fluorescence imaging of MGH human bladder tumor xenografted on 
the CAM model. (A) White light image of the tumor before drug administration, 
(B) Ce6-PVP induced red fluorescence in tumor imaged under blue light 
illumination at 3 h post drug administration. Minimal fluorescence was observed 
in the adjacent normal CAM. (C) By displaying the fluorescent image in a pseudo 
color using simple image processing technique, a clear discrimination of the 
tumor border can be visualized. 
 
Figure 4.8 The Ce6–PVP fluorescence kinetics on normal CAM (●) and bladder 
tumor cell xenografts on CAM (■) plotted against time. The CAM was topically 
incubated with the drug for 30 min prior to the fluorescence measurement. A 
logarithmic trendline (solid line) was used to best fit a curve to the data. Higher 
fluorescence intensity was observed in the tumor xenografts compared to the 
normal CAM tissue. Each point represents a mean of 7 eggs. Bars = SE. 
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Figure 4.9 A scatter plot comparing the fluorescence intensity in tumor and the 
adjacent normal CAM tissue was compiled from 1 – 5 h post topical drug 
administration. The points on the scatter plot are normalized individual 
measurements from 24 eggs. The dotted line is the cut-off fluorescence intensity 
threshold derived from the ROC curve to classify tumor from normal tissue with a 
sensitivity and specificity of 70.8% (95% CI 48.9% to 87.4%) and 83.3% (95% CI 
62.6% to 95.3%) respectively. 
 
Figure 4.10 (A) Representative images of MGH tumor (tu) xenografted on the 
CAM under white light. (B) Selective red fluorescence was observed on the MGH 
tumor at 3 h post topical administration of Ce6-PVP while no fluorescence was 
observed on the normal CAM tissue. (C) Receiver operating characteristic (ROC) 
curves illustrating the ability of various drug dose of Ce6-PVP to separate MGH 
tumor from adjacent normal chorioallantoic membrane (p< 0.0001). The ROC 
curve of two indistinguishable populations (i.e. tumor versus normal region), 
represented by the 45-degree line (area under the ROC curve = 0.5), is included 
for comparison. Area under the ROC curve was 0.83 ± 0.02, 0.78 ± 0.02 and 
0.79 ± 0.03 for 0.0625 and 0.0313 and 0.016 mg/mL respectively. The y axis 
represents the specificity of the Ce6-PVP induced fluorescence and the x axis 
represents the sensitivity of the Ce6-PVP induced fluorescence. 
 
Figure 4.11 Optical coherence tomography (OCT) imaging of the CAM. OCT is a 
high-resolution noninvasive imaging technique based on laser interferometry, 
used to assess CAM thickness. The chorionic epithelium, mesoderm and 
allantoic epithelium layers can be visualized in the OCT structural image. The 
thickness of the CAM was estimated to be around 100 ± 1.9 µm. 
 
Figure 4.12 Drug transport study comparing Ce6 and Ce6-PVP in the CAM 
model. (A) Uptake studies of Ce6 and Ce6-PVP in the receptor chamber, (B) 
comparison of diffusion coefficient of Ce6 and Ce6-PVP across the CAM. *p < 
0.05 and (C) uptake studies of Ce6 and Ce6-PVP  in the chick embryo . 
 
Figure 4.13 Fluorescence confocal microscopy imaging in the CAM. Different 
increase in fluorescence on CAM treated with Ce6 or Ce6-PVP captured by 
confocal microscopy and its corresponding topographical contouring  image.  
Confocal images of (A) CAM with no photosensitizer showed some 
autofluorescence; (B) CAM incubated with Ce6 for 2 mins showed a minimal 
fluorescence; and (C) CAM incubated with Ce6-PVP for 2 mins showed a 14-fold 
fluorescence increase after correction for background autofluorescences. Scale 
bar, 100 µm. 
 
Figure 4.14 CAM with bladder tumor xenografts after topical administration of 
Ce6-PVP (0.625 mg/mL) and exposed to increasing light doses (1, 10, 15 and 20 
J/cm2) at 665 nm. The efficacy of Ce6-PVP mediated PDT for eradication of 
bladder tumor in the CAM model seems to be inversely proportional to the light 
dose used. *p < 0.05 compared to 1, 15 and 20 J/cm2. 
 
Figure 5.1 Partition coefficients of the Ce6 and Ce6-PVP between 2-octanol and 
PBS at various pH values. 
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Figure 5.2 Graphs showing representative emission spectra of Ce6-PVP in (A) 
water, (B) PBS (C) 5% fetal calf serum (D) 10% fetal calf serum at room 
temperature assessed as a function of time (from 0 to 27 days). 
 
Figure 5.3 The effect of (A) water, (B) phosphate buffered saline (PBS), (C) 5% 
fetal calf serum (FCS) and (D) 10% fetal calf serum (FCS) on the emission 
intensity of Ce6-PVP (0.5 mg/mL) at room temperature (RT 21°C) (■), 37°C (▲) 
and 4°C (▼) for a period of up to 27 days. Each data point represents the 
average of 3 measurements. Experiments were repeated twice and showed 
similar trends. 
 
Figure 5.4 The fluorescence emission spectra of Ce6 dissolved in saline with (A) 
HDL, (B) LDL and (C) VLDL at concentrations of 0% (red), 0.005% (green) and 
0.05% (blue).  The fluorescence emission spectra of Ce6-PVP dissolved in saline 
with (D) HDL, (E) LDL and (F) VLDL at concentrations of 0% (red), 0.005% 
(green) and 0.05% (blue).  
 
Figure 5.5 The equilibrium titration of Ce6 (■) and Ce6-PVP (▼) in various 
lipoprotein buffer solutions at pH 7.0. Low concentration (0.01mg/mL) of the 
photosensitizers combined with (A) HDL, (B), LDL and (C) VLDL and high 
concentration (0.06 mg/mL) of the photosensitizers combined with (D) HDL, (E), 
LDL and (F) VLDL. Curves were fitted and constants derived from one site 
binding equation and are presented in the main text. Y axis units are relative 
fluorescent units per mL of the solution. On graphs (A) and (F) trendlines are not 
presented for some of the data sets because the data did not fit in the binding 
equation. 
 
Figure 5.6 MGH cells were incubated with PVP-FITC (green) for 30 min and co-
stained (A) rhodamine-phalloidin (red) and, (B) DAPI (blue). Cells were also 
incubated with (C) Ce6 (red) and (D) Ce6-PVP (red) for 30 min and and co-
stained with rhodamine-phalloidin (yellow).   
 
Figure 5.7 Determination of Ce6 and Ce6-PVP fluorescence intensities 
distribution in MGH cells by image analysis. Each bar represents average 
intensities of 10 cells divided by the area of the cell. Error bars represent the 
standard error of the mean. 
 
Figure 6.1 (A) Ultrasound image of the position of the fiber tip (white arrow) and 
balloon (red arrow) in the bladder (red circle). (B) Schematic diagram of the 
intensity output of the fiber for various bladder volumes was prepared for the 
clinician. 
 
Figure 6.2  White light image (A) and its corresponding fluorescence image (B) 
of angiosarcoma lesion and the surrounding normal skin at 3 h post intravenous 
administration of Ce6-PVP. Spectra kinetic of Ce6-PVP intensity at 1 hr (C) and 3 
hr (D)  in normal skin and angiosarcoma lesions from patient. The fluorescence 
spectra from the cancerous lesion were found to be higher than the surrounding 
normal skin. 
 
Figure 6.3 Scatter plot of red-to-blue intensities in normal skin and angiosarcoma 
lesions plotted against time from 3 patients after intravenous administration of 
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Ce6–PVP. Red fluorescence from the cancerous lesion was found to be higher 
than the surrounding normal skin.  
 
Figure 6.4 Urine sample collected before and after PDT from patient given 
intravenous administration of Ce6-PVP. Blood was observed after 24 h post 
treatment. There was no blood detected at 48 h post treatment. 
 
Figure 6.5 Emission spectra of Ce6-PVP in serum at 1 h post drug 
administration, recorded with a spectrophotometer after excitation at 400 nm. 
Ce6-PVP was not detected in the serum of patient that received intravesical 
administration (red line), indicating that no systemic absorption of the 
photosensitizer was observed. 
 
Figure 6.6 Uptake kinetic of Ce6-PVP in serum (A) and urine (B) from patient 
after intravenous administration as determined using spectrofluorimetry. 
Fluorescence emission was measured from 665 nm – 670 nm (λex = 400 nm). For 
urine, triplicates sample/time point was analysed for each data point while for 
serum, 4 replicates/time point for each data point were analysed. 
 
Figure 6.7 Representative images of optical detection of human bladder 
carcinoma using Ce6-PVP as a fluorescent marker. (A) Normal bladder under 
white light illumination and (B) its corresponding image taken using blue light 
excitation. (C) Carcinoma of the bladder under while light illumination and (D) its 
corresponding image using HAL fluorescence cystoscopy (B). Lesion was clearly 
visualized under blue light. 
 
Figure 6.8 Laser confocal microscopy and histopathology of cross section of 
biopsy sample of bladder wall. Laser confocal microscopy of cryo-section of 
bladder biopsy; images show Ce6 fluorescence for acute and chronic 
inflammation (A), low grade papillary urothelial carcinoma (B) and high grade 
papillary transitional cell carcinoma C). Bar = 100 µm.  
 
Figure 6.9 Fluorescence kinetics of different histopathological grades of bladder 
biopsies. Error bars represent the standard error of the mean of 6 patients. 
 
Figure 6.10 Cross section of fluorescence image (A, B) and corresponding 
hematoxylin–eosin-stained image (C, D) and measurement of fluorescence 
intensity and depth of penetration of Ce6-PVP  (E, F) in bladder tumor biopsy 
tissue at 2 h after oral administration of Ce6-PVP. 
 
Figure 6.11 Serum cytokines (IL-1 β, IL-8, IL-10, IL-12, IFN-γ and TNF-α) levels 
after PDT. Serum samples were obtained before PDT and 24 h post PDT for 
patient treated with intravenous mediated PDT (A – F). Results are presented as 
average of duplicate experiments. 
 
Figure 6.12 Comparison of IL-6 for patient treated with intravenous or 
intravesical Ce6-PVP mediated PDT. Results are presented as average of 
duplicate experiments.  
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GLOSSARY OF ABBREVIATIONS 
 
AMD = Age macular degeneration 
ALA = 5-aminolevulinic acid 
BPD-MA = benzoporphyrin derivative monoacid ring A  
Ce6 = Chlorin e6 
CAM = Chick chorioallantoic membrane 
CI = Confidence interval 
CIS = Carcinoma in situ 
EA = Embryo age 
CCD = Charge-coupled device 
CLSM = Confocal laser scanning microscopy 
DMSO = Dimethyl sulfoxide 
FCS = Fetal calf serum 
HBSS = Hank’s buffered saline solution 
HSA = Human serum albumin 
HPMA = N-(2-hydroxypropyl) methacrylamide 
LCLC = Large cell lung carcinoma 
NSCLC = Non small cell lung carcinoma 
NMP = N-methyl-pyrrolidone 
MACE = Mono-L-aspartyl chlorin e6 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
OSCC = Oral squamous cell carcinoma 
PI = Propidium iodide 
PVP = Polyvinylpyrrolidone 
PDT = Photodynamic therapy 
 xxii 
PBS = Phosphate buffered saline 
ROS = Reactive oxygen species 
SOSGR = Singlet oxygen sensor green reagent 
SCLC = Small cell lung carcinoma 
SCID = Severely combined immuno-deficient 
 




1.1 Historical perspective 
Light alone or in combination with chemical compounds has been used for a long 
time to induce therapeutic effects. Light was used in ancient India, China and 
Egypt for the treatment of vitiligo and light alone was often used for the treatment 
of psoriasis [1; 2]. However, the first experimental evidence of photosensitization 
was reported around the turn of the last century from von Tappeiner's laboratory 
in Munich; one of his medical students, Oscar Raab, observed that low 
concentrations of acridines in the presence of light could be lethal to the 
protozoan paramecium [3]. Thus, the term 'photodynamic reaction' was coined 
for such reactions in the presence of molecular oxygen. Today, photodynamic 
therapy (PDT) is an approved treatment modality against some forms of cancers, 
precancerous lesions and age-related macular degeneration (AMD). The earliest 
attempts to exploit the phenomenon of photosensitization for potential antitumor 
therapy were made by Jesionek and Tappeiner by light exposure of tumor in the 
presence of eosin [4]. The modern interest in PDT as a treatment modality for 
cancer therapy began around 1960 with Lipson et al. and Schwartz et al., who 
used a fluorescent tumor-localizing mixture of porphyrins termed 
'haematoporphyrin derivative'. Since their pioneering work, compounds including 
photofrin, purpurins, xanthenes, phthalocyanaines, oxazines, cyanines, chlorines 
and others have been tested in vitro and in vivo with some degree of success; 
however, in the clinical setting, porphyrins or porphyrin-related compounds 
continue to form the bulk of the photosensitizers used in PDT.  
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1.2 Photodynamic therapy 
Photodynamic therapy (PDT) is a treatment modality for premalignant and 
malignant conditions that depends on the dynamic interaction of light, oxygen, 
and a photosensitizer to induce oxidative damage in target tissues [5]. PDT has 
emerged as a promising modality for the treatment of cancer [6]. The molecular 
and pharmacological basis for photodynamic therapy is well known [7]. 
Essentially, the therapeutic effect is mediated through the generation of reactive 
oxygen species (ROS), a process dependent on the intracellular interaction of 
the photosensitizer with light and oxygen. ROS generated by this photochemical 
mechanism have an irreversible damaging effect on tumor cells. The specificity 
and selectivity of the photosensitizer is mainly based on its mechanism of 
accumulation in cellular or vascular compartments of the tumor and clearance 
from its normal cells. PDT is now well established as a clinical treatment modality 
for the treatment of lung, esophagus, bladder, skin and head and neck cancers 
[3; 8; 9]. It involves the administration of a photosensitizer, followed by light 
irradiation in the presence of molecular oxygen in the target tissue. The 
combined action of these results in the formation of singlet oxygen, which is 
thought to be the main mediator of cellular death induced by PDT [7; 8]. In 
addition, fluorescence diagnosis based on the accumulation of the 
photosensitizer which emits fluorescence upon light excitation, is also emerging 

















Figure 1.1 Principles of photodynamic diagnosis and therapy  
 
changes. The significance of PDT is that there is a degree of treatment selectivity 
that allows tumor destruction with minimal involvement of healthy tissue. This is 
achieved by a combination of selective accumulation of photosensitizer within the 
tumor and by control of the light geometry and illumination parameters [10].  
 
Many new generations of photosensitizers are being introduced and discovered 
regularly. Photosensitizers can be categorized by their chemical structures and 
origins. In general, they can be divided into three broad families: (i) porphyrin-
based photosensitizers (e.g., Photofrin, 5-aminolevulinic acid (ALA), 
benzoporphyrin derivative monoacid ring A (BPD-MA), (ii) chlorophyll-based 
photosensitizers (e.g., chlorins, purpurins, bacteriochlorins), and (iii) dyes (e.g., 
phtalocyanine, napthalocyanine) [2, 12]. With the advent of improved 
photosensitizers and the availability of information from well-controlled, 
randomized phase III clinical trials, PDT has gained a niche in the 
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comprehensive cancer care regime [13], 14]. The most widely used sensitizer in 
PDT is haematoporphyrin derivative with Photofrin being approved in U.S., 
Japan, Canada and eleven European countries [15]. However, these complex 
mixtures of porphyrin oligomers have substantial limitations. This has led to a 
search for improved photosensitizers, thus allowing production of a second and 
third generation of efficient photosensitizers. Such photosensitizers are actively 
being sought among chlorin, bacteriochlorin, purpurin, benzoporphyrin, 
texaphyrin, etiopurpurin, naphthalocyanine, phthalocyanine and 
perylenequinones derivatives. 
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1.3 Photosensitizer for fluorescence diagnosis of cancer. 
As with most cancers, early diagnosis is critical to achieve favorable prognosis. 
Currently, surveillance biopsy is the existing gold standard for the identification of 
lesions in pre-neoplastic conditions. However this method is prone to sampling 
error, time-consuming, subjective and cost-inefficient. A diagnostic method that 
could provide rapid, automated classification of cancer lesions would increase 
the efficiency and comprehensiveness of malignancy screening and surveillance 
procedures. A variety of optical techniques have recently been utilized for the 
diagnostic study of cancerous tissue. These include fluorescence spectroscopy 
[16], Raman spectroscopy [17], light scattering spectroscopy [18], and Fourier-
transform infrared spectroscopy [19]. These optical spectroscopic techniques are 
capable of providing both biochemical and morphological information within short 
integration times, and may be adapted for automated diagnosis on intact tissue. 
However, in order to be useful as a comprehensive screening procedure, the 
optical technique must allow rapid real time imaging of a large area of tissue 
rather than point by point measurements, such that suspicious regions could be 
identified accurately and biopsied for histopathologic correlation [20].  
 
With the advent of molecular probes, imaging methods such as ultrasound, 
microCT (Computed Tomography), microMRI (Magnetic Resonance Imaging), 
and microPET (Positron Emission Tomography) can be conducted not only to 
visualize gross anatomical structures, but also to visualize substructures of cells 
and monitor molecular dynamics [21]. Imaging of endogenous or exogenous 
fluorochromes has several important advantages over other optical approaches 
for tumor imaging. This imaging technique relies on fluorochrome induced 
fluorescence, reflectance, absorption or bioluminescence as the source of 
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contrast, while imaging systems can be based on diffuse optical tomography, 
surface-weighted imaging, phase-array detection, intensified matrix detector and 
charged-coupled device camera detection, confocal endomicroscopy, 
multiphoton imaging or microscopic imaging with intravital microscopy [22] [23]. 
Fluorescence ratio imaging is a method widely used for optical diagnosis of 
cancer after administration of a photosensitizer [24] [25]. Enhanced contrast 
between tumor and adjacent normal tissue can be obtained based on calculating 
the ratio between red intensity of the photosensitizer (600–700 nm) over the 
blue/green intensity of the back-scattered excitation light or tissue 
autofluorescence (450–550 nm). Many investigations have confirmed good 
agreement with the histopathological extent of the tumor, implying that this 
technique can be applied as a useful tool for indicating tumor boundary [26].  
 
A number of fluorochromes such as fluorescein, toluidine blue, cyanine dyes and 
indocyanine green have been described with variable stabilities, quantum 
efficiencies, and ease of synthesis. However, most of the fluorochromes are not 
tumor specific and are rapidly eliminated from the organism. Chemically and 
endogenously synthesized fluorochromes such as porphyrin-based 
photosensitizers have properties that may be utilized both experimentally and 
clinically. Porphyrins have been known to naturally localize in malignant tissue 
where they emit light when irradiated at certain wavelengths, providing a means 
to detect tumor by the location of its fluorescence. However, one of the major 
limitations is its relative long half-life causing prolong skin photosensitivity. 
Moreover, the porphyrin’s core absorbs light too short for optimal penetration in 
tissue. However, by reducing a pyrrole double bond on the porphyrin periphery, a 
chlorin core compound can be generated with a high absorption at longer 
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wavelengths of 660 – 670 nm that can penetrate deeper in human tissue than 
those of porphyrins. 
 
1.4 Photochemistry and photophysics of PDT and fluorescence imaging 
With the advent of quantum theory and modern photochemistry, it has become 
obvious that the rate-limiting factor in the success of a photodynamic reaction is 
the inherent ability of the photosensitizer to get excited to a higher, long-lived 
energy rich triplet state upon exposure to light. Organic photosensitizers exist in 
the ground state in the dark with no unpaired electron spin; however, upon 
absorption of a photon, an electron in the sensitizer shifts to a higher orbit that 
could undergo fast spin inversion to generate the triplet state containing two 
unpaired electrons (type I reaction) [27]. In this metastable state, the 
photosensitizer could then collide with molecular oxygen with the subsequent 
transfer of energy (type II reaction) and the return of the photosensitizer to the 
ground state to start another round of excitation.  
 
The type II reaction results in the formation of a highly toxic activated oxygen 
molecule, singlet oxygen (1O2), with a very short lifetime (< 40 nsec) in biological 
systems and a short radius of action (< 0.02 µm) [28]. Depletion of molecular 
oxygen at the site of the photodynamic reaction during high-fluence rate 
irradiation has been reported to counteract the effectiveness of PDT. However, 
the major impediment to this is the fact that light delivered at high fluence rates 
generates 1O2 at a rate that depletes molecular oxygen faster than can be 
replenished, thereby limiting the cellular and tissue damage derived from 1O2 
[29].  
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One of the strategies under investigation to circumvent this problem is by using 
fractionation of the excitation light. This has been observed to allow for re-
oxygenation during dark periods has been shown to increase the effectiveness of 
PDT under some conditions. Another factor that limits the efficacy of PDT is the 
diverse optical property of tissues, which influences the penetration depth of 
activating light, its scattering and absorption properties as well as the intensity of 
light that can be tolerated to produce only non-thermal effects [28]. The 
penetration of visible and near-infrared light as a function of wavelength of light 
through bovine muscle has been described in terms of the 1/e depth 
(approximately 37% of the incident light density). The depth of penetration 
doubles from the 4 mm observed between 500 and 600 nm to 8 mm at 800 nm, 
which defines the 600 – 800 nm range where light penetration is most effective. 
Biological effects can still be observed at two to three times the 1/e depths, which 
correspond to 3 – 10% of the incident light intensity and a depth of penetration of 
nearly 2.5 cm.  
 
Thus, for an optimal photodynamic effect, the prerequisites are: (i) optimal 
concentration of the photosensitizer; (ii) abundant supply of molecular oxygen; 
and (iii) delivery of light at a fluence rate that allows for resupply of molecular 
oxygen within the target tissue. 
 
1.5 Current issues in PDT: Delivery of photosensitizer to mucosal tissue 
Currently, the main photosensitizers used in the clinical setting belong to the 
porfimer sodium family [30]. They are a highly complicated chemical composition, 
containing porphyrin elements, whose coupling is secured by ether bondings 
(simple and complex polyhaemporphyrinether PHP). However, the stability of this 
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preparation is not sufficient. It tends to develop macroparticles, which can be 
explained by the fact that ether bonds easily break up when stored at room 
temperature. Consequently, the preparation needs to be stored and transported 
under cool conditions only. One of the most important features of porphyrin is its 
intensive absorption peaks, both in the UV and in the visible (red and green) 
spectrum, which is particularly important for PDT. However, the extinction 
coefficient is relatively low and therfore a high concentration of the preparation is 
needed for a successful PDT. Its usage has been hampered by the potentially 
serious and prolonged skin photosensitivity due to the long half-life of the drug in 
the body after intravenous administration [31]. Even though the photosensitizer 
has preferential uptake in the tumor cells after intravenous administration, 
extensive distribution of the photosensitizer to other non-targeted area is 
unavoidable.  
 
Topically applied photosensitizers are preferred for dermatological, oral and 
bladder PDT because of the reduced risk for prolonged skin photosensitivity, 
which is often the case after systemic administration. This form of delivery 
appears to offer a series of advantages, including localized treatment area, quick 
and easy removal of the dosage form, relatively good drug absorption, and 
satisfactory patient acceptance and compliance. Even so, the conventional 
topical formulation has its limitation because of the difficulty in reaching 
therapeutic levels due to impediment in penetration effect of the photosensitizer 
in deep-seated tumors. The varying degrees and depths of the tumors might 
contribute to the large variation in the distribution of the photosensitizer and thus 
could be one of the reasons for the poor tumor response observed in most 
clinical trials of PDT. Limited penetration depth of photosensitizer such as ALA 
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might pose a risk of not accurately recognizing the infiltration depth of solid 
tumors [41]. Therefore, the results of ALA mediated PDT in invasive cancers are 
less satisfactory, mainly because the PDT effect is too superficial [42]. Therefore, 
there is a need for the development of an effective topical drug delivery system to 
overcome these problems. 
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1.6 Chlorins as a promising photosensitizer 
Chlorins are reduced forms of porphyrins. The core of porphyrin is oxidatively 
stable, which has allowed for numerous derivatives to be prepared and 




















Figure 1.2 Molecular structure of Ce6 and PVP (C6H9NO) and the absorption spectra of 
Ce6-PVP formulations and Ce6 in 0.9% NaCl measured from 400 to 800 nm. Binding of 
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for optimal penetration in tissue. The reduction of a pyrrole double bond on the 
porphyrin periphery gives the chlorin core a high band I absorption at longer 
wavelengths of 650-670 nm than those of porphyrins and yet remaining efficient 
in generating singlet oxygen. Chlorins are actively being investigated for their 
photodynamic activity in cancer treatment. These photosensitizers have 
improved efficacy and have lesser known side effects compared to first 
generation photosensitizers from porphyrin derivatives. The advantages of this 
group of photosensitizers are: (i) they exhibit deeper penetration of PDT induced 
necrosis as their absorption wavelength is at the “phototherapeutic window” of 
600 - 670 nm, where meaningful PDT activity can be achieved without the 
interference of absorption by endogenous biomolecules, (ii) they accumulate 
preferentially in the tumor rather than in normal tissue, and (iii) they clear faster 
from the skin. Chlorins also exhibit a large extinction coefficient in the red region 
of the visible spectrum that is one order of magnitude higher than the 
corresponding extinction coefficient for porphyrins [47]. In addition, it has been 
shown that molecules with a chlorin-type structure are able to sensitize the 
generation of singlet oxygen with a high quantum yield [48]. The more widely 
used chlorin derivatives are tetrahydroxyphenyl chlorin (mTHPC, Foscan) and 
monoaspartyl-Ce6 (NPe6). 
 
Water-soluble derivatives of chlorophylls were first introduced as potential 
photosensitizer by E. Snyder (USA) in 1942. Since then, several chlorins based 
water soluble preparations have been developed [43, 44]. Of particular interest 
among the evaluated chlorin is the naturally occurring Ce6 [45]. Ce6 has 
improved efficacy and has decreased side effects compared to first generation 
photosensitizers from hematoporphyrin derivatives. It is also known to 
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preferentially accumulate in tumor tissue, exhibiting a deeper penetration of PDT 
induced necrosis since its absorption wavelength is between 600 – 670 nm. In 
addition, Ce6 exhibits a faster clearance from skin tissue. A number of other Ce6 
derivatives, including mono-L-aspartyl chlorin e6 (MACE), diaspartyl Ce6, 
monoseryl Ce6 and other amino acid derivatives, exhibit a better retention ratio in 
tumors and sensitize the photodynamic destruction of tumors better than Ce6 
itself [46]. Subsequently, MACE was patented as prospective photosensitizer for 
clinical PDT in Japan.  
 
Various approaches were undertaken to improve tumor targeting and selectivity 
of chlorin-based photosensitizers. Bachor et al. reported that in comparison to 
free Ce6, conjugation of Ce6 to microspheres were found to be highly specific for 
the MGH-U1 human bladder carcinoma cells [49]. Other methods of delivery 
include the usage of covalent low-density lipoprotein conjugates [50], peptide-
based intracellular vehicles [51], antibody mediated targeting [52], chemical 
alteration such as introduction of a hydrophilic group [53],  liposomes [54] and 
others. Polymer conjugation has also been explored to improve the 
photosensitizer solubility as well as to alter the biodistribution, elimination and 
pharmacokinetic profiles [55]. Among the polymers that are currently known to 
have been used with chlorin derivatives are polyethyleneglycol [56, 57] and N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers [58]. 
 
1.7 Polyvinylpyrrolidone 
Polyvinylpyrrolidone (PVP) is a macromolecular polymer of N-vinylpyrrolidone. It 
is metabolically inert in rat, dog and man as shown by experiments using 14C- or 
131I-labelled PVP [59]. It has been widely used as plasma expander [60]. The 
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excretion of PVP is inversely related to increasing molecular weight. The 
glomerulus can excrete all PVP of molecular weight 40 000 Dalton or below 
within a few days [59]. Low molecular weight PVP adsorbs various substances, 
e.g. bacterial toxins, inorganic poisons, barbiturates, vitamins and hormones in 
the blood, either reducing their toxicity or prolonging their activity [59]. The 
reticuloendothelial system retains PVP with a molecular weight in excess of 
about 100 000 Dalton for a long time [59]. PVP is also accumulated in the 
mitochondria of the kidneys [61]. Transfer of intravenously injected PVP to the 
brain or through the placenta was not observed [59]. PVP of molecular weight 11 
500 Dalton is not absorbed from the intestinal tract by man or by rat and PVP of 
molecular weight 16 000 Dalton is not absorbed from the gastrointestinal tract by 
guinea-pigs [59]. 
 
1.8 Novel association of polyvinylpyrrolidone with chlorin e6 
In parallel with the development of second-generation photosensitizers, this 
thesis was aimed at investigating a new preparation containing Ce6 (as a 
trisodium salt) and the polymer PVP. This formulation was a mixture of the active 
ingredient of Ce6 combined with PVP with mass fraction ratio of 1:1. Ce6 was 
obtained from the plant Spirullina platensis. PVP (molecular mass = 12000) is a 
synthetic, water-soluble, neutral polymer with low toxicity and high degree of 
biocompatibility that is commonly used in pharmaceutical formulations as a 
water-soluble polymeric carrier to improve solubility of lipophilic drugs [62]. The 
highly polar amide group of PVP monomer confers its hydrophilic and polar-
attracting properties, whereas the apolar methylene and methyne group in the 
backbone and the ring contribute to its hydrophobic properties. PVP acts as a 
carrier to modify the distribution of the drug. The use of PVP is based on the 
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principle that polymer conjugated drugs are passively and preferentially absorbed 
by tumors due to the enhanced permeability and retention effect [63]. It has been 
reported that drugs bioconjugated with PVP demonstrated longer mean resident 
time in the blood [64, 65]. Such macromolecular conjugates can potentially 
prolong the blood accumulation of drugs and thus preferentially accumulate in 
solid tumors through enhanced permeability and retention effects [66]. PVP has 
also been shown to inhibit drug crystallization in solution as well as in the solid 
state [67] and protects against drug degradation in solution. Another formulation 
using the photosensitizer Hypericin and PVP was reported to show improved 
water solubility as well as high affinity for cellular membranes [39]. In parallel with 
the development of second-generation photosensitizers using polymers, this 
report investigates a new preparation consisting of Ce6 (as a sodium salt) and 
the polymer polyvinylpyrrolidone (PVP) (Figure 1.2). This formulation was 
prepared as a mixture of at least 75% active ingredient of Ce6 (18-carboxy-20-
(carboxymethyl))-8-ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21H,23H-
porphin-2-propionic acid) and PVP with mass fraction ratio of 1:1.  
 
Currently Ce6-PVP is being used for palliative photodynamic treatment of head 
and neck squamous cell carcinoma lesions in patients not curable with surgery 
and/or radiotherapy in the scientific research centre of Belarus and Russian 
Federation. In its original form, Ce6 is unstable in aqueous solutions at room 
temperature. Aggregation of Ce6 observed in aqueous solutions is known to 
reduce the fluorescence quantum yield. In order to overcome Ce6’s insolubitily, 
PVP was used as a hydrophilic carrier. PVP is a synthetic, water-soluble, neutral 
pharmaceutical polymer with low toxicity, used commonly to improve drug 
dissolution. Mixture of Ce6 with PVP was found to prevent Ce6 aggregation in 
  16 
aqueous media and led to an enhancement of Ce6 fluorescence quantum yield, 
while keeping the quantum yield of the intersystem crossing essentially 
unchanged [68]. 
 
1.9 Experimental purpose and hypothesis 
In the field of photomedicine, there is a continuing need for a drug delivery 
system that is simple, non-toxic, chemically inert, economical and can easily be 
used for formulating different types of photosensitizers. Requirements for a 
photosensitizer formulation include not only maintaining the drug in a stable form, 
but also to achieve effective delivery of a therapeutic dose to target site. The 
underlying aim of this thesis is to evaluate the efficacy of association of polymer 
PVP blends for the photosensitizer, Ce6. It is hypothesized that the Ce6-PVP 
formulation are expected to have increased hydrophilicity, enhanced penetration 
and accumulation at tumor sites, where upon irradiation of laser light, Ce6-PVP 
will cause destruction in the cellular and vasculature within the tumors. They are 
also likely to be rapidly cleared from normal tissue thereby reducing normal 
tissue photosensitivity effect.  
 
The efficacy of Ce6-PVP was evaluated as a topical formulation in a multicellular 
tumor spheroid in the chick chorioallantoic membrane (CAM) model in order to 
have a better understanding of formulation effects in terms of penetration and 
uptake distribution. The CAM tumor model was chosen as this allowed for an 
easy evaluation of the formulation for screening purposes. The use of CAM 
model to culture tumor spheroids and model for photosensitizer transport study 
was a relatively novel concept in this study. 
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In vitro and in vivo preclinical tumor models were next employed to determine 
selectivity of the new Ce6-PVP formulations by measuring its pharmacokinetics 
and photodynamic efficacy and biological responses. The effect of PVP on the 
interaction of Ce6 with plasma proteins and its subcellular localization was also 
investigated to explore the possible mechanisms that had contributed to the 
accumulation of photosensitizer in the tumor. 
 
The final objective of this thesis was to evaluate the efficacy of Ce6-PVP in a 
selected sample of angiosarcorma and bladder cancer patients using 
fluorescence endoscopy imaging and in vivo spectrofluorometric technique. This 
was to enable the quantification of Ce6-PVP in lesions and normal tissue of 
patients. Confocal microscopic imaging on bladder biopsy samples was carried 
out after topical administration of Ce6-PVP to determine the depth of Ce6-PVP 
penetration into the mucosal and submucosal layers within the bladder tissue. 
Measurement of cytokine after Ce6-PVP mediated PDT in bladder cancer 
patients was also performed to evaluate for inflammatory response that was 
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CHAPTER 2 
 
Pharmacokinetic profile of chlorin e6 – polyvinylpyrrolidone in the murine model 
 
2.1 Summary 
This chapter describes the biodistribution and pharmacokinetics profile of Ce6–
PVP on poorly differentiated human bladder and nasopharygeal carcinoma 
murine models with the following specific aims: (i) to qualitatively evaluate the 
fluorescence accumulation in human bladder and nasopharyngeal tumor, (ii) to 
correlate the fluorescence distribution of Ce6–PVP using tissue extraction 
technique and fluorescence imaging technique, (iii) to compare the fluorescence 
distribution of Ce6, Ce6–PVP and Photofrin in skin of nude mice and (iv) to 
evaluate tumor response at post Ce6-PVP mediated PDT. The results presented 
here demonstrated that this formulation had a rapid accumulation in tumor tissue 
within 1 h post intravenous administration. The fluorescence of Ce6–PVP 
determined either by fluorescence imaging or by chemical extraction from the 
tissues displayed similar trends of distribution. It was also confirmed that Ce6–
PVP had a faster clearance from the skin of nude mice compared to Ce6 alone 
or Photofrin..The photodynamic activity of Ce6-PVP and its acute toxicity effect 
induced by different parameters such as drug-light interval, drug dose, irradiation 
fluence rate and total light fluence were also investigated. It was demonstrated 
that Ce6–PVP had less in vivo phototoxic effect compared to Ce6 alone. The 
phototoxicity revealed a strong dependence on the drug and light dosimetry as 
well as on the drug-light interval. Ce6–PVP was most toxic at 1 h drug-light 
interval, irradiated at 200 J/cm2, while Ce6 alone was most toxic at a light dose of 
more that 50 J/cm2 at the 1 and 3 h drug-light interval PDT. Although high 
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selectivity in tumor tissue was found between the period of 3 and 6 h, the efficacy 
of Ce6–PVP mediated PDT was best at 1 h drug-light interval. It was observed 
that the extent of tumor necrosis post PDT was dependent on the plasma 
concentration of Ce6–PVP, implying a vascular mediated cell death mechanism. 
In conclusion, the Ce6–PVP formulation appeared to be a promising 
photosensitizer for fluorescence imaging and PDT of cancer. 
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2.2 Introduction 
PDT is gradually becoming a widely used medical tool and has received 
regulatory approval for the treatment of a number of diseases worldwide, 
particularly age-related macular degeneration and certain solid tumors [69]. 
However, the use of PDT in clinical applications is frequently limited by 
associated side effects, such as nonspecific biodistribution and prolonged 
accumulation in non-neoplastic tissue. First-generation PDT photosensitizers, 
such as Photofrin®, exhibited prolonged skin photosensitivity and lacked long 
wavelength absorption. Therefore, there is a need for increased selectivity of 
photosensitizers for tumor tissue over healthy tissue. The synthesis of improved 
second-generation photosensitizers which have longer wavelength absorption 
moved towards modified tetrapyrrolic compounds, such as benzoporphyrin 
(Visudyne®), chlorin (Temoporfin®) and porphycene (ATMPn) to metallated 
derivatives such as  AlPcS4, SiNC (Nc—naphthalocyanine); and SnEt2. More 
recently, targeting strategies using nanoparticles have been shown to increase 
the affinity of photosensitizer for tumor tissue [70]. Conjugating a targeting 
component, such as an antibody (directed against the tumor antigens), towards 
the photosensitizer allows the drug to localize, accumulate and bind selectively at 
the diseased site [71]. The photosensitizer bioconjugate is then able to 
photodynamically inactivate in tumor cells expressing the tumor-associated 
antigen, and could greatly improve PDT's therapeutic margin with minimal side 
effects. Other alternative approaches include the use of a molecular carrier such 
as a liposome or targeted nanospecies [72, 73].  
 
The chemical structure of a photosensitizer plays a key role in the success of the 
compound as a PDT agent. A number of promising photosensitizers exhibit poor 
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solubility in aqueous media, thus preventing intravenous delivery into the 
bloodstream and affecting their efficacy and use in physiological media in the 
clinic. Photosensitizer needs to be soluble in physiological media as the degree 
of photosensitizer hydrophilicity and amphiphilicity directly affects its route of 
administration and its pharmacokinetic profile [74]. Lipophilic photosensitizers 
were found to accumulate in high amounts in the vessels, especially in the 
endothelial cells, whereas hydrophilic photosensitizers are cleared from the 
plasma more quickly and accumulate in the tumor cells after a short incubation 
time [75]. Photosensitizers with anionic substituents, such as sulphonate or 
carboxyl groups, have been observed to localize preferentially in the cytoplasm 
and relocate to the nucleus upon illumination, whereas lipophilic photosensitizers 
functionalized with cationic groups are believed to traverse the mitochondrial 
membrane and accumulate in the mitochondrion.  However, it remains to be 
established whether total drug distribution to neoplastic tissues or concentration 
in specific subcellular sites is the more important factor for an efficient PDT effect 
[76]. Exactly which physicochemical/structural properties and mechanisms 
behind these specific distributions and localizations and how to maximize tumor 
tissue selectivity over normal tissue accumulation are issues still under 
investigation [77]. 
 
During the past decade much research has been focused on developing effective 
drug delivery systems for the preparation of chlorins as potential photosensitizers 
for PDT. Ce6, a second-generation photosensitizer has been reported to have 
significant efficacy in killing cancer cells in vivo [78]. In its original form, Ce6 has 
the disadvantage of having poor solubility in aqueous solutions at room 
temperature. Aggregation of Ce6 observed in aqueous solutions is known to 
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reduce the fluorescence quantum yield as well as its cytotoxic effect. This 
provided the rationale for the development of Ce6 using PVP, an alternative 
water-soluble formulation with which the monomeric form of Ce6 can be 
administered intravenously. A spectroscopy study using multiple scattering 
experiments have shown that Ce6-PVP was present in the monomeric form in 
whole blood [79]. This is important as the ability to introduce the drug in a 
monomeric form into the circulation has been proven to correlate well with the 
efficacy of the photosensitizer in tumor destruction in the murine tumor model 
[80].  
 
The photochemical generation of singlet oxygen and other reactive oxygen 
species is responsible for the cytotoxicity induced by PDT. Lethal toxicity induced 
by various photosensitizers has been documented and systemic toxicity has 
been reported following whole body and abdominal light exposure of porphyrin 
PDT in mice. In previous studies, high levels of acute lethality in mice were 
reported using the photosensitizer Photofrin II-mediated PDT [81] and it was 
suggested that the localized PDT elicits systemic toxicity in the form of a 
traumatic shock syndrome. Traumatic shock can be produced by tissue injury, 
which in turn leads to inadequate peripheral perfusion that leads to circulatory 
collapse. The characteristics of traumatic shock includes induction of significant 
levels of ischemia or hypoxemia, the release of prostaglandins and kinins, as well 
as production of large amounts of cell necrosis.  
 
In this chapter, the ability of PVP to enhance the accumulation of Ce6 on the 
human bladder (MGH) and nasopharyngeal (CNE2) tumor model was 
investigated. Using fluorescence imaging and tissue extraction methods, the 
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fluorescence distribution in tumor and normal tissue were made by comparing 
the fluorescence distribution of Ce6, Ce6-PVP and Photofrin in the skin of nude 
mice. Visual presentation on Ce6-PVP induced fluorescence in tumor and gross 
anatomical structure of normal organ of a murine model were made. 
Fluorescence spectroscopy measurements were also performed to characterize 
emission spectra from these tissue samples as well as to corroborate results 
from fluorescence images. Comparisons were also made on the therapeutic 
efficacy of the formulation Ce6-PVP against Ce6 in a human bladder tumor 
xenograft model. Experiments were designed to evaluate effects of drug and light 
dose rate on Ce6 or Ce6-PVP mediated PDT on tumor and its lethal toxity 
response in mice. 
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2.3 Materials and methodology 
2.3.1 Preparation of photosensitizers 
Ce6-PVP also known as Fotolon or Photolon preparation was prepared at RUE 
Belmedpreparaty, Minsk, Belarus by our collaborator [114]. For each experiment, 
the photosensitizer stock solution was freshly prepared by dissolving 1 mg of 
Ce6–PVP in 1 mL of 0.9% sodium chloride while 1 mg of Ce6 (Frontier Scientific, 
USA) was dissolved in 0.5 mL dimethyl sulfoxide (Sigma, USA) to constitute a 
stock concentration of 2 mg/mL. During administration of Ce6, the stock solution 
was further diluted with 0.9% sodium chloride to obtain the desired dose. 
Photofrin was obtained from Sinclair Pharmaceuticals, UK. Photofrin was 
prepared by dissolving 1 mg of drug in 1 mL of 0.9% sodium chloride, to 
constitute a stock concentration of 1 mg/mL 
 
2.3.2 Cell culture conditions and xenograft tumor model 
Male Balb/c nude mice, 6 – 8 weeks of age, weighing an average of 24 g were 
obtained from the Animal Resource Centre, Western Australia. The epithelial-like 
carcinoma of the human bladder cell, MGH, and nasopharyngeal carcinoma 
cells, CNE-2, were used to establish the tumor xenograft model. The cells were 
cultured as a monolayer in RPMI-1640 medium supplemented with 10% fetal 
bovine serum, 1% non-essential amino acids (Gibco, USA), 1% sodium pyruvate 
(Gibco, USA), 100 units mL−1 penicillin–streptomycin (Gibco, USA) and incubated 
at 37 °C, 95% humidity and 5% CO2. Before inoculation, the cell layer was 
washed with phosphate-buffered saline, trypsinized, and counted using a 
hemocytometer. Approximately 3.0 × 106 cells suspended in 150 µl of Hanks’ 
Balanced Salt Solution (Gibco, USA) were injected subcutaneously into the lower 
flanks of the mice (Figure 2.1). All procedures were approved by the Institutional 
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Figure 2.1 Subcutaneous injection of tumor cells onto the flank 
 
2.3.3 Serum uptake of Ce6–PVP 
A dose of 5 mg kg−1 of the photosensitizer was administered intravenously 
through the tail vein. The mice were anaesthetized with 120 µL cocktail of 
ketamine hydrochloride (50 mg/mL, Trittau, Germany), dormicum (5 mg/mL 
Midazolam HCl, David Bull Laboratories) and deionized water (1 : 1 : 2 
volume/volume) through intraperitoneal injection. Blood was collected by cardiac 
puncture at 1, 3 and 6 h time points. Following this, the mice were sacrificed by 
cervical dislocation. Serum was collected by allowing blood to coagulate at room 
temperature and centrifuged at 3500 rev min−1 for 15 min. 100 µL of serum was 
added to 1900 µL of SolvableTM (Packard Instrument, USA). The mixture was 
incubated at 50 °C for 16 h. Subsequently, 1 mL of the solution was placed in a 
cuvette and the fluorescence emission at 665 nm was detected upon excitation 
at 400 nm using the spectrofluorophotometer RF-5301 PC (Shimadzu).  
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2.3.4 Fluorescence imaging  
A fluorescence endoscope system (Karl Storz, Tuttlingen, Germany) was used to 
perform the macroscopic fluorescence digital imaging. A modified xenon short 
arc lamp (D-Light system, Karl Storz) filtered by a band pass filter (375 – 480 nm) 
was used for excitation of Ce6–PVP in tissue. Fluorescence was captured via a 
sensitive CCD camera (Tricam SL PAL, Karl Storz) attached to a modified 
endoscope integrated with a long pass filter (cut-off wavelength 560 nm). The red 
channel registered the photosensitizer’s fluorescence and the blue channel 
captured the diffusely back-scattered excitation light. Mice were administered 
with various doses of the photosensitizers. At various time points, mice were 
anaesthetized and the skin overlaying the tumor was carefully removed to 
expose the tumor and normal peritumoral muscle. Fluorescence images of the 
tumor, muscle and dorsal skin were then captured. The distance between tissue 
surface and probe lens was standardized before imaging. This was done to 
minimize variations due to geometrical factors such as fluorescence excitation 
and collection angles. In addition, a short exposure of the surface of tumor and 
muscle to the excitation light (10 seconds) was performed to avoid excessive 
photobleaching effects. The intensities of the red and blue channels of the 
fluorescence images were quantified using the software MicroImage (Olympus 
Optical Co. (Europa) GmbH, Germany). By applying the red-to-blue pixel ratio of 
the same tissue of interest, the relative photosensitizer kinetics based on 
fluorescence intensity was determined. The red-to-blue pixel ratio algorithm is 
independent of the observation geometry, the distance between the endoscope 
tip and the observed tissue as well as the fluctuation of the excitation irradiance. 
This allowed for a more accurate quantitative assessment of the drug kinetics in 
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the tissue. The red-to-blue pixel ratios of all tissue were normalized with the red-
to-blue pixel ratio of the tissue before drug administration. 
 
2.3.5 Spectroscopic measurement using fiber optics-based fluorescence 
spectrometer 
The spectral measurement was performed on mice sacrificed at 1 and 3 h post 
Ce6-PVP administration. A fiber optics-based fluorescence spectrometer (Spex 
SkinSkan, JY Inc., Edison, NJ, USA) was used for the measurement of 
fluorescence intensity of Ce6-PVP. A monochromator with a 150-W Xenon lamp 
was used as the excitation light source. The excitation light (400 nm) was guided 
to illuminate samples by one arm of a Y-type quartz fiber bundle, and the 
emission fluorescence was collected by another arm of the fiber bundle, guided 
to another motor-controlled monochromator. The resulting emission spectra were 
recorded from 650 to 750 nm, in 1 nm increments, collected using the DataMax 
version 2.20 (Instruments SA, Inc.) software package. The optical fiber tip was 
placed on the measuring sites and fluorescence intensity spectra were 
measured. After each measurement, the optical fiber tip was carefully cleaned to 
remove the possible remaining drug on the tip. 
 
2.3.6 Determination of Ce6-PVP concentrations in tissues in mice 
For analyzing the fluorescence intensity distribution in skin, mice were 
intravenously injected with 5 mg/kg with all three different photosensitizers (Ce6, 
Ce6-PVP and Photofrin). Fluorescence images of dorsal skin were taken in 
unanaesthetized mice at different time points over 42 h. For the analysis of the 
distribution of Photofrin, chemical extraction method was used because the 
fluorescence endoscope system was not suitable to detect Photofrin 
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fluorescence. Skin tissue samples were placed with 2 mL of Solvable™ (Packard 
Instrument, USA) tissue solubilizer and incubated at 50°C for 16 h in the dark. 
The level of fluorescence of the solubilized samples were measured by a 
spectrofluorophotometer (model RF-5301 PC, Shimadzu) with λex = 400 nm, slit 
width 1.5 nm and λem = 665 nm, slit width 1.5 nm. 
 
2.3.7 Confocal fluorescence microscopy and image analysis.  
After administration of Ce6-PVP and macroscopic imaging, the animals were 
sacrificed and the tumor tissue was harvested at various time points (15 min, 30 
min, 1 h, 3 h and 6 h). The tumors were then snapped frozen in liquid nitrogen. 
Cryo sections with a thickness of 15-20 mm were obtained using Microtome 
Cryostat (Cryo-Star HM 560MV, Germany). The sections were mounted on 
microscope slides covered with fluoromount (Ingram and Bell, USA). Fluorescent 
microscopic images were obtained from these sections. A laser confocal 
fluorescence microscope (Meta LSM 510, Carl Zeiss, Germany) was used to 
obtain the fluorescence microscopic images. An argon laser was used as an 
excitation source of 488 nm. Fluorescence emissions in the wavelength range of 
600 – 670 nm were spilt by a diachronic filter and detected through a band-pass 
filter (BP-610 nm, Omega Optical, USA). Voltage gain, PMT voltage and 
sensitivity (contrast, brightness and filters) were fixed for all fields and slides 
imaged. The images were stored on an optical disk and analyzed using an image 
analysis software package. 
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2.3.8 Statistical analysis 
Fluorescence half-life (t1/2) values were derived by non-linear fitting to one phase 
exponential decay equation and comparison of fits was performed using Graph-
Pad PrismTM (San Diego, USA) and results were expressed as mean t1/2 with 
95% confidence interval (95% CI). Statistical evaluation on the t1/2 values was 
performed using the nonparametric Friedman test to compare the matched 
groups for each time points whereas multiple comparison of Bonferroni post hoc 
test was used to compare the effect of various PDT parameters on tumor 
response. All the mean differences were significant at the 0.05 level. 
 










Figure 2.2 Light irradiation procedure on mouse 
 
A portable diode laser (Ceralas PDT 665, Biolitec) emitting at a wavelength of 
665 ± 3 nm was used for irradiation (Figure 2.2). The peak power output was 
calibrated to 1.75 – 1.85W at the fiber tip before commencement of irradiation. 
The laser energy was delivered to the surface of the tumor via a silica fiber 
Laser 
Light fiber 
Mouse covered in blanket 
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frontal light distributor (FD model, Medlight, Switzerland). The fiber was 
positioned to produce a 0.5 – 1.0 cm2 circular spot of uniform light irradiation. 
Fluence rate was measured using a power meter (LaserCheck, Coherent). PDT 
treatment was performed at various parameters on anaesthetized mice bearing 
MGH tumors. Experiments were designed to study the effect of variation of four 
variables: the drug dose (2.5, 3.5 and 5 mg kg−1), the drug-light interval (DLI, the 
time from the bolus injection of drug to the start of light delivery at 1, 3 and 6 h), 
the fluence (from 50 – 200 J cm−2) and the fluence rate (from 41.7 – 165 mW 
cm−2). Prior to irradiation, animals were wrapped in aluminum foil layered with 
brown paper towel in order to avoid irradiation to the other parts of the body. 
After illumination, the animals were kept in microisolator cages wrapped in 
aluminium foil to avoid light exposure. 
 
2.3.10 Assessment of tumor response post PDT 
The evaluation of tumor necrosis was performed using Evans Blue (Merck, 
Germany) vital staining. At 48 h post PDT, 1% Evans Blue in PBS was injected 
intraperitoneally at a volume of 0.4 mL in mice. Six hours later, animals were 
sacrificed and the tumors were excised. Around 2 – 3 mm thick cross-section 
slices were cut and imaged under a stereoscopic microscope (Stemi 2000C, 
Zeiss, Germany). The unstained area was attributed to tissue necrosis, whereas 
the stained area indicated viable tissue. Digital images were saved in JPEG 
format, and all analyses were carried out using NIH Image v1.62 software. Each 
image captured had the same calibration values to allow uniformity in the 
processing of the images. The tumor was outlined using the freehand drawing 
tool to measure the total tumor area. Similarly the necrotic area of the tumor was 
measured. The percentage of necrosis was calculated as the necrotic area 
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divided by the total tumor area multiplied by 100. In addition, a short-term tumor 
growth evaluation was performed to evaluate the efficacy of the treatment. Tumor 
volume was determined in a double-blinded manner at 7 and 14 days post PDT 
through caliper measurements using the formula: V = p/6 x d1 x d2 x d3 where V 
represented volume (mm3) and d1, d2 and d3 represented the three mutually 
orthogonal diameters (mm) of the ellipsoid tumor. For evaluation of lethal toxicity 
effects of the photosensitizers, the evaluated endpoint was survival of the 
animals at 24 h post PDT. 
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2.4 Results and discussions 
2.4.1 Fluorescence distribution in serum 
The uptake kinetics of Ce6-PVP in serum was determined spectrofluorimetrically 
as shown in Figure 2.3. The fluorescence level of the photosensitizer in serum 
peaked after 1 h post administration. Subsequently, the concentration of the drug 
decreased steadily over the next few hours and approximately 4 % of its 
maximum concentration was retained in serum at 24 h. The calculated t1/2 value 
of Ce6-PVP in serum was 1.4 h (95% CI 0.8 – 3.7).  
Figure 2.3 Serum uptake of Ce6-PVP at various time points post drug administration. 
Each time point represents a mean of 5 animals ± SE. 
 
 
PVP alone was effectively retained in the blood and showed little tissue-specific 
localization following its intravenous administration [82]. Previous research has 
demonstrated that drugs bioconjugated with PVP demonstrate a decreased 
minimum volume of distribution and longer mean resident time in the blood [64, 
65]. Such macromolecular conjugates may prolong the residency of drugs in 
blood and therefore preferentially accumulate in solid tumors through enhanced 
permeability and retention effects [66].  
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2.4.2 Qualitative assessment of Ce6-PVP accumulation in MGH tumor xenograft 
 
Fluorescence imaging approaches are increasingly being used as a medical 
diagnostic procedure to assess tissue malignancy over conventional methods 
because they do not use potentially harmful ionizing radiation [84]. In situations 
where discrimination of suspicious lesion is clinically problematic, fluorescence 
imaging may provide added advantage in demarcating abnormal tissue. The 
development of photosensitizer based fluorescence imaging is hindered by 
problems such as skin photosensitivity, poor selectivity of the photosensitizer, 
and formulation issues. For these reasons, Ce6 was formulated with PVP to 
address these issues. Formulations using biocompatible polymers such as PVP 
are increasingly being used in the pharmaceutical industry for enhancing drug 
solubility and bioavailability. Figure 2.4 shows fluorescence images of the 
bladder tumor (A-D) post Ce6-PVP administration and their fluorescence 
intensity distribution images (E-H). The red fluorescence is an indicator of Ce6-
PVP accumulation. The fluorescence intensity distribution map monitored the 
intensity of the fluorescence kinetics whereby red regions represented the hot 
spots for localization of Ce6-PVP followed by yellow and green. Intense 
fluorescence observed in the tumor indicated a tumor specific uptake of the 
compound. When compared to the images of normal bladder, no evident 
fluorescence was observed, demonstrating a clear fluorescence contrast 
between bladder tumor tissue and the normal bladder tissue. Only mild 
fluorescence was observed at 3 and 4 h post administration. At 6 h post drug 
administration, fluorescence was not detected, indicating clearance of the 
photosensitizer from normal bladder tissue. 
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Figure 2.4 Upon intravenous administration of Ce6-PVP, tumor fluorescence at 2, 3, 6 
and 27.5 h was observed under blue light illumination (A-D). The intensity of the 
fluorescence kinetics can be monitored in a fluorescence intensity distribution map, with 
red regions being hot spots for localization of Ce6-PVP followed by yellow and green (E-
H). Normal bladders of mice (arrow) were imaged at 2, 3, 4 and 6 h post drug 
administration (I-L) and their corresponding intensity distribution images were acquired 
(M-P).  
 
The use of preferential accumulation of photosensitizers in neoplastic lesions is 
already approved for detection of bladder cancer and undergoes further 
development for the detection of other cancer diseases [85]. However, PDT is 
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also associated with significant rates of bladder contracture because of the 
nonspecific accumulation of photosensitizers in the detrusor muscle. Selectivity 
of the photosensitizer between layers of hollow organs such as the bladder is 
one area in which PDT can demonstrate a therapeutically important advantage 
[38]. Even though, the selectivity of the photosensitizer is relatively poor at times, 
optimizing this selectivity using an improved formulation such as Ce6-PVP could 
provide a useful alternative to currently used photosensitizer.  
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2.4.3 Qualitative assessment of Ce6-PVP accumulation in CNE2 tumor xenograft 
Macroscopic fluorescence images of CNE2 tumors were obtained using the  
fluorescence endoscopy system (Figure 2.5). Fluorescence intensity in tumor 
and tumor vasculature of nude mice xenografts was observed as early as 15 min 
post drug administration. Higher fluorescence was observed in tumor and 
adjacent normal tissue at 30 min and at 1 h. The tumor fluorescence selectivity 
was highest at 3 h. The overall fluorescence started to decrease from 6 h, and by 
24 h, the fluorescence was negligible. These results were consistent with the 
results of the bladder tumor xenografts, demonstrating good fluorescence 
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A - 15 min B - 30 min 
C - 1 hr D - 3 hr 





































Figure 2.5 Ce6-PVP macroscopic fluorescence of NPC tumor xenografts and the 
surrounding tissue captured at various time points. 
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2.4.4 Fluorescence imaging of normal organs in mice  
Representative fluorescence images of skin and various internal organs taken at 
1 h post Ce6-PVP administration are presented in Figure 2.6. The internal organs 
were found to yield substantial fluorescence especially the gall bladder, liver, 
stomach, small and gastrointestinal tracts. Minimal fluorescence was observed in 
the heart and spleen. The fluorescence intensity in skin, lung, liver, and bladder 
dropped at 3 h post drug administration. There was little or no fluorescence 
remaining in heart and spleen. In contrast, the tumors showed sustained 
fluorescence intensity at 3 h post drug administration. By 6 h post drug 
administration, minimal fluorescence was detected in the gastrointestinal tract, 
liver and bladder (Figure 2.7). 


























Figure 2.6 Macroscopic white light and fluorescence imaging in skin, heart, lung, gall 
bladder, liver, spleen, kidney and gastrointestinal tract at 1 h post-intravenous 
administration of 5.0 mg/kg Ce6-PVP. 








































Figure 2.7  Macroscopic white light (A, C, E) and fluorescence (B, D, F) imaging in 
normal bladder, liver, gall bladder, and gastrointestinal tract at 6 h post-intravenous 




Macroscopic fluorescence imaging showed that there was considerable 
distinction in the localization of fluorescence in tumor compared to other organs 
that could enable discrimination between tumor and normal organs. Organs of 
elimination and detoxification such as skin, gall bladder and gastrointestinal 
tracts were characterized by high photosensitizer accumulation efficiency. In 
contrast, all other normal organs such as muscle and bladder had much lower 
photosensitizer accumulation at 1 h post drug administration. Blood vessels 
growing on the tumor can also be observed because they contrast with the 






gall bladder gall bladder 
intestines intestines 
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fluorescence of the tumors. At 3 - 6 h post drug administration, a decrease of 
fluorescence intensity became evident on all normal organs, confirming that Ce6-
PVP has fast clearance rate from normal organs. In some instances, variability of 
fluorescence intensity on the surface tissue such as stomach and lung was 
observed. This is possibly attributed to the variations of the tissue optical 
properties of the organs given by their color, density and composition.  
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2.4.5 In vivo fiber optic spectrofluorometric measurement 
Typical fluorescence emission spectra from tumor, adjacent peritumoral muscle 
and normal bladder after i.v. administration of Ce6-PVP are shown in Figure 2.8. 
In general, the peak fluorescence intensities of tumor were higher than those of 
normal sites. The greatest intensity occurred in the region between 660 – 670 
nm. When the spectra were normalized to baseline value, changes in peak 
intensity became evident. The line-shape differences were predominantly due to 
















Figure 2.8 Comparison of emission spectra of bladder tumor xenograft, normal bladder 
and muscle of the murine model at 1 and 3 h post administration of Ce6-PVP using 400 
nm excitation. The spectral signatures showed a peak at the wavelength 665 – 670 nm 
in tumor while the fluorescence intensity of normal bladder and muscle is weaker than 
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Figure 2.9 Comparison of emission spectra in the 650 – 700 nm region using 400 nm 
excitation in various normal organs at 1 and 3 h post Ce6-PVP administration. Except for 
skin and gall bladder, it is evident that the emission spectra of normal organs were lower 
compared to the emission spectra of tumor. 
 
 
Fluorescence emission spectra of skin, heart, lung, gall bladder, liver, spleen, 
kidney and gastrointestinal tract are shown in Figure 2.9. Except for the gall 
bladder, all other organs showed a decreased of fluorescence emission of Ce6-
PVP at 3 h compared to 1 h post drug administration. Essentially, fluorescence 
images that showed greater red fluorescence intensity had visibly higher spectral 
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peak, thus suggesting that that the macroscopic fluorescence imaging were 
reproducible. The key issue in fluorescence imaging is that the emitted 
fluorescence intensity measured from a tissue surface is not necessarily 
proportional to the fluorophore concentration because the light is altered by the 
tissue's intrinsic absorption and scattering properties. Hence the utility of 
spectrometric point fluorescence detection was employed as a complimentary 
technique. Spectra measurements were carried out at 1 and 3 h post drug 
administration to correlate the tumor intensity ratios obtained with fluorescence 
imaging to the tumor fluorescence spectral signal of the tissue. All the 
macroscopic fluorescence images correlated well to the spectra measurement. 
The Ce6-PVP induced spectra emission after normalization demonstrated a good 
separation to differentiate malignant tumors from normal tissues. Besides 
measuring physical parameters such as concentration of photosensitizer and 
tissue properties, this method can potentially improve the assessment of cancer 
location and its extent within the local-regional area. While fluorescence point 
spectroscopy studies are promising, it has several drawbacks as a screening tool 
as it can only interrogate a small volume of tissue (typically, 0.5 – 1 mm3) directly 
beneath the probe tip. Point measurements inevitably involve a degree of 
random sampling, which may not allow identification of early stage disease [86]. 
Hence, the combination techniques of fluorescence imaging and spectroscopy 
have been proven in good agreement with the actual tumor boundary found by 
histopathological mapping and early stage of disease [87, 88].  
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2.4.6 Quantitative assessment of Ce6-PVP accumulation in human 
nasopharyngeal tumor (CNE2) xenograft 
Maximum fluorescence was observed in CNE2 tumor tissue at 30 min and 1 h 
post drug administration (Figure 2.10). At 3 h post drug administration the 



























Figure 2.10 (A) Quantification of Ce6-PVP fluorescence intensity in tumor and normal 
tissue in CNE2 tumor model as a function of time as determined by fluorescence 
imaging technique. Each time point represents a mean of at least 3 animals ± SE. (B) 





  46 
and 90% at 6 h and 24 h respectively. At all time points, the difference between 
the level of fluoresce between tumor and normal tissue were statistically 
significant (p<0.05).  Selectivity of Ce6-PVP was evaluated by determining the 
ratio of drug fluorescence in CNE2 tumor versus normal tissue at the following 
time points – 30 min, 1 h, 3 h, 6 h and 24 h. The tumor to normal tissue ratio was 
2.6 at 30 min. The ratio increased gradually from 4.6 to 7.6 at 1 h and 3 h time 
points respectively. The tumor to normal tissue selectivity ratio was highest at 6 h 
with a value of 28.1. Ce6-PVP microscopic fluorescence was also observed in 
the CNE2 tumor tissues as early as 30 min post drug administration (Figure 
2.11). Overall microscopic fluorescence peaked at 3 h, correlating to the 
fluorescence of the macroscopic images. Fluorescence thereafter gradually 
started to decline, and only mild microscopic fluorescence was observed in the 
tumor tissues at the 6 h time point.  




















Figure 2.11 Fluorescence confocal microscopy of Ce6-PVP localization in tumors at 
various time points. 
A - 30 min B - 1 hr 
C - 3 hr D - 6 hr 
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The main advantage of the fluorescence imaging technique lies in its ability to 
precisely label neoplasm by means of preferential uptake of photosensitiser by 
the target cells. Our studies showed that Ce6-PVP selectively localized in NPC 
tumors whereby fluorescence peaked rapidly within 30 min to 1 h post drug 
administration. The accumulation of Ce6-PVP in CNE2 tumor tissue was almost 
twice as much compared to normal tissue at the 3 h time point. The drug started 
to clear from the tumor tissue at about 6 h, thus making it a promising agent for 
systemic application for PDD. In the macroscopic images, at 30 min post drug 
administration, the tumor to normal ratio was lower, since the normal tissue also 
exhibited high fluorescence. However, at the later time points from 3 h to 6 h the 
fluorescence in the normal regions started to clear and the fluorescence 
selectively accumulated in the tumor thus increasing the tumor to normal ratio. 
This is in agreement with a study peformed by Kikuchi et. al. where the authors 
noticed that the mean Ce6 fluorescence intensity calculated from the fluorescent 
images was significantly higher in tumors than normal mucosa at the 6 h time 
point [89]. 
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2.4.7 A comparison of Ce6-PVP induced fluorescence quantification using image 
processing and tissue extraction method in human bladder tumor (MGH) 
xenografts 
Figure 2.12 A comparison of fluorescence quantification using image processing and 
tissue extraction method. (A) Fluorescence intensity tabulated as the ratio of red to blue 
pixel intensity in normal (■) and tumor (●) tissue at various time points post drug 
administration using the fluorescence image processing technique. (B) Fluorescence 
intensities expressed as per gram of tissue using the tissue extraction technique. The 
best-fit logarithmic trend line were plotted in order to compare the correlation coefficient 
value between two methods of quantification. Each time point represents a mean of at 
least 3 animals ± SE. 
 
Fluorescence distributions of the photosensitizer in MGH tumor and normal 
tissue were assessed at various time points post intravenous administration of 
Ce6-PVP using the fluorescence imaging technique (Figure 2.12 A), thereafter 
these results were compared to those using tissue extraction technique (Figure 
2.12 B). Both methods showed similar trends in fluorescence kinetics with higher 
fluorescence intensity observed in the tumor compared to normal tissue. 
y = -0.6969Ln(x) + 2.641
R2 = 0.9446
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Logarithmic trendlines showed a higher correlation coefficient values (R2) for 
MGH tumor than normal tissue. When both trendlines were compared, the image 
processing technique and the tissue extraction method displayed very similar 
results. However, the fluorescence imaging data underestimated the 
concentration of the photosensitizer in tumor and normal tissue. The present 
work also confirmed that direct fluorescence imaging on the surface of the 
subcutaneous bladder tumor xenograft gives consistent results for relative 
concentrations of the photosensitizer when compared to results derived from the 
tissue extraction method. In order to be compatible with the tissue extraction 
data, direct fluorescence readings from the fluorescence endoscope system have 
to be multiplied by factors in the range 4 - 5. Due to differing pigmentations and 
structures of various tissues, light absorption and scattering make direct 
fluorescence measurements unsuited for quantitative comparisons of 
photosensitizer levels in tissues [90]. Nevertheless, cautious interpretation of the 
data of in vivo fluorescence imaging could allow real-time estimation of relative 
drug concentration in normal as well as in tumor tissue. 
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2.4.8 Comparison of fluorescence distribution of Ce6-PVP versus Ce6 only in MGH 









Figure 2.13 The kinetics of fluorescence intensity of Ce6-PVP (A) and Ce6 (B) in normal 
tissue of femoral muscle and tumor tissue at various time points post drug administration 
based on fluorescence image analysis. Each time point represents a mean of 5 animals 
± SE. 
 
The fluorescence distribution profiles of Ce6-PVP and Ce6 in MGH tumor and 
surrounding normal muscle exhibited very similar kinetics (Figure 2.13). Tumor 
fluorescence of both compounds peaked at 1 h post drug administration with Ce6 
having a higher fluorescence intensity compared with that of Ce6-PVP. The 
fluorescence in normal tissue was low compared to fluorescence in tumor tissue 
at all time intervals. Minimal fluorescence in both tumor and normal muscle were 
observed at 27.5 h, as 98 % of its maximum detected was cleared. The 
calculated t1/2 values of fluorescence in tumor and normal muscle were 4.0 h (95 
% CI 2.6 – 8.9) and 0.9 h (95 % CI 0.5 – 2.4) respectively for Ce6-PVP whereas 
for Ce6, the calculated t1/2 values were 2.7 h (95 % CI 1.9 – 4.7) and 1.3 h (95 % 
CI 0.7 – 5.6) for tumor and normal muscle, respectively. This inferred that Ce6-
PVP resided longer in tumor tissue and eliminated faster from normal tissue 
compared to Ce6. 
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Table 2.1 In order to study the in vivo selectivity of the photosensitizers in MGH tumor, 
the ratio of drug fluorescence in tumor over normal tissue were tabulated. Each time 
point represents a mean of 5 animals for Ce6-PVP and 4 animals for Ce6. 
 
Time points 1 h 3 h 6 h 
Ce6-PVP 2.2 8.7 9.3 
Ce6 1.9 3.5 4.5 
 
At 1 h post drug administration, the tumor to normal tissue selectivity ratio of both 
photosensitizer was low, since normal muscle also exhibited high levels of 
fluorescence (Table 2.1). However, from 3 to 6 h, the fluorescence in normal 
muscle started to clear and fluorescence selectively accumulated in the tumor 
tissue, thus increasing the tumor to normal tissue selectivity ratio. Overall, Ce6-
PVP exhibited higher selectivity compared to Ce6.  
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2.4.9 Fluorescence monitoring in skin 
The fluorescence distribution of the photosensitizer in skin was assessed at 
various time points post intravenous administration of Ce6-PVP (Figure 2.14). 
Regardless of the drug doses administered, the fluorescence kinetics exhibited 
similar trends in the skin. It was observed that peak photosensitization occurred 
at 1 h post drug administration. However, the fluorescence intensity decreased 
from 6 h post administration onwards. The calculated t1/2 values for 2.5, 3.5 and 5 
mg/kg of the photosensitizer in skin were 0.7 h (95 % CI 0.4 – 1.8), 0.8 h (95 % 
0.5 – 1.3) and 0.8 h (95 % CI 0.6 – 1.5) respectively. Irrespective of the 
photosensitizer concentration administered, fluorescence of the skin was not 
detected at 42 h post drug administration. It was observed that peak 
photosensitization of the skin occurred at 1 h post drug administration of the Ce6-
PVP. However, the fluorescence intensity decreased from 6 h post administration 
onwards. By 24 to 42 h, no Ce6-PVP fluorescence was detected. For Ce6 alone, 
similar trends of distribution and clearance were observed. When data for Ce6-
PVP and Ce6 alone of skin were compared, Ce6-PVP had a faster clearance 
rate with t1/2 values of 0.8 h (95 % CI 0.6 to 1.5) compared to t1/2 values of 2.7 h 
(95 % CI 1.9 to 4.4) for Ce6 alone. In contrast, the fluorescence level of the skin 
after the administration of 5 mg/kg Photofrin showed an increasing trend and still 
detected up to 72 h post administration.  











































Figure 2.14 Fluorescence intensities of (A) Ce6-PVP, (B) Ce6 alone and (C) Photofrin 
measured over time in skin of Balb/c nude mice. For Ce6-PVP and Photofrin, mice were 
given a dose of 2.5, 3.5 and 5 mg/kg whereas for Ce6, mice were given 5 mg/kg only. 
Each plot represents a mean of at least 8 animals. Bars = standard deviation. 
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It is important to realize that following the administration of chemicals such as a 
photosensitizer, the skin is susceptible to photosensitivity and photoallergy [91]. 
Photosensitizers alone may have no toxic side effects, but when present in 
significant levels in the skin, they are known to exert severe cutaneous 
phototoxicity such as erythema or edema in the presence of light. Thus, 
photosensitizers with fast elimination rate from the skin are desirable in order to 
avoid prolonged photosensitivity in patients. Compared to Ce6 alone or Photofrin, 
the new formulation of Ce6-PVP uses its PVP component to alter its 
pharmacokinetics, thereby giving a faster clearance rate from the skin. It was 
documented that Photofrin induces cutaneous photosensitivity for up to 4-6 
weeks during which time patients have to protect themselves from bright light, 
especially sunlight. In a comparative study to quantify the concentrations of 9 
different photosensitizers in a C3H mammary carcinoma model, Qian et al. found 
that Ce6 had lower skin to tumor concentration ratios than Photofrin II [92]. 
Gomer et al. then compared another chlorine e6 derivative, NPe6 to Photofrin II, 
and the results showed significantly less skin damage using NPe6 with the same 
light and drug doses [93]. Following this, several studies have shown that NPe6 
has good efficacy against superficial malignancies with temporary generalized 
skin photosensitivity that usually resolves within 1 or 2 weeks of dosing [94-96]. 
Similarly, our studies showed that Ce6-PVP exhibit even faster clearance from 
normal tissue and skin compared to Ce6 as detected by fluorescence imaging. In 
comparison to other photosensitizers such as Photofrin, 5-aminolevulinic acid, 
Foscan and Hypericin that are already in clinical use, the clearance rate of Ce6-
PVP is faster, thus could potentially avoid the problem of prolonged skin 
photosensitization. 
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2.4.10 Tumor response post PDT  
Using cross section from the center of the treatment field of the tumor, the 
volume of overall tumor necrosis was compared between control and PDT-
treated animals using different combination of drug-light intervals (DLI), drug and 
light doses. Generally, tumor necrosis was enhanced with the increase in dosage 
of the photosensitizer and light. The region of necrosis in the tumor decreased 
with increasing DLI. Greater necrosis was observed for the 1 h DLI at all three 
drug doses compared to DLI between 3 and 6 h (Figure 2.15, Table 2.2). When 
the drug doses were increased to 3.5 and 5 mg/kg, and the light dose was 
increased to 150 J/cm2, the percentage of necrosis was found to increase 
significantly (p<0.05) compared to tumors treated at the drug dose of 2.5 mg/kg 
at 100 J/cm2. At 200 J/cm2, complete necrosis was observed at 2.5, 3.5 and 5 
mg/kg (p<0.05).  However, drug toxicity to animals was observed when mice 
were administered more than 3.5 mg/kg at irradiations of 150 and 200 J/cm2. 
When tumors were treated at 3 h DLI, significant tumor necrosis was observed 
with higher light doses of 150 and 200 J/cm2 when compared to tumors treated 
with 100 J/cm2
 
at a drug dose of 2.5, 3.5 and 5 mg/kg, respectively (Figure 2.16, 
Table 2.2). At 3 h DLI, lower drug and light doses did not seem to be as effective 
as 1 h DLI in inducing tumor necrosis. At 6 h DLI, no tumor necrosis was 
observed when the animals were treated with 5 mg/kg of Ce6-PVP at 50 J/cm2 
and less than 32 % of tumor necrosis was observed when the light dose was 
increased to 300 J/cm2. 






















Figure 2.15 Cross-section of tumors xenografted on mice stained with Evans Blue dye 
at 48 h post PDT after treatment with various drug and light dose at 1 h drug-light 

























Figure 2.16 Cross-section of tumors xenografted on mice stained with Evans Blue dye 
at 48 h post PDT after treatment with various drug and light dose at 3 h drug-light 
interval. Blue region indicated viable tissue while white region indicated tumor necrosis.
  58 
Table 2.2 Percentage of tumor necrosis evaluated at 48 h post PDT after treatment with 













1 50 41.5 5.0 74.8 ± 7.1 
1 100 85 2.5 55 ± 31.7 
1 100 85 3.5 62.5 ± 15.7 
1 100 85 5.0 79.6 ± 10.8 
1 150 125 2.5 70.4 ± 6.5 
1 150 125 3.5 85.6 ± 14.0 
1 150 125 5.0 95.1 ± 5.6 
1 200 165 2.5 100 
1 200 165 3.5 100 
1 200 165 5.0 100 
3 100 85 2.5 0 
3 100 85 3.5 0 
3 100 85 5.0 37.1 ± 32.6 
3 150 125 2.5 46.1 ± 26.9 
3 150 125 3.5 55.3 ± 30.6 
3 150 125 5.0 71.6 ± 12.8 
3 200 165 2.5 86.3 ± 7.3 
3 200 165 3.5 89.8 ± 2.7 
3 200 165 5.0 87.6 ± 10.5 
6 50 41.5 5.0 0 
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Table 2.3 Percentage of tumor necrosis evaluated at 48 h post PDT after treatment with 












1 50 41.5 2.5 62 ± 15.1 
3 50 41.5 2.5 25.5 ± 13.1 
6 50 41.5 2.0 43.2 ± 10.0 
6 100 85 2.5 67.9 ± 4.9 
 
  
Tumor responses were also assessed after irradiation with Ce6 only (Table 2.3). 
Mice administered with more than 2.5 mg/kg of Ce6 and irradiated with light dose 
of more than 50 J/cm2 at 1 and 3 h DLI did not survive up to 48 h post treatment 
due to phototoxicity. Only data from surviving mice is presented in Table 2.3. At 
the dose of 2.5 mg/kg at 1 h DLI, Ce6 mediated PDT was able to induce 62 % of 
tumor necrosis without causing any mortalities. At the same drug dose, the 
percentage of necrosis dropped to an average of 25.5 % when tumors were 
irradiated at 3 h DLI. However, when irradiation was performed at 6 h DLI with 
only 2 mg/kg, the percentage of necrosis increased to 43.2 %.  
 
PDT requires an optimum dual dosimetry of drug and light dose to ensure tissue 
response. In order to achieve irreversible tumor necrosis it is necessary to 
surpass a certain threshold of light absorption. The light dose applied to the 
surface of the tumor must be sufficient to allow penetration to the deepest part of 
the tumor. In this chapter, it was demonstrated the dependence of fluence and 
fluence rate in determining the extent of necrosis in tumor using Ce6-PVP. 
Depending on the drug-light intervals, low light intensities could result in an 
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inefficient activation of the photosensitizer leading to poor tumor response 
whereas high light intensity could result in a better treatment outcome. In this 
experiment, for every drug-light interval where irradiation of the tumors was 
performed, the percentage of tumor necrosis increased with total fluence, but for 
longer drug-light intervals (3 or 6 h), high total fluences failed to produce a 
significant delay in tumor regrowth. This is in line with other literatures 
documenting well-known reciprocity between drug-light interval and light dose, 
which has been demonstrated in various experimental tumors [97]. Long drug-
light interval However, high light intensity also causes the deoxygenation of 
tissue and possible hyperthermia which impede the subsequent biological 
processes [98]. Furthermore, a high light dose can also cause systemic toxicity, 
as has been demonstrated in this study. In addition, when a high light dose was 
administered, serious damage to normal tissue as well as internal organs beyond 
the irradiation area was observed. 
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Figure 2.17 Short term evaluation of MGH tumor growth post PDT using various drug 
and light dosimetry.  Mice were treated with the following parameters: Group 1 = 100 
J/cm2; 85 mW/cm2 at 1 h DLI, Group 2 = 150 J/cm2; 125 mW/cm2 at 3 h DLI, Group 3 = 
200 J/cm2; 165 mW/cm2 at 3 h DLI, Group 4 = 300 J/cm2; 167 mW/cm2 at 3 h DLI and 
Group 5 = 300 J/cm2; 167 mW/cm2 at 6 h DLI. (A) Tumor volumes at 7 days post PDT 
and (B) tumor volumes at 14 days post PDT, with each point represent the mean of 4 
animals. Bars = SE. 
 
Based on the tumor necrosis study, selected parameters were chosen for the 
tumor growth delay studies. Tumors in all treatment groups exhibited growth 
inhibition at 7 days post PDT compared to the control group (Figure 2.17 A). 
However, after 14 days post PDT, only tumors treated at 1 h DLI at the light dose 
exhibited significant tumor growth inhibition (p<0.05) compared to the control 
group (Figure 2.17 B). At the light dose of 300 J/cm2, treatment at the 3 h DLI 
gave a better response when compared to the 6 h DLI. However, no significant 
growth inhibition of tumor was observed when treated at 3 and 6 h DLI compared 
to the control. 
 
 (A) (B) 
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2.4.11 Toxicity effects 
Mice were evaluated for survival after treatment with various parameters using 
Ce6 and Ce6-PVP. It was found that Ce6 alone was highly toxic at light doses 
exceeding 50 J/cm2 at 1 and 3 h drug-light interval (Table 2.4). Even at 6 h drug-
light interval, survival after treatment with 2.5 mg/kg of Ce6 and light dose of 100 
J/cm2  was 83%. On the contrary, Ce6-PVP was only toxic during the 1 h drug-
light interval irradiation (Table 2.5). Ce6-PVP phototoxicity was mainly attributed 
to the combination of high light (200 J/cm2) and high drug doses (5 mg/kg) during 
which high bioavailability of the photosensitizer in serum as well as in normal 
tissue was detected at 1 h. There was a positive correlation between increasing 
doses of light and drug and toxicity, at the 1 h drug-light interval irradiation. When 
both photosensitizers were compared at the same drug-light interval, Ce6 was 
found to be more toxic than Ce6-PVP. 
 
Table 2.4 The survival of mice was expressed as the number of mice that recovered 
from treatment 24 h post treatment with Ce6 alone.  
Mice were subjected to various parameters such as differing drug-light intervals, 










1 50 41.5 2.5 100 (3/3) 
1 100 85 5 0 (0/3) 
1 150 125 2.5 0 (0/3) 
1 150 125 3.5 0 (0/3) 
3 50 41.5 2.5 100 (4/4) 
3 100 85 2.5 0 (0/4) 
3 300 165 5 0 (0/4) 
6 100 85 2.5 83 (5/6) 
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Table 2.5 The survival of mice was expressed as the number of mice which recovered 
from treatment 24 h post treatment with Ce6-PVP.  
Mice were subjected to various parameters such as differing drug-light intervals, 










1 50 41.5 5.0 100 (3/3) 
1 100 85 2.5 100 (3/3) 
1 100 85 3.5 100 (3/3) 
1 100 85 5.0 100 (3/3) 
1 150 125 2.5 100 (3/3) 
1 150 125 3.5 86 (6/7) 
1 150 125 5.0 43 (3/7) 
1 200 165 2.5 0 (0/3) 
1 200 165 3.5 0 (0/3) 
1 200 165 5.0 0 (0/3) 
3 50 41.5 2.5 100 (3/3) 
3 100 85 2.5 100 (3/3) 
3 100 85 3.5 100 (3/3) 
3 100 85 5.0 100 (3/3) 
3 150 125 2.5 100 (3/3) 
3 150 125 3.5 100 (3/3) 
3 150 125 5.0 100 (3/3) 
3 200 165 2.5 100 (3/3) 
3 200 165 3.5 100 (3/3) 
3 200 165 5.0 100 (3/3) 
6 50 41.5 5.0 100 (3/3) 
6 300 165 5.0 100 (3/3) 














Figure 2.18 Cross section images of tumor and kidneys stained with Evan’s Blue dye 
using a camera mounted on a stereomicroscope. The white area represents necrotic 
tissue whereas the blue area represents viable tissue. (A) The depth of necrosis in tumor 
was found to be around 8 mm. (B) Control tumor was administered with photosensitizer 
but not irradiated with light. (C) The kidney located underneath the irradiated side of the 
flank, showed necrosis (white line) after PDT, indicating that the depth of necrosis could 
reach more than 1 cm. (D) The kidney located on the opposite site of irradiation did not 





















Figure 2.19 Ce6-PVP induced depth of necrosis on the rat tumor model. Drug-light 
interval: 3 h; drug dose: 2.5 mg/kg for Rat 1 and 5 mg/kg for Rat 2; light dose: 200 J/cm2 
and 165 mW/cm2 
 
In this experiment, mortality after PDT was mainly attributed to deeper 
penetration of necrosis beyond the tumors and into normal tissue. When post 
mortem was performed in mice treated at 1 h drug-light interval with high drug 
and light dose using Ce6-PVP, necrosis was observed to penetrate into the 
kidney (Figure 2.18). Total depth of necrosis was estimated to be around 1 - 1.2 
cm. Preliminary experiments were conducted on two SD rats tumor model in 
order to confirm the depth of necrosis induced by Ce6-PVP mediated PDT 
(Figure 2.19). When a dose of 2.5 mg/kg Ce6-PVP was administered for rat 1 
with a tumor height of 7.50 mm, complete tumor necrosis was found with a depth 
of 7.50 mm. When a higher dose of 5 mg/kg Ce6-PVP administered for rat 2, with 
a tumor height of 12.6 mm, the depth of tumor necrosis was found to be 
approximately 12 mm. Therefore, high-dose PDT at early time points using Ce6-
PVP require stringent precautions due to its phototoxic effects.  
 
A recent study had reported that PDT induced damage to other parts of organs 
besides the irradiated tumor [99]. Even death was reported in patients who 
underwent PDT treatment as a direct result of dose related toxicity [100]. 
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Therefore, determining the correct drug and light dosimetry plays a crucial role in 
PDT to avoid unnecessary damage to normal tissue and to secure survival post 
PDT. Incorporating Ce6 with PVP has resulted in a potent, water-soluble 
photosensitizer preparation with less toxicity. A study has shown a reduced 
toxicity of a drug when conjugated to PVP when compared to its parent 
compound [62]. Furthermore, it was suggested that by coupling PVP to 
potentially immunogenic drugs, enzymes and hormones, it may be possible to 
diminish allergic hazards and drug inactivation due to specific antibodies in 
prolonged treatments [101]. Therefore, it was hypothesized that PVP may be 
used to improve the pharmacological activity and to reduce phototoxic effects of 
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2.4.12 Correlation of Ce6-PVP uptake in serum and percentage of tumor necrosis 
at post PDT 
It was demonstrated that the intensity ratio of Ce6-PVP in tumor to healthy tissue 
of femoral muscle was higher compared to that of Ce6. This shows that Ce6 
achieved higher specificity in the PVP formulation compared with that of Ce6 
only. However, this higher specificity was not due to a higher permeability of the 
tumor tissue towards Ce6-PVP formulation. Rather, higher specificity was 
achieved through enhanced accumulation in tumor and rapid elimination of Ce6- 


















Figure 2.20 Correlation of percentage of necrosis post Ce6-PVP mediated PDT and 
level of Ce6-PVP in serum. The fluorescence intensity measured spectrometrically 
determined the level of Ce6-PVP in serum. Drug dose: 5.0 mg/kg, light dose of 200 
J/cm2 at 165 mW/cm2. Each bar represents a mean of 3 animals. Bars = SE.  
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Even though a high tumor to normal tissue selectivity ratio of the Ce6-PVP was 
observed at 3 – 6 h DLI, tumor regression study performed in this chapter did not 
show an improved tumor response after 2 weeks post PDT (Figure 2.17). It was 
hypothesized that by the time a high selectivity was achieved (3 – 6 h post drug 
administration), the threshold concentration of the photosensitizer to produce 
reactive cytotoxins (i.e. free radicals and singlet oxygen) was probably not 
sufficient to induce a complete PDT response, thus the poor tumor response. 
This led us to believe that the tumor response for Ce6-PVP mediated PDT was 
strongly dependent on the drug-light interval.  
 
A correlation between the percentage of tumor necrosis at post Ce6-PVP 
mediated PDT and the level of Ce6-PVP in serum was derived (Figure 2.20). The 
efficacy of Ce6-PVP mediated PDT was significantly more effective when 
irradiation was performed at 1 h DLI using high drug and light doses in which the 
drug level in the plasma was at its peak. The degree of relationship between the 
mean area of tumor necrosis after PDT and the mean fluorescence intensity of 
Ce6-PVP in serum was found to have a R2 value of 0.7613. This observation 
further suggests that the mechanism of action of Ce6-PVP was much dependent 
on the drug accumulation in the vasculature rather than in the tumor tissue. This 
is in accordance with other studies of another form of water soluble Ce6, NPe6, 
where its efficacy was reported to be attributed mainly to the destruction of tumor 
vasculature by PDT. Maximal tumor response was achieved when light 
irradiation started within 2 h post intravenous administration of NPe6 and this 
effectiveness decreased when light treatments were initiated after 6 h [102]. In 
another investigation by Saito et al., NPe6 was found primarily in the plasma 
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during the first 2 h [103]. Their results ascertained that the NPe6 efficacy is 
dependent on its levels in the plasma rather than in the tumor tissue. The efficacy 
of NPe6 could be improved by increasing the drug dose, but this had to be done 
at the expense of tissue selectivity [94]. However, it has been contended that the 
necrosis of a margin of normal tissue surrounding the tumor is deemed 
necessary to achieve tumor cure [104]. Interestingly, our studies showed that 
Ce6-PVP concentration in plasma correlated well with fluorescence intensity in 
the tumor tissue. It is known that photosensitizers with hydrophilic properties are 
primarily transported by serum albumin and localize in the vasculature of the 
tumor, whereas hydrophobic photosensitizers tend to bind to lipoproteins and are 
internalized by cells though receptor-mediated endocytosis [80]. Cunderlikova et 
al. have reported that a decrease in the pH increased Ce6 binding to lipoproteins 
thereby implying that protonation could change the target of the photosensitizer’s 
localization [105]. Ce6-PVP, being a hydrophilic compound, would tend to 
circulate in the blood and could be protonated in the proximity of a low pH 
environment of the tumor tissue and internalized by cells. This could explain the 
high level of fluorescence in blood as well as in the tumor tissue (Figure 2.10 and 
Figure 2.12).  
 
2.5 Conclusion 
Of late, constant efforts are being made to produce an ideal photosensitizer that 
is (i) a single compound; (ii) has increased absorbance in the red region of visible 
light; (iii) gives a high quantum yield of triplet formation; (iv) has good cytotoxic 
oxygen species generation; (v) shows increased selectivity for malignant tissue 
over normal tissue; (vi) and exhibits no dark toxicity. To date, Ce6-PVP seems to 
fulfill these requirements as an ideal photosensitizer. Polyvinylpyrrolidone in the 
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final formulation of Ce6-PVP ensures a higher relative bioavailability in healthy 
and tumor tissue compared to suspended chlorin, based on the same parenteral 
route of administration. This leads to several advantageous effects in the tumor 
tissues such as (a) high specific activity (the photosensitizing effect and the 
subsequent necrosis is higher than with chlorin alone) (b) selective accumulation 
in the tumor tissue, which is 2 to 4.8 times higher than with chlorin. It was 
demonstrated that Ce6-PVP accumulated selectively in a human bladder and 
nasopharyngeal tumor xenograft indicating the clinical potential in the detection 
of these cancer using fluorescence endoscopy. Fluorescence imaging modality 
may be able to identify the progression and margin of cancer in real-time, thereby 
providing a more sensitive and specific detection tool for bladder cancer. The 
preclinical evaluation of Ce6-PVP presented in this study has shown to have 
many desirable properties of an ideal photosensitizer and displays great potential 
to be an effective therapeutic agent. It was demonstrated that Ce6-PVP mediated 
PDT was most efficient when greatly localized in the circulating serum tumor as 
well as in the tumor tissue. The effectiveness of PDT also depends on the 
optimization of factors such as fluence (total light dose) and fluence rate. The 
frequency of complete tumor necrosis that can be achieved is considerably 
higher than those of chlorin (according to depth and frequency of complete tumor 
necrosis, inhibition of tumor growth) and Ce6-PVP has reduced systemic toxicity 
compared to Ce6 only at post PDT. 
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CHAPTER 3 
 
New formulation of chlorin e6 – polyvinylpyrrolidone shows improved selectivity 




The focus of this chapter is to compare both the temporal and spatial kinetics of 
fluorescence intensities and PDT efficacy of an improved formulation of Ce6-PVP 
compared to Ce6 delivered using dimethylsulfoxide (DMSO) or 0.9 % sodium 
chloride. The Ce6-PVP used in this chapter had a purity of > 92%. Fluorescence 
data at 1, 3 and 6 h post drug administration were fitted into nonlinear regression 
analysis and receiver operating curves. In vitro and in vivo photodynamic 
efficiency were also studied using peripheral mononuclear cells, K562 leukemic 
cells and MGH poorly differentiated human bladder carcinoma cells. Temporal 
and spatial fluorescence results showed that Ce6-PVP had the higher tumor to 
normal tissue ratio compared to the other formulations. The sensitivity and 
specificity derived from the area under the receiver operating characteristic curve 
shows that the formulations are able to discriminate tumor from peritumoral 
muscle in the following order: Ce6-PVP > Ce6 > Ce6-DMSO. The present study 
also evaluated the potential use of Ce6-PVP for fluorescence detection and PDT 
on NSCLC and SCLC xenografts. Human NSCLC (NCI-H460) and SCLC (NCI-
H526) tumor cell lines were used to establish tumor xenografts in the chick 
chorioallantoic membrane (CAM) model as well as in the Balb/c nude mice.  In 
the CAM model, Ce6-PVP was applied topically (1.0 mg/kg) and fluorescence 
intensity was charted at various time points. Tumor-bearing mice were given 
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intravenous administration of Ce6-PVP (2.0 mg/kg) and laser irradiation at 665 
nm (fluence of 150 J/cm2 and fluence rate of 125 mW/cm2). Fluorescence studies 
in CAM tumor xenografts showed that Ce6-PVP had a selective localization and 
a good accuracy in demarcating NSCLC compared to SCLC from normal 
surrounding CAM after 3 h post drug administration. Irradiation at 3 h drug-light 
interval showed greater tumor necrosis against human NSCLC xenografts in 
nude mice. SCLC xenografts were observed to express resistance to 
photosensitization with Ce6-PVP. In vitro PDT results proved that Ce6-PVP was 
found to induce selective phototoxicity in leukemic cells compared to peripheral 
mononuclear blood cells. In addition, light irradiation at 1 h was found to induce 
greater tumor necrosis without causing animal toxicity. In conclusion, PVP 
significantly enhanced the Ce6 concentration in tumors compared with Ce6 alone 
and increased the therapeutic index of phototreatment without any side effects. 
This findings highlight the importance of optimising formulations as a way to 
improve photosensitizer accumulation in tumor tissue. 
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3.2 Introduction 
Among the problems that are not yet adequately solved in the area of 
photosensitizer delivery are the difficulties in preparing pharmaceutical 
formulations that enable parenteral administration of the photosensitizer, poor 
tumoral selectivity, and a possible prolonged cutaneous photosensitivity due to 
slow elimination of the photosensitizer. Chlorins are promising photosensitizers 
with respect to their high phototoxic potential and relatively strong absorption in 
the red region of the visible spectrum leading to destruction of diseased tissue in 
deeper tissue layers. Although promising, chlorins are in general very lipophilic, 
making its administration in vivo relatively complicated.  Water-soluble chlorin 
derivatives have been known to be prepared through stabilization and chemical 
transformation of lipophilic chlorophylls into a freely water-soluble sodium salt 
mixture. However, aqueous formulations or emulsions may not be suitable for 
tetra- or polypyrrole-based structures such as chlorins as these photosensitizers 
have an inherent tendency to aggregate by molecular stacking, which can 
severely curtail subsequent photosensitization processes [106, 107]. Therefore, 
multiple means of delivering chlorin-based photosensitizers have been explored 
ranging from liposomal formulation, glycoconjugation, microspheres, entrapment 
in biodegradable nanoparticles, to the use of excipients such as 
dimethylsulfoxide (DMSO). Due the amphiphilic nature of DMSO, it is used 
frequently to dissolve chemicals with poor water solubility. But the toxicological 
consequence of its interaction with a photosensitizer still remains unclear. 
Biocompatible block copolymers are also used increasingly in the pharmaceutical 
industry to enhance drug solubility and bioavailability [108]. Polymer-
photosensitizer conjugation or encapsulation of the photosensitizer in colloidal 
carriers such as oil-dispersions, liposomes and polymeric particles has been 
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investigated [109, 110]. Polymers currently being used with chlorin derivatives 
are polyethyleneglycol and N - (2-hydroxypropyl) methacrylamide (HPMA) [56, 
58, 111].  
 
In the pursuit for strategies to optimize the photosensitizer Ce6 for improved 
fluorescence diagnosis and photodynamic therapy of cancer, formulation of Ce6 
with PVP was investigated. Ce6 has improved efficacy and has decreased side 
effects compared to first generation photosensitizers from hematoporphyrin 
derivatives. PVP is nontoxic, biocompatible, generally recognized as safe, and is 
a widely used soluble additive in the pharmaceutical area.  PVP is known to form 
water-soluble complexes with a number of pharmacological substances and 
investigations into the formation of PVP – complexes with drugs have been 
described [65, 112].  
 
In the previous chapters, the purity of Ce6 in the PVP formulation used in the 
experiments contained not less than 75% with the remaining composition 
consisting of purpurins [113].  In this chapter, the uptake and photodynamic 
activity of the newly improved formulation of Ce6-PVP was investigated. The 
weight ratio of the sodium salt of Ce6 and PVP remained at 1:1 and the purity 
level of Ce6 was optimized to 92 – 99 %.  
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3.3 Materials and methodology 
3.3.1 Photosensitizers and chemicals 
The earlier Ce6-PVP used in Chapter 2; hereafter designated as 75% Ce6-PVP. 
The new formulation of Ce6-PVP was manufactured by ORPEGEN Pharma 
GmbH, Heidelberg, Germany, the external collaborator for this research project. 
The new Ce6-PVP was relatively free of impurities and the purity of the drug is 
around 92 – 99 %. Reversed phased HPLC chromatograms were provided by 
ORPEGEN Pharma. The detection wavelength used in the spectrophotometric 
detector was set at 400 nm.  Instrument settings were optimized to obtain 
fragmentation spectra of chlorin e6 as follows: gradiet: 50 –100%, column: 
Lichrospher RP-18e 250 × 4.6 mm (Merck, Germany) and elution temperature: 
25°C. In both cases it was a co-lyophilisate of Ce6 sodium salt and PVP 
(pharmaceutical grade polymer, molecular mass ≈ 12,000 g/mol) in a 1:1 mass 
ratio. Ce6 sodium salt lyophilized without further addition of PVP and is readily 
soluble in aqueous solution. An alternate source of Ce6 in the acetic acid form 
was obtained from Frontier Scientific (Logan, Utah). It was dissolved in 
dimethylsulfoxide (DMSO), (Sigma, USA) to give a 1 mM stock solution; and 
diluted further with 0.9% sodium chloride (NaCl) to consititute a 10% DMSO 
concentration in the final preparation immediately before intravenous 
administration. 
 
3.3.2 In vitro photosensitizing efficacy 
To distinguish between necrotic and apoptotic cells following PDT, Annexin V 
binding and propidium iodide (PI) uptake were assessed by flow cytometry using 
a commercially available kit according to the instructions by the manufacturer. 
Peripheral mononuclear blood (PMN) cells obtained from healthy volunteers and 
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a K562 leukemic cell line were used for this experiment. Cells were incubated 
with 10 µM of either Ce6 or Ce6-PVP for 30 min before exposure to a light dose 
of 1 J/cm2. Cells were harvested and resuspended in binding buffer provided in 
the kit. Designated concentration of the Annexin V stock solution and PI stock 
solution were added to the cell suspension. After incubation for 10 min in the 
dark, the cells were immediately analyzed with a FACScan flow cytometer 
(Becton Dickinson) equipped with an excitation laser line at 488 nm. The FITC – 
Annexin V (green fluorescence) and the PI (orange fluorescence) were collected 
in log scale through 530 ± 20 nm and 575 ± 15 nm band pass filter respectively. 
 
3.3.3 Bladder tumor model 
Male Balb/c athymic nude mice, 6–8 weeks of age, weighing an average of 24 g 
were obtained from the Animal Resource Centre, Western Australia. The cells 
were cultured as a monolayer in RPMI-1640 medium supplemented with 10% 
fetal bovine serum, 1% non-essential amino acids (Gibco, USA), 1% sodium 
pyruvate (Gibco, USA), 100 units mL−1 penicillin–streptomycin (Gibco, USA) and 
incubated at 37°C, 95% humidity and 5% CO2. Before inoculation, the cell layer 
was washed with phosphate-buffered saline (PBS), trypsinized, and counted 
using a hemocytometer. Approximately 3.0 × 106 MGH cells in 150 µL of Hanks’ 
Balanced Salt Solution (Gibco, USA) were injected subcutaneously into the lower 
flanks of the mice. The animals were used for experiments when the tumors 
measured around 5 – 10 mm in diameter. All procedures were approved by the 
Institutional Animal Care and Use Committee, SingHealth, Singapore, in 
accordance with international standards.  
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3.3.4 Cell culture 
MGH, a poorly differentiated human bladder carcinoma cells were grown as 
subcutaneous tumor xenografts. The NCI-H460 cell line originates from human 
carcinoma of the large cell lung cancer. NCI-H526 cell lines originate from human 
carcinoma of the lung from the variant small cell lung cancer were obtained from 
the American Type Culture Collection, USA. NCI-H460 cells were cultured as a 
monolayer whereas NCI-H526 cells were cultured in suspension in RPMI-1640 
medium supplemented with 10 % fetal bovine serum, 1% non-essential amino 
acids (Gibco, USA), 1 % sodium pyruvate (Gibco, USA), 100 units/mL penicillin/ 
streptomycin (Gibco, USA) and incubated at 37°C, 95 % humidity and 5 % CO2. 
Before inoculation, the monolayer cells were washed with phosphate-buffered 
saline, trypsinized, and counted using a haemacytometer. Suspension cells were 
directly counted using a haemacytometer without trypsinization. 
 
3.3.5 Chick chorioallantoic membrane (CAM) tumor xenograft  
Fertilized chicken eggs were incubated at 37°C in a humidified atmosphere 
inside a hatching incubator equipped with an automatic rotator (Octagon 20, 
Brinsea, Somerset, UK). At embryo age (EA) 7, a window of about 1.5 cm was 
opened in the eggshell to detach the shell membrane from the developing CAM. 
Then, the window was sealed with sterilized parafilm to avoid contamination and 
the eggs were returned to the static incubator for further incubation until the day 
of experiments. On EA 9, approximately 5 x 106 NCI-H460 and NCI-H526 cells 
were inoculated on the CAM. The window of the eggs were resealed with sterile 
parafilm and returned to the static incubator. Grafted cells were allowed to grow 
on the CAM for up to 5 days. On EA 14, Ce6-PVP was dissolved in 0.9% sodium 
chloride to constitute a stock solution of 1 mg/mL. The stock solution was further 
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diluted to obtain a volume of 80 µL containing a dose of 1 mg/kg body weight of 
the chick’s embryo. The photosensitizer was applied on the entire surface of the 
CAM and left to incubate for 30 min. The window was resealed to avoid 
evaporation of the drug solution from the CAM. After 30 min incubation, imaging 
was performed at 0.5, 1, 2, 3, 4, 5, 6, and 24 h post drug administration. All 
procedures involving preparation and administration of the photosensitizer were 
conducted under low ambient lighting. 
 
3.3.6 Fluorescence imaging and image analysis 
Mice were randomly assigned to receive a dose of 2.5 mg/kg of the Ce6-PVP, 
Ce6 or Ce6-DMSO via tail vein injection. At 0, 1, 3 and 6 h post drug 
administration, mice were sacrificed and the skin overlaying the tumor was 
carefully removed to expose the tumor and normal peritumoral muscle for 
fluorescence imaging. A commercially available fluorescence endoscopic system 
(Karl Storz, Tuttlingen, Germany) was used to perform the macroscopic 
fluorescence digital imaging. A modified xenon short arc lamp (D – Light system 
in blue light mode, Karl Storz) filtered by a band pass filter (375 – 480 nm) was 
used for excitation of the photosensitizer in tissue. Fluorescence was captured 
via a sensitive CCD camera (Tricam SL PAL, Karl Storz) attached to an 
endoscope integrated with a long pass filter (cut-off wavelength 560 nm). The red 
channel registered the photosensitizer fluorescence and the blue channel 
captured the diffusely back-scattered excitation light. The distance between 
tissue surface and probe lens was standardized before imaging. This was done 
to minimize variations due to geometrical factors such as fluorescence excitation 
and collection angles. In addition, a short exposure of the surface of tumor and 
peritumoral muscle to the excitation light (10 s) was performed to avoid 
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excessive photobleaching effects. The intensities of the red (IR) and blue 
channels (IB) of the fluorescence images were extracted using the software 
MicroImage (Olympus Optical Co. (Europa) GmbH, Germany) according to the 
following equation: 
   
 IRN  =  [IRt/IBt] - [IRt0/IBt0] / (equimolar dose of Ce6 administered) 
 
with IRN = normalized relative fluorescence intensity of tumor or peritumoral 
muscle at time, t ,
 
after drug administration; IR = intensity of red channel; IB =  
intensity of blue channel; t = time in hours after drug administration; t0 =  time 
before photosensitizer administration. The red-to-blue intensity ratio algorithm is 
independent of the observation geometry, the distance between the endoscope 
tip and the observed tissue as well as the fluctuation of the excitation irradiance 
[26]. 
 
3.3.7 Nonlinear regression and statistical analysis of fluorescence intensity 
The normalized relative fluorescence intensities (after substraction of background 
signal of fluorescence intensities) versus time obtained from equations (1) were 
analyzed by means of nonlinear regression method (Graph-Pad PrismTM Version 
4.03) by fitting a three parameter monoexponential decay curve to fit the K, 
decay rate constant (in hours-1). Bi-exponential decay curves fit the data more 
poorly than the mono-exponential ones and were therefore not considered for the 
analysis. The validity of K in the mono-exponential model was verified with the 
test of runs in each case. For all of the fits, the test of runs did not detect any 
deviation from the model of monoexponential decay. To compare the fits of the 
Ce6 formulations to each data set, the K was compared using extra sum-of-
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squares F test by comparing a global fit (one shared best-fit K value for all the 
data sets) to individual fits (a different best-fit K value for each data set). For all 
the formulations, the F tests showed that the individual fits for tumor, peritumoral 
muscle and skin was determined as the preferred fit in the analysis. These ratios 
for tumor and peritumoral muscle from 1 to 6 h post drug administration were 
then analyzed for sensitivity and specificity in demarcating tumor from 
peritumoral muscle by fitting the data into the receiver operating characteristic 
(ROC) curve (Graph-Pad PrismTM Version 4.03). The ROC curve illustrates the 
tradeoff between sensitivity and specificity by plotting the tumor fluorescence 
against the peritumoral fluorescence for the different possible probability 
thresholds of a fluorescence diagnostic test of the various Ce6 formulations. 
White light imaging was used to confirm the presence of tumor and peritumoral 
muscle.  
 
3.3.8 Statistical analysis of fluorescence image 
To statistically evaluate the temporal fluorescence of Ce6-PVP, logistic 
regression and receiver operating characteristics (ROC) curve [115] was 
determined using the GraphPad software for Windows (GraphPad, San Diego, 
CA). The elimination rate constant of Ce6-PVP was calculated by a method fitting 
the data to a one-phase exponential decay equation. The validity of fitted curve 
was verified with the test of runs (F test) in each case. Area under the curve 
(AUC), P value, and cut-off point were obtained from the ROC curve. The area 
under the ROC curve measures accuracy of the fluorescence images. The 
accuracy of the ROC curve analysis is based on how well the fluorescence 
images discriminates the tumor region from the normal CAM, as defined by white 
light imaging. The closer the curve follows the left border and then the top border 
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of the ROC space, the more accurate the test. The closer the curve comes to the 
45-degree diagonal of the ROC space, the less accurate the test. In addition, 
likelihood ratios (where the likelihood ratio is defined as the ratio of the probability 
of the fluorescence signal for tumor to the probability of the fluorescence signal 
for normal region) were calculated to help determine the ‘best’ cut-off point to 
compare sensitivity and specificity between NSCLC and SCLC. 
 
3.3.9 Chemical extraction and spectrofluorimetry analysis 
After imaging at 1, 3 and 6 h, the following tissues were removed and rinsed with 
PBS: tumor, muscle, skin, liver, spleen, kidney, brain, heart, lung, large intestine 
and small intestine. The organs were then blotted dry on tissue paper, weighed 
and frozen at −80 °C until extraction. Samples of each tissue (15 – 35 mg) were 
mixed with 1 – 2 mL of SolvableTM (Packard Instrument, USA) and incubated at 
50°C for 16 h in the dark as described previously by Bellnier et al [116]. 
SolvableTM contains 3% N,N-dimethyl lauryl amine oxide, 3% 
alkyloxypolyethyleneoxyethanol and 2% sodium hydroxide in water. It was 
confirmed that this method did not affect the fluorescence property of Ce6 
(unpublished data). The fluorescence (λem = 665 nm) of the solubilized samples 
was measured by a spectrofluorophotometer (model RF-5301 PC, Shimadzu; λex 
= 400 nm). The level of fluorescence intensity of the tissue samples is 
proportional to the tissue concentration of Ce6. The background fluorescence 
before drug administration was also subtracted and was normalized to the weight 
of organs. Dunn’s multiple comparison test were performed on the various 
groups. Statistical significance was accepted at p < 0.05 
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3.3.10 PDT treatment on murine xenograft model 
Male Balb/c athymic (nu+/nu+) mice were used for tumor xenografting at the age 
of 8–10 weeks. Approximately 3.0 × 106 NCI-H460 and NCI-H526 cells 
suspended in 150 µL of Hank’s buffered saline solution were injected 
subcutaneously into both lower flanks of the mice. The animals were used for 
experiments when the tumors measured around 5-10 mm. For the bladder tumor 
model, a dose of 5 mg/kg of the photosensitizer was administered intravenously 
through the tail vein. For the lung tumor model, a dose of 2.0 mg/kg of the 
photosensitizer was administered intravenously. The mice were anaesthetized 
with 50 µL cocktail of ketamine hydrochloride (50 mg/mL, Trittau, Germany) and 
valium (1:1 vol/vol) through intraperitoneal injection. A portable diode laser 
(Ceralas PDT 665, Biolitec) emitting at a wavelength of 665 ± 3 nm was used for 
irradiation. The peak power output was calibrated to 1.65 W at the fiber tip before 
commencement of irradiation. The laser energy with a total fluence of 100 J/cm2 
and a fluence rate of 83 mW/cm2 was delivered to the surface of the bladder 
tumor via a silica fiber frontal light distributor (FD model, Medlight, Switzerland). 
For the lung tumor, a total fluence of 150 J/cm2 and afluence rate of 125 mW/cm2 
was delivered. The fiber was positioned to produce a 1.0 cm2 circular spot of light 
irradiation. Fluence rate was measured using a power meter (LaserCheck, 
Coherent, USA). PDT treatment was performed after a drug-light interval (DLI) of 
either 1, 3 or 6 h one tumor while the contralateral tumor that was not irradiated 
served as controls. All procedures were approved by the national experimental 
animal welfare institution (Institutional Animal Care and Use Committee, 
SingHealth, Singapore), in accordance with international standards. 
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3.3.11 Assessment of tumor response post PDT 
The evaluation of tumor necrosis was performed using Evans Blue (EB) (Merck, 
Germany) vital staining. At 48 h post PDT, 1% EB in PBS was injected 
intraperitoneally at a volume of 0.4 mL. Six hours later, mice were sacrificed and 
the tumors were excised. Gross images of the whole tumor were first taken for 
fractal analysis of blood vessel. Fractal analysis has been shown to be an 
effective technique for measuring the complexity of blood vascular networks 
(Kirchner et al., 1996). This kind of analysis can be summed up as simply a 
measure for space-filling. Rectangular region of interests which maximally 
covered the tumors were selected from the captured images. These images were 
inverted and skeletonized with a fixed thresholding. The fractal dimensions of the 
2-D binary images were then computed using the box-counting method [117]. 
The computed fractal dimension, Df, gives us a statistical measure of the space 
filled by the blood vessels. Then, around 2 – 3 mm thick cross-section slices 
were cut and imaged under a stereoscopic microscope (Stemi 2000C, Zeiss, 
Germany). The unstained area was attributed to tissue necrosis, whereas the 
stained area indicated viable tissue. Digital images were saved in JPEG format, 
and all analyses were carried out using NIH ImageJ 1.37v software. Each image 
captured had the same calibration values to allow uniformity in the processing of 
the images. The tumor was outlined using the freehand drawing tool to measure 
the total tumor area. Similarly the necrotic area of the tumor was measured. The 
percentage of necrosis was calculated as the necrotic area divided by the total 
tumor area multiplied by 100. Statistical analysis (Student t test) was used for 
multiple comparisons. The criterion for statistical significance was set at the 0.05 
level. 
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3.4 Results and discussions 
3.4.1 HPLC chromatogram of two formulations of Ce6-PVP and Ce6 
A representative chromatogram of the new Ce6-PVP with higher purity in normal 
phase conditions is shown in Figure 3.1. It was concluded that the new Ce6-PVP 

















Figure 3.1 HPLC chromatogram describing the chemical purity of 75% Ce6-PVP and 
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Figure 3.2 (A) Representative of flow cytometry analysis of PDT induced apoptosis and 
necrosis for PMN blood (normal) cells (left panel) and K562 leukemic cells (right panel) 
after treated with Ce6 and Ce6-PVP. Apoptosis and necrosis was detected through the 
accumulation of Annexin – V and propidium iodide (PI) stained cells respectively. Cells 
were incubated with a concentration of 10 µM of either Ce6 or Ce6-PVP for 30 min 
before light irradiation of 1 J/cm2. Three main subpopulations, corresponding to viable 
cells (lower left quadrant), apoptotic cells stained with Annexin – V (upper right 
quadrant), and dead/necrotic PI-stained cells (lower right quadrant), can be readily 
differentiated. (B) In terms of apoptosis, both Ce6 and Ce6-PVP demonstrated lower 
percentage of apoptotic cell death in PMN cells compared to K562 leukemic cells. 
However, Ce6 displayed higher photocytotoxicity in both PMN and K562 cells compared 
to Ce6-PVP, indicating the potency of Ce6. (C) When the total percentage of cell death 
(apoptosis and necrosis) was tabulated, Ce6 was found to induce significant cell death in 
PMN cells compared to Ce6-PVP, indicating toxicity to normal cells, while for K562 cells 
photocytotoxicity was comparable between the Ce6 and Ce6-PVP. For K562 cells, data 
for Ce6-PVP represent a mean value of 6 replicates while data for Ce6 represents a 
mean value of 3 replicates. For PMN cells, data for Ce6-PVP represent a mean value of 
15 replicates taken from 5 volunteers while data for Ce6 represents a mean value of 6 
replicates taken from 2 volunteers. Bars = SD. * p < 0.05 and ** p < 0.01 with respect to 
Ce6-PVP). 
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Ce6-PVP and Ce6 were evaluated for their photocytotoxicity against K562 
leukemic cell line and peripheral mononuclear cells (Figure 3.2). Necrotic cells 
were identified through PI staining and apoptotic cells were identified through 
Annexin V staining, detected by flow cytometry after PDT. Cells illuminated 
without the photosensitizers and cells kept in the dark in the presence of the 
photosensitizers did not present any significant loss of viability. For the K562 cell 
line, total dead cells were estimated to be around 90% and 100% for Ce6-PVP 
and Ce6 respectively. On the contrary, under the same treatment condition, the 
peripheral mononuclear blood cells treated with Ce6-PVP exhibited relatively 
lower percentage of total dead cells (70%, p < 0.01) compared to Ce6 (90%). 
Often, photosensitizers are administered in relatively high doses, which lead to 
nonspecific toxicity in normal cells. Thus it is of interest to evaluate the intrinsic 
sensitivity of normal (PMN cells) and cancerous (K562 cells) leukemia cells to 
PDT using Ce6 formulated with or without PVP using in vitro phototoxicity 
experiment that strictly controlled for light and photosensitizer exposure. In vitro 
Ce6-PVP mediated PDT studies demonstrated that leukemic cells were 
considerably more affected than PMN cells, supporting the hypothesis that Ce6-
PVP accumulated preferentially in tumor cells compared to normal cells. This is 
extremely important for the application of PDT in cancer, since Ce6-PVP is 
administered intravenously and is supposed to localize and kill only the malignant 
cells after light irradiation. A recent in vitro investigation on cervical and 
esophageal cancer cell lines determined that the mechanism of Ce6-PVP 
induced cell death involves the induction of ROS via a type I mechanism which 
resulted in the rapid increase in lactate dehydrogenase that suggested 
characteristics of necrotic cell death pathway [118]. In our experiment, more 
apoptotic cells were observed and this contrary results may be due to differences 
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in drug dosage, formulation, light dose/source and cell lines since work carried 
out by us and other groups has shown the proportion of PDT-induced apoptosis 
and necrosis is dependent on the treatment parameters used.  
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Figure 3.3 Comparison of biodistribution of Ce6-PVP, Ce6 and Ce6-DMSO in tumor, 
muscle and skin at 1, 3 and 6 h post drug administration respectively using chemical 
extraction method. For all data points, n = 4 ± SD. Statistical significance was calculated 
by two-way ANOVA with Bonferroni post hoc test (* p < 0.05; ** p < 0.01, *** p < 0.001 
with respect to Ce6). All Ce6-DMSO data points were statistically significant with respect 
to Ce6. 
 
The amount of photosensitizers from tumor, peritumoral muscle and skin were 
quantified using the chemical fluorescence extraction technique and cuvette-
based spectrofluorimetry (Figure 3.3). The amount of Ce6-PVP accumulation 
was significantly higher in the tumor, muscle and skin compared to Ce6 at all 
time points. Ce6-DMSO tumor accumulation was observed to increase 24 fold 
compared to Ce6 at 1 h. Similarly, Ce6-DMSO accumulation was higher in 
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to normal peritumoral muscle ratio for Ce6-PVP was higher compared to Ce6 
(Table 3.1) suggesting that Ce6-PVP has a good tumor tissues accumulation 
ratio, with no significant accumulation in other normal tissue. Although Ce6-
DMSO showed the highest tumor to normal peritumoral muscle ratio, it also 
resulted in higher accumulation in other normal organs. Figure 3.3 shows 
comparative biodistribution of Ce6-PVP, Ce6 and Ce6-DMSO in eight organs 
using chemical extraction method. The data demonstrates that the amount of 
drug was comparable in all the organs between Ce6 and Ce6-PVP. In contrast, 
the amount of the Ce6-DMSO accumulation was significantly 10-fold higher in 
the liver, spleen, kidney, brain, heart and lung. The most significant amount of 
photosensitizer detected from all of the tested formulations was concentrated in 
the small and large intestines with relatively similar concentrations. The 
accumulation of Ce6-PVP in tumor significantly exceeded liver, spleen, kidney, 
brain, and heart tissues compared to Ce6. 
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Figure 3.4 Comparison of biodistribution of Ce6-PVP, Ce6 and Ce6-DMSO in normal 
tissue of various organs in mice using chemical extraction method. Each data point 




Table 3.1 Comparison of tumor to normal tissue ratio in various organs after intravenous 
administration of 5 mg/kg Ce6-PVP, Ce6 or Ce6-DMSO.  
 Muscle Skin Liver Spleen Kidney Brain Heart Lung 
Ce6-PVP 1.8 1.5 2.0 23.5 10.1 16.6 15.5 2.9 
Ce6 1.0 0.4 1.2 2.9 3.0 3.9 3.1 4.3 
Ce6-DMSO 2.6 1.0 1.2 8.5 15.6 0.9 3.1 5.9 
Ratio was calculated by dividing the fluorescence intensity span of tumor to the 
fluorescence intensity span of the various tissues from 1 to 6 h post drug administration. 
The span was tabulated using nonlinear regression analysis. 
 
In vivo biodistribution data indicated that the tumor uptake of Ce6 in the PVP 
formulation was enhanced compared to Ce6 alone. At the same time, Ce6-PVP 
accumulation in the skin was also higher than Ce6 suggesting that Ce6-PVP has 
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the potential for skin photosensitivity in mice due to their relatively thin skin. 
However, this may not be a significant problem for human skin since human skin 
is considerably thicker than mice skin [119]. It was further confirmed that Ce6-
PVP had preferential tumor accumulation in comparison with all normal tissues, 
with tumor to normal tissue ratio ranging from 1.5 to 23.5 (Table 3.1). The 
excretion of organic photosensitizer normally starts from the liver into the bile via 
the gall bladder. The bile is routed into the duodenum where it was possible for 
unchanged Ce6 to be absorbed into the circulation a second time from the small 
intestine as well as being excreted via fecal elimination. Hence, high 
photosensitizer level was observed in the small and large intestines.  Not 
surprisingly, Ce6 delivered using DMSO showed 6-fold enhancement of Ce6 
accumulation in tumor, muscle and skin compared to Ce6 alone or Ce6-PVP. 
This was mainly due to the membrane penetrant-carrier properties of DMSO. 
However, the decay rate constant of Ce6-DMSO was found to be greater than 
the decay rate constant of Ce6 and Ce6-PVP in tumor. This resulted in rapid 
elimination Ce6-DMSO from the tumor tissues that could limit its therapeutic 
effect. Furthermore, it was an indication that the penetration effect provided by 
DMSO was irreversible in tumor and even in normal cells. Moreover, the 
enhanced uptake was indiscriminate and also accumulating in normal organs. 
This effect was clearly seen in our in vivo study. 
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Figure 3.4 ROC curves comparing fluorescence intensities of Ce6-PVP, Ce6 and Ce6-
DMSO for classifying tumor from peritumoral muscle. The areas under the curve (AUC) 
were then compared in order to make a fair judgment of the effectiveness of Ce6 
formulations without being constricted to single values of sensitivity and specificity, 
which largely depend on the cut-off fluorescence intensity value chosen to distinguish 
normal from malignant tissue. The closer the curve comes to the 45-degree diagonal 
solid line, the less accurate the fluorescence diagnostic. The following is a rough guide 
for classifying the accuracy of fluorescence intensities based on the AUC: 1 – 0.9 = 
excellent; 0.9 – 0.8 = good; 0.8 – 0.7 = fair; 0.7 – 0.6 = poor; and 0.6 – 0.5 = fail. The 
AUC for Ce6-PVP, Ce6 and Ce6-DMSO were 0.98 ± 0.02, 0.95 ±0.05 and 0.83 ± 0.1 
respectively. The ROC curves also potentially demonstrate how the fluorescence 
diagnostic scheme can be adjusted to obtain the desired degree of sensitivity at the cost 
of specificity. Ce6-PVP induced fluorescence showed the highest sensitivity and 
specificity in detecting tumor from peritumoral muscle. 
 
Figure 3.4 displays a ROC curve that illustrates the ability of Ce6, Ce6-PVP and 
Ce6-DMSO induced fluorescence to discriminate between tumors and 
peritumoral muscle. Area under the ROC curve was used to compare the 
sensitivity and specificity of the temporal fluorescence of the three formulations. 
A non-discriminative fluorescence has an area of 0.5. A perfect discriminative 
fluorescence has an area of 1.00. The area under the ROC curve was 0.98 ± 
0.02 for Ce6-PVP (p = 0.0001), 0.95 ± 0.05 for Ce6 (p = 0.003) and 0.83 ± 0.1 (p 
= 0.0246) for Ce6-DMSO. The optimal cut-off level of fluorescence intensity that 
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maximizes 100% sensitivity for Ce6-PVP yielded 83% specificity, but a lower 
specificity of 73% and 58% for Ce6 and Ce6-DMSO respectively. Thus. based on 
this results, Ce6-PVP induced fluorescence was found to yield high sensitivity 
and specificity in demarcating tumor from normal peritumoral muscle of the 
xenograft model compared to Ce6 alone and Ce6-DMSO. This data signifies that 
fluorescence imaging using Ce6-PVP could be clinically relevant for determining 
the location of invisible cancerous lesions/tissue. To further evaluate the effect of 
PVP on the retention rate of Ce6 fluorescence in comparison to Ce6 alone or 
Ce6 delivered using DMSO, the decay rate constant (K) of the photosensitizer 
fluorescence in tumor tissues have been estimated from 1 to 6 h post drug 
administration. Fluorescence intensity of Ce6-PVP (K = 0.1386 ± 0.04 hour -1) 
was retained longer in tumor compared to Ce6 (0.1755 ± 0.04 hour -1) and Ce6-
DMSO (0.2007 ± 0.08 hour -1). As such, the half-life was calculated to be 5.0, 
3.9 and 3.4 h for Ce6, Ce6-PVP and Ce6-DMSO respectively. 
 
The decrease in the constant decay rate of Ce6-PVP in tumor and muscle 
compared to Ce6 and Ce6-DMSO could also reflect the possibility that PVP may 
have a retention effect on the uptake of Ce6. At the moment, it was hypothesized 
that the major therapeutic effect of Ce6-PVP observed in this study was likely to 
have been the result of the traditional role of PVP as a plasma expander [120]. 
As with any effective plasma volume expander, PVP decreases the viscosity of 
blood by hemodilution and thus may dilute the active Ce6 in the circulation. 
Interestingly, PVP has also been reported to localize in malignant tumors [121] 
and remained mainly in blood with no specific normal tissue distribution [122]. 
Furthermore, the administration of PVP was found to cause significant decreases 
in the plasma concentrations of total cholesterol, phospholipid and triglyceride 
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concentrations in normal rats and hyperlipidemic human subjects [123, 124]. 
Therefore, another hypothesis that PVP has a biological effect on the in vivo 
transport of Ce6 seems to be an appealing one. 
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3.4.5 In vivo photodynamic therapy on tumor xenografts  
The extent of tumor necrosis in the MGH bladder tumor model was identified 
using vital staining with EB at 48 h post PDT (Figure 3.5). The results of these 
experiments are presented in Table 3.2. Complete tumor necrosis was achieved 
when irradiation was performed at 1 h drug-light interval using Ce6-PVP. At 3 h 
drug-light interval, Ce6-PVP treated tumors exhibited 40 ± 9.8 % necrosis. No 
adverse side effects were observed in any animal at post PDT after 
administration of Ce6-PVP. At the same drug and light dose, complete tumor 
necrosis was observed for only 67% of Ce6 treated animals at 3 h drug-light 
interval. Severe side effects were observed for animals treated at 1 h drug-light 











Figure 3.5 A representative macroscopic view of whole MGH tumor xenograft stained 
with Evans Blue dye at 48 h post PDT after treatment at 1 h drug-light interval mediated 
PDT with Ce6-PVP (A) and control tumor (with Ce6-PVP, no light irradiation) (B). 
Necrotic tumor tissue appeared white and was almost devoid of vital staining. Shrinkage 
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Table 3.2 A comparison of the percentage of necrotic tumor and survival of mice 
evaluated at 48 h post PDT after administration of 5 mg/kg Ce6-PVP, Ce6 or Ce6-
DMSO with irradiation at a fluence and fluence rate of 100 J/cm2 and 85 mW/cm2 
respectively. Each data point represents a mean of 3 – 5 animals.  
 
Percentage of necrotic tumor 
tissue, % Survival 
a
, % 
Drug-light interval, h Drug-light interval, h  
Photosensitizer 
1 3 1 3 
Ce6 NA b 100 c 0 67 
Ce6-PVP 100 40 ± 9.8 100 100 
Ce6-DMSO NA b NA b 0 0 
a The survival of mice was expressed as the number of mice which recovered from 
treatment at 24 h post treatment.  
b
 Tumor necrosis could not be evaluated in animals that died due to treatment toxicity.  
c
 Necrotic tissue was evaluated from the 67% animals that survived PDT. 
 
 
Fractal dimension analysis of tumor vasculature at post PDT were studied to 
draw some general preliminary conclusions on the effect of Ce6- PDT on tumor 
vasculature (Figure 3.6). The fractal dimension score indicates the amount of 
space-filled by blood vessels (Figure 3.7). Vessel fractal dimension was spatially 
heterogeneous. In the tumor treated with Ce6 at 3 h drug-light interval, fractal 
dimension was lower compared to tumor treated at 1 h drug-light interval and 
control, showing evidence of vascular occlusion. In Ce6-PVP treated tumors, 
however, fractal dimension did not differ from controls. 
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Figure 3.6 Extent of tumor vascular destruction following treatment with PDT post 
injection of Ce6 and Ce6-PVP at 1 (A, B) and 3 h (C, D) drug-light interval. The fractal 
dimension analysis was performed to evaluate the damage of tumor blood vessels post 
PDT. Shrinkage of tumor blood vessels was observed at post PDT. Control tumor with 












Figure 3.7 Preliminary analysis of tumor blood vessel fractal dimension on PDT treated 
tumor xenografts. Columns indicates the amount of space-filled by blood vessels; bars, 
standard deviation. Data analysis was only based on 1 animal for each treatment group. 
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1 h drug-light interval 3 h drug-light interval Control – no irradiation 
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The phototoxicity of Ce6, Ce6-PVP and Ce6-DMSO was examined in vivo using 
human bladder tumor-bearing mice. Ce6-PVP was found to cause greater tumor 
necrosis at 1 h compared to 3 h drug-light interval after exposure to 100 J/cm2 
delivered at 85 mW/cm2 as a single fraction without causing any side effects to 
the mice at post treatment. However, administration of Ce6 alone or Ce6-DMSO 
mediated PDT resulted in severe side effects (paralysis and death) at post PDT. 
This phenomenon of acute toxicity in animals with other modes of PDT has been 
reported previously [125].  Adverse side effects are mainly due to PDT induced 
damage to normal organs [99]. This could be due to the increased solubility of 
Ce6 by DMSO and thus the increased uptake of Ce6-DMSO in normal tissue 
which resulted in acute toxicity due to irradiation to the surrounding normal tissue 
[126]. Furthermore, many studies have reported adverse results with respect to 
DMSO effects on metabolism and toxicity of other xenobiotics. It is known that 
DMSO is not a biologically inert compound and combinations of DMSO with other 
toxic agents could constitute its greatest toxic potential [127]. Therefore, the 
interaction of DMSO with Ce6 suggests a serious toxicological implication that 
needs to be taken into consideration when giving parenteral administration. Post 
PDT toxicity observed for Ce6 alone can be attributed to the fact the chlorins is 
extremely potent photosensitizer. One known chlorin-based photosensitizer that 
was reported to have acute PDT toxicity effect is m-tetrahydroxyphenylchlorin 
[128]. In Chapter 2, it was demonstrated that using a formulation with PVP, a 
significant reduction in the post PDT systemic toxicity of Ce6 could be achieved. 
Because of this reduced toxicity, higher doses of Ce6-PVP than that of the parent 
drug can be used in PDT, allowing the treatment to be potentially repeated many 
times to improve efficacy without any adverse effects. However, it is important to 
note that PDT performed to date only used a single dose of Ce6 (e.g., 5 mg/kg). 
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A smaller dose of Ce6 may preclude PDT related toxicity in the animals, and this 
warrants further studies. 
 
3.4.6 Ce6-PVP induced fluorescence on human lung carcinoma  
Little is known about the comparative efficacy of PDT in treating non-small cell 
lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), despite ongoing 
clinical trials treating lung cancers. Lung cancer became one of the first cancers 
to be considered for PDT which has been used as an adjuvant treatment over the 
last 27 years [129]. Currently, PDT is used either to treat microinvasive 
endobronchial NSCLC or to palliate patients with completely or partially 
obstructing endobronchial NSCLC [130]. Despite the generally refractory nature 
of these type of tumors, central type of tumors with identifiable endobronchial 
lesions which could be easily accessed bronchoscopically for illumination have 
been successfully treated with PDT [131]. PDT can preserve lung function, 
limiting surgical trauma and postoperative pain as well as used in combination 
with other therapeutic modalities such as chemotherapy [130]. Photosensitizer-
induced fluorescence detection aimed at enhancing optical contrast to improve 
tumor visibility has been extensively investigated to develop ‘tumor selective’ 
imaging methods [132, 133]. The lack of tumor selectivity, complex 
pharmacokinetics and the fact that some photosensitizers may cause prolonged 
skin photosensitivity, make the clinical application of fluorescence detection and 
PDT more complex [134, 135]. These limitations have led to the development of 
second-generation photosensitizers, which usually produce shorter periods of 
photosensitivity, longer activation wavelengths, higher tumor-to-normal tissue 
concentration, excellent antitumor effect and higher quantum yields of 1O2 [136]. 
Studies showed that derivatives from chlorophylls are potent photosensitizers 
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[137, 138], of which mono-L-aspartyl chlorin e6 (NPe6, Laserphyrin) is 
undergoing clinical trials in Japan for the treatment of endobronchial lung cancer 
[139]. Fluorescence bronchoscopy has been reported to enhance the diagnostic 
accuracy and definition of the intra-epithelial cancer within the bronchi [140]. This 
technique has become more attractive for clinical use since more effective 2nd 
generations of photosensitizers have been clinically implemented and tested. 
Newer formulations of photosensitizers were intended to reduce common side 
effects such as skin photosensitivity, nausea, vomiting and transiently raised liver 
transaminase levels. Following the above rationale, the use of PVP in 
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Figure 3.8 Fluorescence imaging of lung cancers xenografted on the CAM model. 
Representative of white light images of NSCLC and SCLC grafted on CAM before 
administration of photosensitizer (A, C). Before incubation of Ce6-PVP, the CAM tumor 
xenografts were imaged under blue light illumination, to confirm that there was no 
autofluorescence. Tumor fluorescence images at 3 h post-topical administration of 1 
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As it was important to establish if cellular localization of Ce6-PVP was also 
exhibited in human lung tumor, the CAM tumor xenograft was employed here. It 
was demonstrated that this method of examining fluorescence uptake and 
retention in tissue explants on the CAM model provided a reliable means for 
direct, comparative visualization in situ of human tumors [141]. Inoculation of 
human NSCLC (NCI-H460) and SCLC (NCI-H526) into highly vascularized CAM 
led to the disseminated tumor growth on the surface of the CAM (Figure 3.8 A, 
C). Typical fluorescence intensity image of NSCLC and SCLC are illustrated in 
Figure 3.8 B and D, respectively. Intense red fluorescence was macroscopically 
visible in the tumor cells under blue light, as compared to non-malignant 
epithelium of the CAM after 30 minutes post incubation with Ce6-PVP. The 
fluorescence retention by the lung tumor xenografts after topical administration 
was quantitatively evaluated using image-processing techniques and charted as 
a function of time (Figure 3.9). High differential fluorescence intensity was 
observed between NSCLC xenografts and its surrounding normal CAM tissue 
compared to SCLC xenografts.  The average intensity of the red-to-blue intensity 
ratio of NSCLC xenograft was higher than that of SCLC xenograft. The 
fluorescence intensity elimination rate constant for NSCLC, SCLC and normal 
CAM was calculated to be 0.13, 0.25, and 0.38 min-1 respectively, suggesting 
that Ce6-PVP is being retained longer in NSCLC than SCLC. Normal CAM had a 
faster elimination rate of Ce6-PVP. 









Figure 3.9 Fluorescence kinetics of Ce6-PVP on NSCLC (▲) and SCLC (■) xenografted 
on CAM examined up to 24 h post topical drug administration. Values are expressed as 
red-to-blue intensity ratio of fluorescence images post administration of drug normalized 
with images before drug administration. For tumor, each point represents a mean of 5 
eggs whereas for normal (●), each point represents a mean of 10 eggs. Bars = standard 
error of the mean. Non-linear regression analysis demonstrated that all the curves were 
statistically different with each other. The elimination rate constant for NSCLC, SCLC 
and normal CAM was in the following order: NSCLC < SCLC < normal CAM. 
 
 
ROC curve analysis was applied from 0.5 to 5 h post administration of Ce6-PVP 
to validate the ability of the photosensitizer to discriminate NSCLC and SCLC 
from normal CAM membrane. The area under the curve (AUC) were then 
compared in order to make a fair judgment of the effectiveness of Ce6-PVP 
without being constricted to single values of sensitivity and specificity, which 
largely depend on the cut-off fluorescence intensity value chosen to distinguish 
normal from malignant region (Table 3.3). The following is a rough guide for 
classifying the accuracy of Ce6-PVP based on the AUC: 1 – 0.9 = excellent; 0.9 
– 0.8 = good; 0.8 – 0.7 = fair; 0.7 – 0.6 = poor; and 0.6 – 0.5 = fail. The AUC for 
NSCLC were 0.52, 0.68, and 0.66, at 0.5 h, 1 h and 2 h respectively (P values 
were not statistically significant) indicating that shorter exposure times resulted in 
lower accuracy. The greatest AUC was observed from 3 h post drug 































  104 
administration onwards: i.e. 0.88, 0.94 and 0.90 at 3 h, 4 h and 5 h respectively 
(all P values were statistically significant). For SCLC, the AUC were 0.52, 0.70, 
0.68, 0.70, 0.74, and 0.58 at 0.5 h, 1 h, 2 h, 3 h, 4 h and 5 h respectively (P 
values were not statistically significant). This result showed no improvement in 
fluorescence accuracy in demarcating SCLC from the normal surrounding CAM.  
 
Table 3.3 A comparison of areas under the ROC curves between NSCLC and SCLC at 
various time post drug administration. 
NSCLC SCLC 










0.5 0.52 0.9024 0.52 0.9025 
1 0.68 0.2704 0.70 0.2207 
2 0.66 0.3272 0.68 0.2704 
3 0.88 0.0200* 0.70 0.2207 
4 0.94 0.0071* 0.74 0.1417 
5 0.90 0.0143* 0.58 0.6242 
An area of 1 represents a perfect discrimination of tumor from normal tissue; an area of 
0.5 represents no discrimination between normal and abnormal. The P value indicates 
whether the area under the ROC is significantly different from 0.5. *If the P value is < 
0.05, the area under the ROC curve is significantly different (see description of statistical 
analysis). For tumors, each point represents a mean of 5 eggs whereas for normal, each 
point represents a mean of 10 eggs. 
 













Figure 3.10 Receiver operating characteristic curves illustrating the ability of Ce6-PVP 
to separate NSCLC (solid line) and SCLC (dotted line) from normal chorioallantoic 
membrane in the CAM model. The ROC curve of two indistinguishable populations (i.e. 
abnormal versus normal region), represented by the 45-degree line (area under the 
ROC curve = 0.5), is included for comparison. Area under the ROC curve was 0.82 ± 
0.04 (p < 0.0001) and 0.70 ± 0.05 (p = 0.0009118) for NSCLC and SCLC respectively. 
 
To evaluate the overall quality of fluorescence intensity discrimination between 
NSCLC and SCLC, a combined ROC was generated from 0.5 to 5 h post drug 
administration. The sensitivity and the specificity were calculated using different 
threshold (cut-off) values to distinguish healthy from malignant tissue (Figure 
3.10). For NSCLC, the highest combined sensitivity and specificity were 90% and 
78% (cut-off value > 4.0; likelihood ratio = 4.03), whereas for SCLC it was 57% 
and 79% respectively (cut-off value > 4.1; likelihood ratio = 2.68), implying that 
fluorescence mediated Ce6-PVP has distinctly higher rate of sensitivity for the 
detection of disseminated lesions of NSCLC than with SCLC.  















  106 
3.4.7 Ce6-PVP induced PDT on human lung carcinoma 
To determine the efficacy of Ce6-PVP mediated PDT, nude mice bearing NSCLC 
and SCLC tumors were administered with 2.0 mg/kg of the photosensitizer. PDT 
was performed on using light generated by a diode laser system (λ = 665 nm) at 
the light dose of 150 J/cm2 and fluence rate of 125 mW/cm2. The area of tumor 
necrosis was measured by Evan’s blue dye staining at 48 h post PDT. Strong 
heterogeneous staining was observed in the untreated controls (Figure 3.11 A, 
B) indicating occurrence of spontaneous, albeit limited necrosis, whereas in the 
PDT treated tumor, tissue damage was clearly evident as an unstained area (Fig 
3.11 C – F). NSCLC tumors irradiated at 3 and 6 h drug-light interval exhibited 
extent of tumor necrosis of 84 ± 7% and 50 ± 4% respectively. When PDT 
treatment was performed on SCLC models using the same parameter, it was 
observed that irradiation at 3 h drug-light interval resulted in 50 ± 9% of tumor 
necrosis while irradiation at 6 h drug-light interval resulted in 26 ± 8 % tumor 
necrosis. Thus, we conclude that SCLC was only moderately sensitive to Ce6-
PVP mediated PDT. 
 















Figure 3.11 A morphologic study of NSCLC and SCLC tumor damage efficiency using 
the method of vital staining with Evans blue at 48 h post Ce6-PVP mediated PDT. 
Strong homogeneous staining was observed in the untreated controls (A, B), whereas in 
the treated tumor at 3 h drug-light interval (DLI) (C, D) and at 6 h DLI (E, F), tissues 
damage was clearly distinguishable as an unstained area in the tumor. Drug dose: 2.0 
mg/kg; light dose: 150 J/cm2; 125 mW/cm2. Each data point is an average of at least 5 
animals, Bars = standard error of the mean. *The mean difference is significant at the 
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Almost all PDT studies were concerned with NSCLC due to the referral patterns 
in the clinics [131]. Although PDT has also been shown to be effective in the 
clinical treatment of SCLC [142], little preclinical data exist comparing the efficacy 
or tendency for resistance toward photosensitization between these two tumor 
histologies. In this study, a certain degree of resistance to PDT in SCLC 
xenografts observed. There are already a variety of molecular markers that have 
been implicated in the pathogenesis of SCLC [143] thus making it difficult to 
hypothesize the molecular basis of acquired resistance towards 
photosensitization in this experiments. Generally, in lung cancer four types of 
multidrug resistance have been identified, i.e., classical multidrug resistance 
(MDR), non-P-glycoprotein MDR (also called MRP), atypical MDR (mediated 
through altered expression of topoisomerases II) and lung resistance-related 
protein [144]. Previous evidence indicates that SCLC cell lines and tumors 
express multidrug resistance-associated protein i.e., MRP1, ATP binding 
cassette [ABC]C1 [145] and ABCG2 (ATP-binding cassette protein for breast 
cancer resistance protein)  [146] . Hence, one plausible reason to explain the 
lack of activity of Ce6-PVP in SCLC is the possible existence of ABC transporters 
of chlorin-based photosensitizers in this tumor histology. It was reported that 
cancer cell lines that expresses ABCG2 was found to efflux some of the 
chlorophyll based photosensitizers and thus may confer resistance to this 
treatment modality [147, 148]. It has been suggested that by inhibiting ABCG2 
transport using tyrosine kinase inhibitors (e.g. Gleevec), it is likely to be a more 
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3.5 Conclusion 
In conclusion, the studies demonstrated that the new formulation of Ce6-PVP 
has a higher sensitivity and specificity for tumors and is able to induce cell death 
in tumor following PDT without acute toxicity in mice compared to Ce6 alone or 
Ce6-DMSO. Photosensitization with Ce6-PVP for 3 hours of exposure time 
appeared to be most effective in detecting NSCLC in CAM model. Furthermore, 
PDT at 3 h drug-light interval resulted in a better tumor necrosis in NSCLC 
xenograft model. SCLC xenografts were found to manifest a certain degree of 
resistance to photosensitization with Ce6-PVP. Despite the limited activity of 
Ce6-PVP in the SCLC xenografts, it is conceivable that the combined modality of 
fluorescence imaging and targeted photodynamic therapy using Ce6-PVP may 
still have a potential role in SCLC. This warrants for additional studies on the 
molecular mechanisms of photosensitization resistance in SCLC to overcome 
this important clinical problem.  
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CHAPTER 4 
 
Membrane transport enhancement of chlorin e6 - polyvinylpyrrolidone and its 
photodynamic efficacy on the chick chorioallantoic model 
 
4.1 Summary 
The aim of this chapter is to investigate the use of Ce6–PVP for the detection of 
human bladder cancer cells (MGH) implanted on the chick chorioallantoic 
membrane (CAM) model. The CAM was used to model tumor spheroids that 
resemble small residual bladder tumors prior to vascularization. Uptake kinetics 
studies were determined for both systemic and topical administrations of Ce6–
PVP to the normal CAM as well as the MGH human bladder tumor implanted on 
CAM using fluorescence imaging technique. Rapid elimination of Ce6–PVP was 
observed following topical application compared to systemic administration in the 
normal CAM system. Ce6–PVP was found to localize selectively in the 
xenografted bladder tumor in contrast to the CAM tissue. Neither dark toxicity nor 
irritancy was observed on the CAM tissue at the dose of 2 mg/kg Ce6–PVP. 
Macroscopic fluorescence imaging showed that Ce6-PVP induced fluorescence 
had a higher sensitivity and specificity for delineating tumor from the surrounding 
normal CAM compared to Ce6 alone. The uptake ratio of Ce6-PVP to that of Ce6 
was found to have a 2-fold increase across the CAM, indicating that PVP was 
able to facilitate diffusion of Ce6 across membrane. Confocal laser scanning 
microscopy further confirmed the Ce6-PVP has better penetration in the CAM 
compared to Ce6.  In conclusion, the Ce6–PVP formulation appeared to have the 
potential as a fluorescent marker for fluorescence diagnosis of human bladder 
cancer. 
  111 
 4.2 Introduction 
Bladder cancer is a prevalent disease and is the sixth most common form of 
malignancy worldwide [37]. According to The Singapore Urological Association, it 
is the ninth most common cancer for males but much less frequent in females in 
Singapore. Mortality rates are very high due to the invasive nature of bladder 
cancer. Therefore, the best approach for management of bladder cancer aims at 
early detection as this allows for early treatment that gives more favorable 
prognosis and thereby reduces mortality rates. Regular white light cystoscopies 
with cold cup biopsies are the current methods used in the surveillance of high-
risk patients for recurrent bladder cancer. However, these methods are 
insufficient to detect all urothelial neoplasia especially flat lesions such as 
carcinoma in situ. Therefore, superior methods of detecting flat urothelial 
neoplasia with the use of specific fluorescent dyes are constantly being sought 
after.  
 
In recent years, enhanced visualization of bladder cancer with various 
photosensitizers has been reported [32-35]. However, only two photosensitizers, 
porfimer sodium (Photofrin®) and 5-aminolevulenic acid hexyl ester (Hexvix®), 
were approved for photodynamic therapy (PDT) and photodynamic diagnosis 
(PDD) of bladder cancer [33]. It was previously reported the use of 5-
aminolevulinic acid and hypericin in bladder cancer, concluding that the 
sensitivity of the fluorescence cystoscopy was greater than that of conventional 
cystoscopy [13, 36]. However, one setback is the formulation of lipophilic 
photosensitizers for the instillation into bladder cavities or systemic 
administration. With current formulations, the procedures are time consuming 
and demanding on the patients. Typically, bladder instillation take around 1 to 3 h 
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incubation to allow for selective accumulation of the photosensitizer in the tumor 
[37]. In the case of hypericin, human serum albumin (HSA) was used as 
solubilizing agent for the preparation of bladder instillation fluid. Hypericin was 
incubated in the bladder for 2 h before the PDD procedure [38]. Moreover, 
hypericin is also known to bind tightly to HSA due to which the bioavailability of 
the photosensitizer might be compromised. Recently, a water-soluble hypericin 
derivative (Hyp-S) using polyvinylpyrrolidone (PVP) as a carrier was reported to 
have shown improved water solubility as well as high affinity for cellular 
membranes [39]. In addition, N-methyl-pyrrolidone (NMP) was also proposed as 
a penetration enhancer for hypericin formulation that allowed faster response 
time [40].  
 
Studies have shown that therapeutic outcome of topical photosensitizer-based 
PDT is in part influenced by pharmaceutical and physicochemical considerations, 
such as tissue-penetration characteristics [150]. The delivery control of the 
photosensitizing agent into the cancer cells is one of the major factors, which 
directly affect the therapeutic efficiency of PDT. Ce6 is an asymmetric molecule 
bearing three ionizable carboxylic acid groups. It has been shown that Ce6 is a 
promising cancer phototherapeutic agent [78]. The conjugation of a trisodium salt 
of Ce6 to PVP, a water-soluble polymer, has been reported to improve its clinical 
efficacy [151]. In addition, Ce6-PVP has also been used in photodynamic 
inactivation against bacteria isolated from periodontal diseases, surgical site 
infections and diabetes foot infections [152, 153]. Previous reports from our 
laboratory have shown that the formulation of Ce6 with PVP is an effective 
photosensitizer for the application in photodynamic therapy and fluorescence 
diagnosis of cancer [126, 154, 155].  
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The potential to improve biological activity of topically administered drugs by co-
precipitation with PVP has been extensively investigated. PVP is a biocompatible 
water-soluble polymer with a fast dissolution rate. Numerous studies have shown 
enhanced dissolution rates of drugs in PVP. A maximum enhancement of drug 
dissolution is found when the ratio of drug to polymer in these systems is low. It 
has been proposed that the increased drug dissolution rate is a result of its 
presence as a high energy form, possibly in a non-crystalline state [156]. PVP is 
also often used to obtain an amorphous formulation and it has been shown that it 
is able to interact with weak carboxylic acids via hydrogen bonding.  
 
The chick chorioallantoic membrane (CAM) model is a convenient model for the 
study of early in vivo cancer research and drug delivery [157]. The use of CAM 
model for photosensitizer transport studies across membrane has been 
established [40]. For PDT of urological cancers, the application mode of 
photosensitizers is mostly by intravesical instillation. This environment can be 
simulated by topically applying the photosensitizers in the CAM [158], thereby 
providing a good correlation to the clinical environment of PDT. In the previoius 
chapters, extensive in vivo studies on murine model using Ce6-PVP suggested 
that PVP has a biological effect on the in vivo transport of Ce6. In this chapter, it 
was demonstrated that selective and enhanced visualization of human bladder 
cancer on the CAM tumor model was achieved through topical administration of 
Ce6-PVP.  The diffusion and penetration effect of Ce6 and Ce6-PVP on the CAM 
was also compared. The efficacy of Ce6-PVP as a topical photosensitizer for 
PDT was investigated using a range of light doses intended for irradiation in the 
bladder. 
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4.2.1 Theory: Fick’s Law of diffusion 
The diffusion of the photosensitizer over a membrane barrier was based on the 
theoretical principle of Fick’s Law (Figure 4.1) [150]. With appropriate 
measurement and characterization of the CAM, the diffusion coefficient of 
various formulations of photosensitizer can be calculated using the Fick’s first law 
of diffusion, which describes the passive diffusion of photosensitizer across the 
trans-membrane of CAM mathematically: 
 
   dm = D . A .(K1 . Cg – K2 . Cb)           (1) 
   dt  h 
            
dtdm  is the rate of appearance of drug at the site of absorption, 
D is the effective diffusion coefficient of the drug in the CAM, 
A is the surface area of the CAM available for absorption by passive diffusion 
(which is assumed to be circular and flat), 
K1 is the partition coefficient of drug between CAM and the fluid outside the CAM, 
Cg is the concentration of drug in solution in fluid at the site of absorption, 
K2 is the partition coefficient of drug between the CAM and the fluid inside the 
CAM, 
Cb is the concentration of drug inside the CAM at the site of absorption, 
h is the thickness of the CAM. 
 
Hence, K1.Cg and K2.Cb represent the concentrations of drug inside the CAM 
membrane at the fluid outside CAM/membrane interface and membrane/fluid 
inside CAM interface, respectively. The expression: 
 
     (K1 . Cg – K2 . Cb)            (2) 
    h                                    
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Figure 4.1 A diagrammatic representation of a photosensitizer transport model 
using CAM. The concentrations across the cells are represented in the top part of 
the figure. The concentration gradient across the membrane of thickness h is 
shown at steady state. Cg is not expected to equal C1 unless the partition 
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represents the concentration gradient of drug across the ‘membrane’. The fluid 
inside the CAM acts as a ‘sink’ for absorbed drug and ensures that the 
concentration of drug inside the CAM at the site of absorption is low in relation to 
the concentration of drug in solution in the fluids outside the CAM at the site of 
absorption, i.e. Cg>>Cb. The passive absorption process is driven solely by the 
concentration gradient of the diffusible species of the drug, which exists across 
the CAM/fluid barrier. Under such conditions that   K1.Cg>>K2.Cb   and thus (K1.Cg 
- K2.Cb) approximates to K1.Cg, the equation (1) may be written in the form: 
 
   dm = D  . A  . (K1 . Cg)            (3) 
   dt          h 
 
Therefore, this equation allows the comparison of diffusion coefficients of 
different formulations. 
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4.3 Material and methodology 
4.3.1 Photosensitizer preparation  
Ce6–PVP was dissolved in 0.9% sodium chloride to constitute a stock solution of 
1 mg/mL. On the day of treatment, the stock solution was diluted with 0.9% of 
sodium chloride (NaCl) to obtain a volume of 100 mL containing a dose of 2 
mg/kg body weight of the chick’s embryo. For transport study, Ce6-PVP and Ce6 
from ORPEGEN Pharma GmbH, Heidelberg, Germany was used. UV-VIS 
absorption spectra of the photosensitizers were recorded on a Shidmadzu UV-
VIS spectrophotometer. Fluorescence emissions spectra were recorded on a RF-
5301 PC Shidmadzu spectrofluorimeter. Emission spectra were obtained in the 
λem = 500 – 750 nm range, with excitation at λex = 400 nm. 
 








Figure 4.2 (A) Egg incubator and (B) Xenograft tumor on the CAM. 
 
Ce6-PVP was dissolved in 0.9 % sodium chloride to constitute a stock solution of 
1 mg/mL. On the day of treatment, the stock solution was diluted with 0.9 % of 
sodium chloride (NaCl) to obtain a volume of 100 µL containing a dose of 2 
mg/kg body weight of the chick’s embryo. Fertilized chicken eggs were obtained 
tumor 
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from the specific pathogen free facility of Agri-food and Veterinary Authority of 
Singapore. The eggs were cleaned with 70 % warm ethanol before placing them 
on trays with blunt ends upwards. Eggs were incubated at 37˚C in a humidified 
atmosphere inside a hatching incubator equipped with an automatic rotator 
(Octagon 20, Brinsea, Somerset, UK) (Figure 4.2). On embryo age (EA) 7, a 
window of about 1.5-2 cm was opened in the eggshell to detach the shell 
membrane from the developing CAM using sterilized forceps. Then, the window 
was sealed with sterilized parafilm to avoid contamination and the eggs were 
returned to the static incubator for further incubation until the day of experiments. 
For xenograft experiments, the CAM was prepared as mentioned earlier. Then 
on EA 9, approximately 3 x 106 MGH cells were harvested using routine cell 
culture techniques.  Cells were collected by centrifugation at 1,200 rpm for 5 min 
and the supernatant was discarded. Cells were drawn up into a sterile pipette 
and layered onto the CAM, avoiding contact between the CAM and the pipette. 
The window of the eggs were resealed with sterile parafilm and returned to the 
static incubator. Grafted cells were allowed to grow on the CAM for up to 5 days. 
Experimentations were only performed on eggs of EA 14 to EA 15 during which 
the eggs were mature, in order to minimize biological variations [159]. All 
experiments were performed in the tissue culture hood.  
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Figure 4.3 Topical administration of photosensitizer on CAM 
 
On EA 14, eggs were randomly placed in three groups; the first group received 
topical Ce6–PVP administration, the second group received systemic 
administration of Ce6–PVP, and the third group received topical administration of 
0.9% NaCl as control. For topical administration, 100 mL of the photosensitizer 
was applied on the entire surface of the CAM and left to incubate for 30 min 
(Figure 4.3). The windows were resealed to avoid evaporation of the drug 
solution from the CAM. Prior to imaging, the CAM area was washed thrice with 1 
mL of 0.9% NaCl saline to remove excess photosensitizer on the CAM tissue. 
For systemic administration, 100 mL of the photosensitizer was injected directly 
into the yolk sac using a 26- gauge needle syringe. After 30 min incubation, 
imaging was performed at various time points until 24 h post drug administration. 
During the interval between each imaging sessions, the eggs were sealed with 
fresh parafilms and returned to the static incubator to ensure viability of the 
embryo throughout the experiments. All procedures were conducted under low 
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ambient lighting. Fluorescence imaging was then performed using the Karl Storz 
fluorescence endoscopy system (Karl Storz, Tuttlingen, Germany) to compare 
fluorescence images between the two modes of photosensitizer administration. 
 
4.3.4 Fluorescence intensity imaging on CAM tumor model 
Fertilized chicken eggs were incubated at 37°C in a humidified atmosphere 
inside a hatching incubator equipped with an automatic rotator (Octagon 20, 
Brinsea, Somerset, UK). On embryo age (EA) 7, a window of about 1.5 cm was 
opened in the eggshell to detach the shell membrane from the developing CAM. 
Then, the window was sealed with sterilized parafilm to avoid contamination and 
the eggs were returned to the static incubator for further incubation until the day 
of experiments. On EA 9, approximately 10 x 106 MGH cells were harvested 
using routine cell culture techniques. Cells were collected by centrifugation at 
1200 rpm for 5 min and the supernatant was discarded. Cells were drawn up into 
a sterile pipette and layered onto the CAM, avoiding contact between the CAM 
and the pipette. The window of the eggs were resealed with sterile parafilm and 
returned to the static incubator. Grafted cells were allowed to grow on the CAM 
for up to 5 days. On EA 14, the eggs received a topical administration of 0.0625, 
0.0313 and 0.0156 mg/mL Ce6 or Ce6-PVP constituted in 0.9% sodium chloride. 
A volume of 500 µL of the photosensitizer was applied on the entire surface of 
the CAM and left to incubate for 30 min. The window was resealed to avoid 
evaporation of the drug solution from the CAM. After 30 min incubation, imaging 
was performed at 0.5, 1, 2, 3, 4, 5, and 6 h post drug administration. All 
procedures were conducted under low ambient lighting. Fluorescence images 
were attained using the Karl Storz fluorescence endoscopy system (Karl Storz, 
Tuttlingen, Germany). The intensities of the red and blue channels of the 
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fluorescence images were quantified using the software MicroImage (Olympus 
Optical Co. (Europa), Germany). The red channel registered the 
photosensitizer’s fluorescence and the blue channel captured the diffusely back-
scattered excitation light. By applying the red-to-blue intensity ratio as a 
diagnostic algorithm, the intensities of the red fluorescence of Ce6-PVP are 
determined as a function of time. Such algorithm is independent of the 
geometries of excitation/collection of signals and the power of excitation during 
the fluorescence imaging process. 
 
4.3.5 Statistical analysis of fluorescence image 
To statistically evaluate the fluorescence of Ce6-PVP, logistic regression and 
receiver operating characteristics (ROC) curve was determined using the 
GraphPad software (GraphPad, San Diego, USA). The elimination rate constant 
and fluorescence half-life (t1/2) values of Ce6 and Ce6-PVP were calculated by a 
method fitting the data to a one-phase exponential decay equation. The validity 
of the fitted curve was verified with the test of runs in each case. Area under the 
curve (AUC), P value, and cut-off point were obtained from the ROC curve. The 
area under the ROC curve measures accuracy of the fluorescence images. The 
accuracy of the ROC curve analysis is based on how well the fluorescence 
intensity discriminates the tumor region from the normal CAM. The closer the 
curve follows the left border and then the top border of the ROC space, the more 
accurate the fluorescence. The closer the curve comes to the 45-degree diagonal 
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4.3.6 Transport of photosensitizer across CAM 
One mL of 0.0625 mg/mL Ce6 or Ce6-PVP solution was instilled to cover the 
whole surface area of the CAM. The window was covered with parafilm to 
prevent evaporation of the solution and incubated for 30 min in the dark. After 
incubation, the remaining drug was removed from the CAM surfaces by using 
micropipettes. Each surface was washed once with 1 mL 0.9% w/v NaCl 
solutions to remove excess photosensitizer. Then 1 mL of solution in the receptor 
compartment of the egg was syringed out followed by harvesting the chick 
embryo for photosensitizer quantification. These samples were immediately 
frozen and kept at - 20°C for further analyses. The contact area of each CAM was 
assumed to be circular and the diameter of the CAM was measured thrice 
diagonally across the egg at approximately 60° from each other to cover the 
circumferential perimeter of the CAM when the egg was sitting upright.  For 
extraction of photosensitizers, 200 µL of the sample from the receptor 
compartment was dissolved in 800 µL of SolvableTM where as the chick embryo 
was dissolved in 4 mL of SolvableTM. These samples were then incubated at 50 
°C overnight followed by centrifugation at 1200 rpm. The emission intensity of 
Ce6 or Ce6-PVP in the resulting supernatant was determined 
spectrophotometrically (λex = 400 nm, λem = 665 nm) and assumed as the amount 
of uptake after correcting for weight of the chick embryo. 
 
4.3.7 Laser confocal fluorescence microscopy 
After an incubation period of 2 min with Ce6 or Ce6-PVP, the CAM was 
harvested and fixed immediately in 4% paraformaldehyde. The CAM was then 
embedded with optimal cutting compound (OCT) on the cryostat. Cryo-sections 
of 20 µm thickness were obtained and mounted on the microscope slides for 
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confocal fluorescence imaging (Carl Zeiss, LSM 510, Germany). A 488 nm argon 
laser was used to excite the tissue. Fluorescence emissions in the wavelength 
range of 665 – 670 nm was split by a dichroic filter and detected through a band 
pass filter. Voltage gain, PMT voltage and sensitivity (contrast, brightness, and 
filters) were fixed for all fields and slides imaged. The images were analysed 
using an image analysis software package. Whole images were analysed to 
determine relative fluorescence intensities after correction for background 
autofluorescence. Digital quantification was carried out using contour 
superimposition where the contour of the region of interest was outlined and the 
pixel intensities per unit area determined. 
 
4.3.8 Photodynamic therapy of CAM model 
A portable diode laser (Ceralas PDT 665, Biolitec) emitting at a wavelength of 
665 ± 3 nm was used for irradiation on the CAM model. The peak power output 
was calibrated to 1.65 – 1.75 W at the bulb-shaped diffusing fiber tip (Medlight, 
Lausanne, Switzerland) before commencement of irradiation. Fluence rate was 
measured using a power meter (LaserCheck, Coherent). PDT treatment were 
designed to study the effect of increasing light doses: 1 J/cm2 delivered at 1 
mW/cm2, 10 J/cm2 delivered at 10 mW/cm2, 15 J/cm2 delivered at 15 mW/cm2 
and 20 J/cm2 delivered at 20 mW/cm2) and the fluence rate. All experimentation 
was performed under dim lighting. 
 
4.3.9 Flow cytometry analysis 
After 1 – 2 h post PDT treatment on the CAM, tumors and adjacent tissues were 
harvested.  The tissues were meshed and put through a 70 µm cell strainer 
(Becton Dickinson, USA) to obtain single cell suspension.  According to the 
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manufacturer’s protocol, all cells were washed with cold PBS and stained with 
the dual dyes, namely YO-PRO-1 and Propidium Iodide (PI) nucleic acid stains 
(Vybrant Apoptosis Assay Kit #4, Molecular Probes, USA). After 30 mins 
incubation on ice, cells were washed in 1 mL of PBS. Erythrocytes were lysed 
using 500 µl of FACSLysing Solution (1:10 dilution) and cells were analysed 
using the flow cytometer (FACS Calibur; Becton Dickinson, USA) at excitation 
wavelength of 488nm.  Viable cells do not take up any of the dyes and showed 
low fluorescence.  Cells undergoing early apoptosis will be more permeable to 
YO-PRO-1 dye while cells that are in the late apoptosis and secondary necrosis 
will uptake both YO-PRO-1 and PI dye. The uptake proportion of fluorescence 
dyes was quantified using CellQuest software (Becton Dickson). 
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4.4 Results and discussion 
4.4.1 Multicellular spheroids on the CAM model  
The CAM model serves as a convenient model for the study of PDD effects [141] 
This model has several advantages including its simplicity, rapidity, sensitivity, 
ease of performance and its relatively lower cost, thus suitable for large-scale 
screening. Here, we have demonstrated that the CAM can be used as a three 
dimensional short-term cell culture system to culture poorly differentiated human 
bladder cancer  cells (Figure 4.4). After 2 days of cell inoculation, there were 
visible opaque areas on the CAM membranes and a formation of fine capillaries 
in the tumor seeding area, indicating tumor growth [141]. The well vascularized 
CAM is a suitable system for in vivo induction of tumor for cancer research. This 
model was used to achieve highly reliable growth of established human prostate 
cancer cell lines [160], endometrium tissue [161] and human larynx carcinoma 
cells [162] as to name just a few. The extra-embryonic membrane acts as an 
excellent host to grow human cells since developing eggs are not yet 
immunocompetent, thereby enabling the grafting of the foreign cells. In contrast 
to conventional in-vitro cell cultures, 3-dimensional cultures using the CAM model 
may preserve specific biochemical and morphological features similar to the 
corresponding tissues in vivo. A major advantage of establishing 3-dimensional, 
spherical aggregate from permanent cell line on the CAM is that basic 
mechanisms of cell growth, proliferation, and differentiation can be studied in a 
reproducible format. Multicellular spheroids have been used as surrogates of tiny 
tumors for studying distribution and efficacy of chemotherapeutic agents. These 
spheroids resemble small residual tumors prior to vascularization. 





































Figure 4.4 Xenografting of tumor spheroids on the CAM model. (A) MGH tumor (tu) was 
xenografted on the CAM. (B) Formation of neovasculature (arrow) surrounding the 
implanted cells after 2 days of xenografting. (C). Formation of spheroid like structure of 
the tumor on the CAM. 
 
Low magnification view of the 
tumor cell implanted on the CAM 
High magnification view of the tumor cell 
at day 2 post xenografting 
tumor 
Formation of tumor spheroids of the MGH tumor 
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4.4.2 Fluorescence imaging of Ce6-PVP in normal CAM 
Following systemic administration of Ce6-PVP, non selective red fluorescence on 
the CAM was observed upon excitation of the blue light at 0.5, 4 and 24 h post 
administration (Figure 4.5). However when Ce6-PVP was applied topically, non 
selective red fluorescence was only observed at 0.5 h post administration. 
Minimal fluorescence was observed at 4 h post administration and by 24 h, no 
fluorescence was observed on the CAM. Ce6-PVP seemed to localize in the 
vasculature of the CAM as well at 24 h for systemic administration and at  0.5 h 
for topical administration. In the context of this report, the CAM model closely 
simulates a PDT clinical environment of human bladder cancer in terms of (a) 
formation of superficial tumors, (b) mode of photosensitizer application by topical 
administration via intravesical instillation, and (c) the extraembryonic membrane 
mimic of the bladder mucosa. After 30 min of topical or systemic administration of 
the photosensitizer, non selective red fluorescence on the normal CAM was 
observed upon excitation of the blue light. The photosensitizer seemed to 
localize in the vasculature of the CAM as well. The fluorescence kinetics were 
tabulated using red to blue ratiometric analysis and the data was fitted with a 
logarithmic regression trendline (Figure 4.6). Overall, fluorescence on the CAM 
showed a time dependent decrease for both topical and systemic applications. 
For topical application, fluorescence peaked soon after 30 min of drug 
incubation. Fluorescence remained high up to 1 h post administration and then 
started to decrease thereafter. When the data was fitted with the logarithmic 
trendline, the correlation coefficient for topical and systemic administrations were 
found to be 0.89 and 0.36 respectively, indicating that the decreasing rate of 
fluorescence from the normal CAM after topical administration was faster 
compared to the systemic administration of the drug.  
















Figure 4.5 Representative images of normal CAM before and after administration of the 
Ce6-PVP. CAM before administration of the photosensitizer under white light and blue 
light mode (A-B). CAM fluorescence at 0.5, 4 and 24 h after systemic (C-E) and topical 
(F-H) administration of the photosensitizer. 
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Figure 4.6 The Ce6-PVP fluorescence kinetics on normal CAM examined up to 24 h 
post drug systemic administration (■) and topical administration (▼). Values are 
expressed as fluorescence intensities after normalization with CAM before drug 
administration. Each point represents a mean of 5-measurements/6 eggs/time point. 









































  130 




















Figure 4.7 Fluorescence imaging of MGH human bladder tumor xenografted on the 
CAM model. (A) White light image of the tumor before drug administration, (B) Ce6-PVP 
induced red fluorescence in tumor imaged under blue light illumination at 3 h post drug 
administration. Minimal fluorescence was observed in the adjacent normal CAM 
suggesting a faster clearance rate from normal tissue of the CAM. (C) By displaying the 
fluorescent image in a pseudo color using simple image processing technique, a clear 
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Having determined the clearance rates from the two modes of drug 
administration, the topically administered mode was used to study the 
photosensitizer on the CAM tumor model. The fluorescence retention of Ce6 and 
Ce6-PVP by the MGH bladder tumor xenografts was assessed using image-
processing techniques (Figure 4.7). Before incubation of the photosensitizers, the 
CAM tumor xenografts were imaged under blue light illumination, to ensure that 
there was no autofluorescence. After topical administration of Ce6-PVP, an 
intense red fluorescence in the bladder tumor xenografts was observed, 
suggesting uptake and localization in the malignant cells on the CAM. 
Fluorescence in the normal CAM tissue was lower compared to fluorescence in 
the tumor tissue, suggesting a faster clearance rate from normal tissue of the 
CAM. When the time-dependent evolution of the fluorescence was plotted and 
fitted with non-linear regression analysis, a higher mean retention profile of Ce6-
PVP was observed compared to Ce6. The fluorescence intensity elimination rate 
constant for tumor and normal CAM after Ce6 administration was calculated to 
be 0.19 and 0.21 min-1 respectively. For Ce6-PVP, elimination rate constant for 
tumor and normal was calculated to be 0.02 and 0.18 min-1 for respectively. Half-
life of Ce6-PVP in tumor was approximately 9 times longer than Ce6, suggesting 
that Ce6-PVP is being retained longer in the tumor. No difference in half-life of 
both photosensitizers was observed in the normal CAM.  














Figure 4.8 The Ce6–PVP fluorescence kinetics on normal CAM (●) and bladder tumor 
cell xenografts on CAM (■) plotted against time. The CAM was topically incubated with 
the drug for 30 min prior to the fluorescence measurement. A logarithmic trendline (solid 
line) was used to best fit a curve to the data. Higher fluorescence intensity was observed 
in the tumor xenografts compared to the normal CAM tissue. Each point represents a 
mean of 7 eggs. Bars = SE. 
 
 
Fluorescence kinetics on normal and tumor CAM were charted as a function of 
time (Figure 4.8). High differential fluorescence intensity was observed between 
tumor and normal CAM tissue, indicating preferential localization of Ce6-PVP in 
the bladder tumor. It was also observed that fluorescence in the tumor remained 
high in the first 2 h post drug administration. Subsequently, fluorescence started 
to decrease but still displayed sustained fluorescence for up to 4 h compared to 
normal. This suggested that fluorescence diagnosis may be delayed as tumor 
fluorescence will still be adequate for 4 h after topical administration of drug. 















Figure 4.9 A scatter plot comparing the fluorescence intensity in tumor and the adjacent 
normal CAM tissue was compiled from 1 – 5 h post topical drug administration. The 
points on the scatter plot are normalized individual measurements from 24 eggs. The 
dotted line is the cut-off fluorescence intensity threshold derived from the ROC curve to 
classify tumor from normal tissue with a sensitivity and specificity of 70.8% (95% CI 
48.9% to 87.4%) and 83.3% (95% CI 62.6% to 95.3%) respectively. 
 
The fluorescence retention from 1 to 5 h post topical administration of Ce6-PVP 
in bladder tumor xenografts on CAM was tabulated using the red to blue ratio 
algorithm and fitted into a ROC curve to validate the ability of Ce6-PVP to 
discriminate tumor from adjacent normal CAM membrane. By applying a cut-off 
value to these ratios as a diagnostic criterion, it allowed the generation of 
sensitivity and specificity values to distinguish tumor from healthy CAM. A cut-off 
red to blue ratio of > 1.08 gave the highest combined sensitivity and specificity of 
70.8% (95% CI 48.9% to 87.4%) and 83.3% (95% CI 62.6% to 95.3%) 
respectively (Figure 4.9). Raising the value to > 1.33 gave the sensitivity and 
specificity values of 62.5% (95% CI 40.59% to 81.20%) and 91.2% (95% CI 
73.0% to 99.0%) respectively. 
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In PDT of the bladder, the favored method for administration of photosensitizer is 
through intravesical instillation because of the non-existence of substantial side 
effects or systemic photosensitivity [163]. In this context, this report has 
demonstrated that Ce6-PVP may be used as a topical formulation as it allows for 
fast tumor accumulation and rapid clearance. In the clinical setting, this is a major 
advantage as it enables shorter drug application time while retaining tumor 
selectivity for reasonable time window without the associated prolonged 
photosensitivity. This in turn improve patient compliance for fluorescence 
diagnosis procedures., The fluorescence kinetics of the photosensitizer was 
charted by applying post digital image processing. Although the data presented 
here is semi-quantitative, the ability to non-invasively measure the fluorescence 
of the photosensitizer represents a straightforward method to correlate drug 
dynamics in the tissue. Furthermore, the Ce6 fluorescence was excited by a 
xenon-arc lamp fluorescence designed for the excitation of ALA-induced PPIX 
fluorescence. This indicates that Ce6 can be used as an alternative fluorescent 
marker with the existing Karl Storz fluorescence endoscope system without 
modification. 
 
A combined ROC curve analysis  was performed from 0.5 to 5 h post 
administration of Ce6 and Ce6-PVP to validate the ability of the photosensitizers 
to discriminate tumor from normal CAM membrane (Table 4.1). The area under 
the curve (AUC) were then compared in order to make a fair judgment of the 
effectiveness of the photo-sensitizers without being constricted to single values 
of sensitivity and specificity, which largely depend on the cut-off fluorescence 
intensity value chosen to distinguish normal from malignant region. The AUC for 
Ce6 and Ce6-PVP were 0.83 ± 0.06 and 0.99 ± 0.01 respectively (p < 0.001) 
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indicating that Ce6-PVP has better accuracy. The sensitivity and the specificity 
were calculated using different threshold (cut-off) values to distinguish healthy 
CAM from tumor. For Ce6, the highest combined specificity and sensitivity were 
79.2% and 79.2% (cut-off value > 4.0), whereas for Ce6-PVP it was 81.8% and 
98.0% respectively (cut-off value > 4.1), implying that fluorescence mediated 
Ce6-PVP has distinctly higher rate of sensitivity for the detection of MGH tumor. 
In order to correlate drug dose to the selectivity and sensitivity of Ce6-PVP 
induced fluorescence on tumor, ROC curves were generated for 3 serial dilution 
of Ce6-PVP dose. Selectivity and sensitivity was observed to be drug dose 
dependent (Figure 4.10). Area under the ROC curve was 0.83 ± 0.02, 0.78 ± 
0.02 and 0.79 ± 0.03 for 0.0625 and 0.0313 and 0.016 mg/mL respectively. 
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Figure 4.10 (A) Representative images of MGH tumor (tu) xenografted on the CAM 
under white light. (B) Selective red fluorescence was observed on the MGH tumor at 3 h 
post topical administration of Ce6-PVP while no fluorescence was observed on the 
normal CAM tissue. (C) Receiver operating characteristic (ROC) curves illustrating the 
ability of various drug dose of Ce6-PVP to separate MGH tumor from adjacent normal 
chorioallantoic membrane (p< 0.0001). The ROC curve of two indistinguishable 
populations (i.e. tumor versus normal region), represented by the 45-degree line (area 
under the ROC curve = 0.5), is included for comparison. Area under the ROC curve was 
0.83 ± 0.02, 0.78 ± 0.02 and 0.79 ± 0.03 for 0.0625 and 0.0313 and 0.016 mg/mL 
respectively. The y axis represents the specificity of the Ce6-PVP induced fluorescence 
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Table 4.1 A comparision of half-life, specificity and sensitivity of Ce6 and Ce6-PVP in 
tumor and normal tissue on the CAM model.  
Non-linear regression of time-dependent changes in fluorescence was used to estimate 
the decay rate constant (K) and half-life from 1 to 5 h post topical administration of Ce6 
and Ce6-PVP in MGH tumor and normal CAM. Half-life = 0.69/K; CI = confidence 
interval; *p < 0.0001 
Ce6 Ce6-PVP 
Best-fit values 
Tumor Normal Tumor Normal 
K 0.19 ± 0.04 0.21 ± 0.08 0.02 ± 0.01 0.18 ± 0.03 
Half life, h 3.7 3.4 34.5 3.8 
Area under the ROC 
curve 
0.8316 ± 0.06* 0.9909 ± 0.01* 
Specificity, % 79.2 (CI 57.9 to 92.9) 81.8 (CI 70.4 to 90.2) 
Sensitivity, % 79.2 (CI 57.9 to 92.9) 98.0 (CI 89.4 to 99.9) 
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4.4.4 Membrane transport study 
This experiment aimed to study the effect of PVP on the uptake of Ce6 across 
membrane using CAM as a drug transport model. Four parameters were 
extracted from the experimental eggs to determine the effectiveness of PVP for 
transporting Ce6 into the membrane after topical application. The thickness of 
the CAM was determined using OCT imaging (Figure 4.11). The average 
thickness was determined to be 100 ± 1.9 µm. Equal volume and concentration 
of Ce6 or Ce6-PVP was applied topically for 30 min on the CAM. A comparison 
between the uptake of Ce6-PVP transported across the CAM in the receptor 
compartment was approximately double compared to Ce6 (0.055 ± 0.0135 and 
0.030 ± 0.003 a.u., respectively, p = 0.0464) (Figure 4.12 A). Since the 
experimental conditions were similar, the difference in the amount of 
photosensitizer transported can be inferred as due to differences in membrane 
permeability. The diffusion coefficient tabulated using Ficks’s law (Eq. (1)), for 
Ce6-PVP was found to be 1.4 fold higher compared to Ce6 indicating a higher 
diffusivity (Figure 4.12 B). However, the diffusion coefficient was not statiscally 
significant. Chick embryos were excised and the photosensitizer were extracted 
and analysed for fluorescence intensities per gram of tissue (Figure  4.12 C). The 
uptake of Ce6-PVP by the chick embryos was roughly two fold lower when 
compared with that of the Ce6 (0.012 ± 0.002 and 0.009 ± 0.002 intensity/g, 












Figure 4.11 Optical coherence tomography (OCT) imaging of the CAM. OCT is a high-
resolution noninvasive imaging technique based on laser interferometry, used to assess 
CAM thickness. The chorionic epithelium, mesoderm and allantoic epithelium layers can 
be visualized in the OCT structural image. The thickness of the CAM was estimated to 
















Figure 4.12 Drug transport study comparing Ce6 and Ce6-PVP in the CAM model. (A) 
Uptake studies of Ce6 and Ce6-PVP in the receptor chamber, (B) comparison of 
diffusion coefficient of Ce6 and Ce6-PVP across the CAM. *p < 0.05 and (C) uptake 




























































































(B) Diffusion coefficient 
(C) Chick embryo 
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Many drug formulations that include the use of polymers to affect the rate of drug 
delivery have been extensively studied. PVP has been utilized to increase the 
solubility of the drug and modulates the delivery of the drug from the composition 
and through the target tissue. Likewise, many investigations in the area of 
photobiology have focused on ways to develop formulation of photosensitizer to 
improve drug selectivity in tumor tissue in order to enhance PDT efficacy. It has 
been found that topical application of photosensitizer is effective for 
photodynamic therapy in superficial bladder cancer [152]. Although the bladder is 
an easily accessible organ for topical treatment, a glycosaminoglycan layer on 
the bladder mucosa can prevent the sufficient uptake and integration of many 
intravesically applied therapeutic compounds [153]. Therefore, the use of PVP 
photosensitizer is expected to overcome this problem. To address the important 
question of whether PVP enhances the transport of Ce6 across membrane, 
transport experiments were designed using the CAM model to assess uptake 
and diffusion coefficient of the photosensitizers using the assumption that 
diffusion was the dominant process for Ce6-PVP distribution. No other published 
data from experimental studies has reported on the effect of PVP on the 
transport of Ce6. PVP was found to increase the transport of Ce6 and acted as a 
co-enhancer for transmembrane delivery. In addition, under the experimental 
conditions employed in this study, enhanced diffusion coefficient was calculated 
for Ce6-PVP compared to Ce6, indicating the improved amphilicity characteristic 
of Ce6-PVP and its diffusivity through a lipophilic matrix. This was further 
confirmed in the in vitro experiment where intracellular accumulation of Ce6-PVP 
in bladder cancer cells was much higher compared to Ce6 alone.  Interestingly, 
Ce6-PVP accumulated to a much lesser extent in the chick embryo, which further 
confirms the lack of apparent Ce6-PVP uptake and retention in normal tissue. 
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4.4.5 Fluorescence confocal microscopy imaging  
In order to determine if Ce6-PVP had higher diffusivity compared to Ce6 through 
membrane at the microscopic level, the CAM was harvested and prepared for 
microscopic sections. The fluorescence intensities of both photosensitizer after 
topical application for 2 min were captured by confocal microscopy. This enabled 
the measurement of relative concentrations of fluorescent molecules inside the 
CAM tissue, as the fluorescence intensity is proportional to the concentration of 
the photo-sensitizer. The images were then analysed using image quantification 
software to calculate fluorescence intensity. Ce6-PVP was found to be 
significantly higher in the CAM compared to Ce6 (Figure 4.13).  






















Figure 4.13 Fluorescence confocal microscopy imaging in the CAM. Different increase 
in fluorescence on CAM treated with Ce6 or Ce6-PVP captured by confocal microscopy 
and its corresponding topographical contouring  image.  Confocal images of (A) CAM 
with no photosensitizer showed some autofluorescence; (B) CAM incubated with Ce6 for 
2 mins showed a minimal fluorescence; and (C) CAM incubated with Ce6-PVP for 2 
mins showed a 14-fold fluorescence increase after correction for background 
autofluorescences. Scale bar, 100 µm. 
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4.4.6 Photodynamic therapy efficacy of Ce6-PVP 
 
All CAM models were sensitized with Ce6-PVP at the dose of 0.0625 mg/mL and 
received various light dose and fluence rate (Figure 4.14). One to two hours after 
PDT, the tumor and its surrounding normal area were harvested from the CAM 
and flow cytometry analysis were performed to assess for total cell death. In 
general, the percentage of cell death of normal CAM area was lower than tumor 
when PDT was performed with the same fluence and fluence rate.There were no 
statistical significance on the percentage of cell death in tumor and normal CAM 
tissue at 24 h following irradiation at the light dose of 1 J/cm2, 15 J/cm2, 20 J/cm2 
delivered at 1 mW/cm2, 15 mW/cm2 and 20 mW/cm2 respectively. Only irradiation 
at 10 J/cm2 delivered at a fluence rate of 10 mW/cm2 resulted in statistically 
significant percentage of cell death in tumor. PDT induced cell death in normal 











Figure 4.14 CAM with bladder tumor xenografts after topical administration of Ce6-PVP 
(0.625 mg/mL) and exposed to increasing light doses (1, 10, 15 and 20 J/cm2) at 665 
nm. The efficacy of Ce6-PVP mediated PDT for eradication of bladder tumor in the CAM 
model seems to be inversely proportional to the light dose used. *p < 0.05 compared to 
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Diffuse superficial transitional cell carcinoma refractory to standard therapies 
poses a clinical dilemma and PDT appears to be a promising treatment and 
palliative modality. A successful PDT of epithelial cancer requires a specific 
photosensitization of malignant tissue. Through fluorescence imaging on the 
CAM tumor model, we have shown that specific localization of Ce6-PVP in the 
bladder tumor can be attained longer compared to Ce6 alone. This suggests that 
in situ application of Ce6-PVP in the bladder is capable of exhibiting selective 
retention in the tumor and thus highly selective photodynamic destruction of the 
tumor tissue can be achieved. However, the complexity of determining light 
dosimetry for irradiation in the bladder makes the clinical application of new 
photosensitizer rather a challenging undertaking. Because it is difficult to 
optimize many parameters in a clinical context for each new photosensitizer, an 
animal model such as the CAM model provides preclinical data of high interest 
for the clinical use of PDT. The rationale for the PDT response study on the CAM 
model was to simulate light dosimetry that is commonly used in PDT of the 
bladder, so as to establish the basis for clinical treatment of the efficacy of the 
new Ce6-PVP formulation. The level of PDT response of tumor tissue analyzed 
using flow cytometry shows a strong dependence on the light dose at the applied 
conditions in the CAM. Higher percentage of cell death was observed at 10 J/cm2 
compared to 15 J/cm2 and 20 J/cm2. No significant tumor cell death observed 
after irradiation at 1 J/cm2. This suggests that there is a threshold for a 
photodynamic reaction to cause cell death using Ce6-PVP. However, as 
addressed by many researchers, experimentation on different animal tumor 
models, and the interdependence of photosensitizer concentration, route of 
administration, and incubation time determines the irradiance and radiant 
exposure to cause PDT-induced tissue damages [164-166].  As such, 
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extrapolation of PDT parameters obtained from preclinical study to clinical 
application warrants further studies. 
 
4.5 Conclusion 
Based on the CAM tumor model, Ce6-PVP has been shown to be a good 
photosensitizer, capable of inducing highly selective fluorescence in cancerous 
cells. Thus, it could become a promising diagnostic tool to enhance visualization 
of surgical margin of the tumor cells as well as allowing for easy visualization for 
targeted biopsy using fluorescene endoscopy. This in turn, can help diagnose 
and treat bladder cancers at their earlier stages.PVP has been successfully 
proven to enhance membrane permeation of Ce6, via the CAM transport model. 
Nonlinear regression analyses have shown that  the new formulation of Ce6-PVP 
has a longer half-life in the tumor than Ce6. Ce6-PVP displayed higher selectivity 
and sensitivity towards tumor xenografts. It is proposed that the use of Ce6-PVP, 
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CHAPTER 5 
 
Effect of polyvinylpyrrolidone on the interaction of chlorin e6 with plasma proteins 
and its subcellular localization 
 
5.1 Summary 
A photophysical study on the binding interaction of chlorin e6 and the polymer 
polyvinylyrrolidone with bovine serum albumin (BSA) and human plasma proteins 
such as very low density lipoprotein (VLDL), high density lipoprotein (HDL) and 
low density lipoprotein (LDL) was performed using a steady-state fluorescence 
technique. Ce6-PVP has good photostability at 3 different temperatures (4°C, 
21°C and 37°C) when dissolved in aqueous solution containing 5% and 10% 
serum.  In the partition coefficient determination, Ce6-PVP was relatively more 
hydrophilic when compared to Ce6. The emission profile of Ce6-PVP underwent 
a marked increased and bathochromic shift upon addition of the proteins, 
indicating that the proteins introduced motional restriction on the Ce6 molecule. 
These results also suggested that the association energy of Ce6-PVP with VLDL 
might be slightly greater than that with other lipoproteins when compared to Ce6 
alone. Colocalization of Ce6 and PVP in cells was also assessed using confocal 
microscopy. PVP was found to localize within the cytoplasma compartment of 
cells and the association of Ce6 with PVP led to an enhanced cellular uptake of 
Ce6 by the cells. The present study supported the hypothesis that PVP improves 
the permeation of Ce6 through biological membranes in cells. 
  147 
5.2 Introduction 
The use of the photosensitizer Ce6 and its derivatives for selective and effective 
photodynamic destruction of human malignant tumors has become increasingly 
apparent [137]. To date, many formulations of Ce6 have been developed and, 
have significant tumor localizing capacity. This present chapter investigated the 
efficacy of Ce6 formulated using PVP. PVP is a water-soluble polymer of 
pharmaceutical grade, known to form water-soluble complexes with a number of 
pharmacological substances and many investigations into the formation of PVP – 
complexes with drugs have been described [65, 112]. The chemically and 
biologically inert PVP has been initially use as a plasma substitute, although this 
has now been discontinued due to accumulation of large molecular weight 
fractions in the body [167]. As the molecular weight of PVP decreases, the rate of 
polymer dissolution, oral absorption and excretion increases. Therefore, lower 
molecular weight PVP is typically preferred for parenteral applications. PVP is 
now a well used pharmaceutical binder although more novel uses include the 
polymer as a controlled release and transdermal penetration enhancer [168].  
Ce6-PVP was developed with the rationale to provide a novel photosensitizer 
formulation of a high chemical and photochemical stability, good solubility both in 
water and in biological fluids, high affinity to tumor tissue, low phototoxicity as 
well as to provide a method of preparation of such photosensitizer [113, 169]. In 
this context, Ce6-PVP is a promising formulation for the photochemotherapy of 
tumors. Many postulations have been proposed for the preferential accumulation 
of a photosensitizer in neoplastic tissue. Among them are (a) greater proliferative 
rates of neoplastic cells thus higher uptake, (b) poorer lymphatic drainage, (c) 
leaky tumor vasculature, (d) specific interaction between the photosensitizer and 
marker molecules on neoplastic cells, and (e) specific low-density lipoprotein 
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(LDL) receptor-photosensitizer interaction leading to increased photosensitizer 
concentrations in neoplastic tissue. Injected photosensitizers bind mostly to 
serum proteins, but the binding protein differs according to the chemical 
characteristics of the photosensitizer. Various pharmacokinetic investigations 
have led to the general agreement that hydrophobic dyes are associated with 
lipoproteins, while their hydrophilic counterparts bind preferentially to other serum 
proteins, such as albumin [170]. Photosensitizer redistribution between plasma 
proteins defines photosensitizer interaction with cells, its intracellular localization 
and kinetics of accumulation in the tumor and photodynamic efficacy in vivo 
[171]. For that reason, plasma proteins binding affinity to photosensitizers play an 
essential role in drug distribution. The objective of this chapter was to investigate 
the interactions of plasma proteins with Ce6 in the presence or absence of PVP 
by examining changes in both the bathochromic and hyperchromic shifts of Ce6 
using spectrophotometry. The rate and extent of binding Ce6 and Ce6-PVP to 
HDL, LDL and VLDL was calculated. Examination of the subcellular localization 
PVP, Ce6 and Ce6-PVP using confocal microscopy were carried out. Since no 
experimental evidence of Ce6–PVP interactions have ever been published, it is 
hope that this study will offer a new insight into the understanding of the 
mechanism of PVP interaction with Ce6. 
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5.3 Materials and methodology 
5.3.1 Photosensitizer and serum proteins 
Ce6-PVP was obtained from ORPEGEN Pharma GmbH, Heidelberg, Germany 
as a co-lyophilisate of Ce6 sodium salt and PVP (molecular mass ≈ 12,000 kDA) 
in a 1:1 mass ratio. Ce6 was also obtained from ORPEGEN Pharma and 
lyophilized without further addition of PVP. Human LDL (6.1 mg/mL; molecular 
weight, 3500 kDa), HDL (16.4 mg/mL; molecular weight, 175–500 kDa) and 
VLDL (2.37 mg/mL, molecular weight, 6000 – 27000 kDa) were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). 
 
5.3.2 Determination of photosensitizer stability using fluorescence spectrometry 
20 µM of Ce6 or Ce6-PVP was dissolved in 1 mL of the following solutions: PBS, 
water, and fetal calf serum (5%, and 10%). Solution stability was assessed as a 
function of time for 27 days at 3 different temperatures (4 °C, room temperature 
(RT) and 37 °C) by measuring the fluorescence emission spectrum using the 
spectrofluorophotometer RF-5301 PC (Shimadzu, Kyoto, Japan). Fluorescence 
emission was measured from 620 to 630 nm upon excitation at 400 nm. Non-
linear regression fitting using one phase exponential decay was used to 
determine the half-life using Graph-Pad Prism™ version 2.0 package (Intuitive 
Software for Science, San Diego, USA). 
 
5.3.3 Preparation of photosensitizer–protein complex and measurement. 
The emission properties of Ce6 and Ce6-PVP at a concentration of 0.01 mg/mL 
in 0.9% physiological saline were investigated..Protein solutions were prepared 
in nine different concentrations; 0%, 0.005%, 0.01%, 0.015%, 0.02%, 0.05%, and 
0.1%. A total of 80 µL of the photosensitizer was added into 720 µL of each 
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concentration of the protein solutions. The solutions were mixed well and 
incubated for 1 h on ice in order to examine only photosensitizer–substrate 
interaction in the absence of active lipolysis, and to exclude the possible effects 
of the changing of the size and composition of lipoprotein particles on the binding 
to photosensitizers. Emission was measured using a HITACHI U-3010 
spectrophotometer. The scan range was from 500 to 800 nm using a WI (VIS) 
lamp. Curves were fitted using GraphPad Prism software. Derived Vmax and Km 
values with standard errors are listed in Table I. 
 
5.3.4 Determination of partition coefficient.  
Log P (logarithm of the partition coefficient in water/1-octanol system) 
determinations were performed using equilibration techniques. Partitioning was 
carried out in centrifuge bottles. Partition coefficients of Ce6 were evaluated in a 
system of 1-octanol–PBS at four different pH values, 5.0, 6.0, 7.0 and 8.0. Fifty 
µL of 0.01 mg/mL Ce6 and Ce6-PVP in 0.9 % NaCl was added to 5 mL of 1-
octanol followed by the addition of an equal volume of PBS at a specified pH (3 
mL). After each phase was presaturated with the other, the tubes were vortexed 
for 2 min at room temperature (21°C). Tubes were centrifuged for 2 min at 3000 
rpm to separate the octanol and water phases. After centrifugation, the solutes in 
both phases were analyzed. 1.8 mL of the buffer phase was pretreated with 0.2 
mL of 10% Triton X-100 to ensure deaggregation of the drug. Absorption was 
measured with a UV-Vis absorption spectrometer. The partition coefficients (P) 
were calculated as:  
P = Coct/ CPBS = absoct/ absPBS 
  151 
where Coct and CPBS represent the photosensitizer concentrations in the organic 
and the aqueous phase, respectively, absoct the absorbance of the compound 
measured in the octanol and absPBS the absorbance in the PBS solution.  
 
5.3.5 Labelling of PVP with fluorescein fluorescein isothiocyanate (FITC) 
PVP (1.25 g) and KOH (1.25 g) were dissolved in 50 mL water. The solution was 
transferred in to a 100 mL pressure bottle. The pressure bottle was closed with a 
teflon screw cap, then placed on a heating mantle and heated to a surface 
temperature of 135 °C for 15 h. The assembly was then cooled, the bottle 
opened and the solution was filtered. The pH of the remaining solution was 
adjusted to pH 7 using HCl.  The solution was then transferred to a dialysis bag 
(MWCO = 3000Da, Spectrapore) and dialyzed against milliQ water (4L x 6) for 
three days.  The contents of the dialysis bag were then transferred to a 250 mL 
round bottomed flask and lyophilized to obtain a pure opened ring PVP (PVPRO) 
(1g).  Potentiometric titration showed that, the percentage of ring opening is 3.5 
(±0.3%).  1H-NMR (D2O): d 0.9-1.4 (br., endgroups), 1.4-1.5 (br. s), 1.5-1.8 (br. 
s), 1.8-2.1 (br. s), 2.1-2.35 (br. s), 3.0-3.4 (br. s), 3.4-3.6 (br. s), 3.6-3.9 (br. s). 20 
mg of PVPRO was dissolved in 20 mL 0.1 M sodium carbonate buffer and 2 mL 
of FITC (1 mg/mL) was added at room temperature and stirred gently with a 
magnetic stir bar. After 2 h, the solution was transferred to a dialysis bag (MWCO 
= 3000Da, Spectrapore) and dialyzed against deionized water for 3 days. The 
content of the dialysis bag was then transferred to a 100 mL round bottomed 
flask and lyophilized to produce PVP-FITC (16.8 mg). This was dissolved into 
16.8 mL PBS. 10 µM of PVP-FITC was then prepared in RPMI medium and used 
for cell culture studies. 
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5.3.6 Intracellular localization by confocal laser scanning microscopy.  
MGH cells were maintained in RPMI medium containing 10% fetal calf serum 
(FCS), sodium pyruvate (110 mg/mL), penicillin (100 U/mL) and streptomycin 
(100 mg/mL) under 5% CO2. The cells were seeded at 1 x 105 per well of the 8-
well Labtek chamber slide (Nunc, Naperville, CT) in 0.5 mL of RPMI medium. 
After a 24 h attachment and growth period at 37°C, the cells were incubated with 
Ce6, Ce6-PVP and PVP-FITC for (10 µM) for 30 min. Cells were then washed 
and fixation was performed in 3.7% formaldehyde and 0.05% Triton X-100 in 
PBS for 5 min. The cells were then stained with DAPI (λex = 378 nm, emission 
filter = BP 400 - 440 nm) rhodamine-phalloidin (λex = 543 nm, emission filter = LP 
590 nm) using the procedure adapted from the experimental protocol 
(Subcellular Structure Localization Kit, Chemicon). The coverslips were then 
mounted on a slide, using antifade mounting medium (Vectashield, Vector), 
before imaging using a confocal laser-scanning microscope (CLSM). Confocal 
parameters are listed as follows: 40´/0.55 objective lens; 488 nm exciting 
wavelengths for Ce6/Ce6-PVP and FITC; 488/568 nm beam-splitter for FITC; 
660 - 670 nm band-pass barrier filter for Ce6/Ce6-PVP fluorescence detection. 
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5.4 Results and discussions 
5.4.1 Partition coefficient 
One of the challenges in formulating photosensitizers is the optimization of their 
amphiphilic properties so that they are hydrophilic enough to be administered as 
aqueous solutions and be eliminated rapidly from the body after photodynamic therapy. 
At the same time, the photosensitizers must be lipophilic enough to be retained by, and 
preferentially localized in tumor tissue. The lipophilicity of photosensitizers is thought to 
be an important parameter in controlling penetration through the cellular membrane and 
cellular uptake of photosensitizers. In this context, this study reported the influence of pH 
on the lipophilicity of Ce6 or Ce6-PVP. One of the traditional ways of evaluating the 
amphiphilicity of medicinal compounds is to determine their partition coefficients 










Figure 5.1 Partition coefficients of the Ce6 and Ce6-PVP between 1-octanol and PBS at 
various pH values. 
 
 
which an organic compound is distributed in the body. It is termed a "two 
compartment or two-phase" system: aqueous (water) and organic (lipid) layers. 
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Figure 5.1 shows the partition coefficients of the Ce6 and Ce6-PVP at various pH 
values. Comparison of the partition coefficients of Ce6 with Ce6-PVP showed 
that the expected effect of PVP, i.e. to decrease the hydrophobicity of Ce6 at pH 
6 and 8. As the pH of the aqueous buffer was lowered from pH 7, the partition 
coefficient was found to increase. The results suggested that a larger fraction of 
Ce6-PVP was incorporated into the 1-octanol phase under more acidic 
conditions. It was documented that the pH 7.4 of blood may cause protonation of 
the photosensitizer. In a previous study, it was shown that the Ce6 fraction bound 
to lipid membranes and low density lipoproteins (LDL) increased whereas the 
one bound to HSA decreased when the pH changed from 7.4 to 6.5 [172]. Ce6 
existed in the amphiphilic form in pH 7.4, thus some Ce6 may be lost because 
the hydrophilic part of the Ce6 may interact with other serum proteins. Thus, the 
results here implied that passive diffusion of Ce6 or Ce6-PVP into tumor cells 
might be enhanced due to the slightly acidic extracellular pH of tumor tissue. 









5.4.2 Fluorescence properties of Ce6-PVP in various biological media 
Qualitative and quantitative changes in emission spectra resulting from a change 
of reaction medium can provide information about interaction between the 
excited states and the environment. Such information can be of great importance 
in explaining the photoreactivity of a photosensitizer in a certain formulation. The 
stability of Ce6-PVP deteriorated drastically when dissolved in water (Figure 5.3 
A). By day 27, the emission intensity of Ce6-PVP had reduced by 98%, 72% and 
100% when dissolved in water at a temperature of 37°C, room temperature 



























Figure 5.2 Graphs showing representative emission spectra of Ce6-PVP in (A) water, 
(B) PBS (C) 5% fetal calf serum (D) 10% fetal calf serum at room temperature assessed 
as a function of time (from 0 to 27 days). 
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Figure 5.3 The effect of (A) water, (B) phosphate buffered saline (PBS), (C) 5% fetal calf 
serum (FCS) and (D) 10% fetal calf serum (FCS) on the emission intensity of Ce6-PVP 
(0.5 mg/mL) at room temperature (RT 21°C) (■), 37°C (▲) and 4°C (▼) for a period of 
up to 27 days. Each data point represents the average of 3 measurements. Experiments 
were repeated twice and showed similar trends. 
 
On the other hand, when Ce6-PVP was dissolved in PBS, the emission intensity 
of Ce6-PVP had reduced by 27% at a temperature of 37°C by day 27 (Figure 5.3 
B). During the same time period, the emission intensity of Ce6-PVP had reduced 
by 45% and 44% when dissolved in PBS at room temperature (21°C) and 
4°C,respectively. Ce6-PVP dissolved in 5% and 10% FCS was found to be very 
stable (Figure 5.3 C and D).  In both concentrations of FCS solutions, the 
fluorescence emission intensities remained stable throughout the 27 day period 
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at all the three temperatures. When the fluorescence emission data of Ce6-PVP 
dissolved in water, was fitted to non-linear regression equation using one phase 
exponential decay, the half-life of the fluorescence intensity was found to be 12 
day (95% CI 10.8 to 14.3) at RT, 7.7 days (95% CI 6.8 to 8.9) at 37°C and 3.0 
days (95% CI 2.5 to 3.5) at 4°C. The half-life of the Ce6-PVP dissolved in PBS 
was found to be 24.2 days (95% CI 20.3 to 30.0) at RT, 114 days (95% 71.4 to 
285.0) at 37°C, and 30.7 days (95% CI 25.2 to 39.3) at 4°C. Ce6-PVP appeared 
to remain stable in the presence of 5% and 10% FCS throughout the 27 days 
survey period. The nature of degradation of Ce6-PVP is not really well 
understood mechanism of photodegradation and has not often been determined 
as this is a new compound. Degradation mechanisms at higher temperature 
could be due to molecules of Ce6-PVP were energized that could either have led 
to hydrolysis, oxidation-reduction, racemization, decarboxylation, ring cleavage 
or photolysis reactions. This would have given rise to a by-product that was not 
fluorescing at 665 nm. It was interesting to observe that at lower temperature of 
4°C, in the absence of 5% and 10% FCS, the fluorescence emission of Ce6-PVP 
was lower than in RT and 37°C. This could be due to the increase of molecular 
aggregation at low temperature and thus could have led to a reduction in the 
fluorescence yield. This effect had been observed for other photosensitizers 
where aggregated species are more easily quenched to than the monomeric 
ones. Further study is warranted to elucidate the mechanism of degradation of 
Ce6-PVP.  
 
Serum is a very complex supplement with serum albumin being the most 
abundant protein. Its concentration is 10 times more the total concentration of all 
lipoproteins. It serves as a carrier for both hydrophilic and amphiphilic 
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photosensitizers. Despite being the most abundant protein in the circulatory 
system, albumin is known to have very limited binding sites for tetrapyrrolic 
photosensitizers [173, 174]. However in this experiment, the high stability of Ce6-
PVP in FCS has led to the hypothesis that Ce6-PVP is a vascular targeting 
photosensitizer whose efficacy is augmented by high plasma protein binding that 
may also contribute to minimal skin photosensitization. 
 
















Figure 5.4 The fluorescence emission spectra of Ce6 dissolved in saline with (A) HDL, 
(B) LDL and (C) VLDL at concentrations of 0% (red), 0.005% (green) and 0.05% (blue).  
The fluorescence emission spectra of Ce6-PVP dissolved in saline with (D) HDL, (E) 
LDL and (F) VLDL at concentrations of 0% (red), 0.005% (green) and 0.05% (blue).  
 
(F) (E) (D) 















































Transform of HDL Ce6:Transformed data















Transform of LDL Ce6:Transformed data































  159 
Lipoproteins are complex particles that consist of spherical hydrophobic cores of 
triglycerides or cholesteryl esters surrounded by amphipathic (polar and non-
polar) mono-layers of phospholipids, cholesterol, and apolipoproteins. 
Lipoproteins are usually classified by their size and density as ‘very low-density 
lipoprotein’ (VLDL), ‘low-density lipoprotein’ (LDL) and ‘high-density lipoprotein’ 
(HDL). Their main function is to transport endogenous and dietary fats in the 
blood and lymphatic vessels. Lipoproteins are also the key components that 
regulate the transport of photosensitizers in the body’s circulatory system. The 
association of photosensitizers to lipoproteins is dependant on the non-polar 
moieties of the photosensitizers and lipids, aggregation properties, polarity, pH 
effects and the chemical nature of side-groups in the photosensitizer. In this 
study it was observed that the peak of the spectral wavelength of both Ce6 and 
Ce6-PVP increased with the increase in concentration of LDL (Figure 5.4). The 
emission spectra of Ce6 with different concentrations of LDL exhibited a major 
shift in wavelength peaks. For example, Ce6 with 0% LDL showed a peak at 
664.8 nm. Ce6 with 0.005% LDL showed a peak at 674.4 nm, producing a shift of 
9.4 nm in the spectral wavelength. Ce6 with 0.05% LDL showed a peak at 680.8 
nm, producing a total shift of 16 nm from Ce6 with 0% LDL.  
 
Ce6-PVP with LDL showed equilvalent wavelength shifts in comparison to Ce6 
with LDL. Ce6-PVP with 0% LDL exhibited a peak at 664.2 nm wavelength. Ce6-
PVP with 0.005% LDL showed a peak at 675.4 nm, producing a shift of 11.2 nm. 
Ce6-PVP with 0.05% LDL exhibited a peak at 680.2 nm, producing a total shift of 
16 nm from Ce6-PVP with 0% LDL. A similar observation was noted in which 
both Ce6 and Ce6-PVP emissions increased with increasing concentration of 
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LDL. Ce6-PVP combined with LDL produced double the emission intensity to that 
of Ce6 with LDL at the same wavelength.  
 
The emission spectra of Ce6 with different concentrations of HDL exhibited major 
shifts in wavelength peaks. Ce6 with 0% HDL exhibited a peak at 664.8 nm. Ce6 
with 0.005% HDL had a peak at 678.2 nm, producing a shift of 13.4 nm. Ce6 with 
0.05% HDL had a peak at 679.8 nm, giving a total shift of 15 nm. Overall, Ce6-
PVP exhibited a slightly higher wavelength shift in comparison to that of Ce6 in 
general. Ce6-PVP with 0% HDL showed a peak at 664.2 nm. Ce6-PVP with 
0.005% HDL had a peak at 678.4 nm, giving a shift of 14.2 nm. However, Ce6-
PVP with 0.005% HDL exhibited a slight decrease of fluorescence emission. 
Ce6-PVP with 0.05% HDL had a peak at 679.4 nm, giving a total wavelength 
shift of 15.2 nm. Here, the emission intensity for Ce6-PVP was twice as high as 
that of Ce6.  
 
The emission spectra of Ce6-PVP with different concentrations of VLDL exhibited 
a slight shift in wavelength peaks. Ce6-PVP 0% VLDL showed a peak at 664.2 
nm. Ce6-PVP with 0.005% VLDL had a peak at 666 nm, giving a shift of 1.8 nm. 
Ce6-PVP with 0.05% VLDL had a peak at 671.4 nm, giving a total shift of 7.2 nm. 
The Ce6-PVP with 0%, 0.005% and 0.05% VLDL produced an almost threefold 
increase in emission intensity. 
 
It was documented that the bathochromic shift of the porphyrin Soret band 
indicates a π-π interaction between the prophyrin and binding protein [175]. The 
induction of a bathochromic shift from the formation of a porphyrin–protein 
complex is well documented [176]. There are two possible factors that can lead 
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to bathochromic shifts. The first possibillty is related to the increased p electron 
orbitals at the periphery of the porphyrin when the tetrapyrrolic macrocycle 
associates with adjacent aromatic ligands in serum proteins via ionic binding and 
van der Waals forces [177]. Ce6 and Ce6-PVP may both form complexes via p–p 
interaction between the aromatic ligands of the lipoprotein and the tetrapyrrolic 
macrocycle of Ce6. Another possible factor leading to bathochromic shift is the 
monomerization from dimers or aggregated states. Porphyrinic compounds that 
has an amphiphilic structure such as Ce6 tend to self-associate in aqueous 
solution that depends on factors such as the nature of the polar side chains, the 
pH of the surrounding medium, and the stereochemistry of the porphyrin 
molecule [178]. It is possible that the addition of lipoprotein might induce 
monomerization and thus lead to bathochromic shift. Hence, the lipoprotein may 
actually function as an endogenous drug carrier for Ce6 via receptor 
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5.4.4 Association binding measurement  
Upon systemic administration, most photosensitizers bind to various serum 
proteins, including HDL, LDL and albumins for their transport and distribution 
Hence, the presence of these serum proteins in the blood may improve PDT to 































Figure 5.5 The equilibrium titration of Ce6 (■) and Ce6-PVP (▼) in various lipoprotein 
buffer solutions at pH 7.0. Low concentration (0.01mg/mL) of the photosensitizers 
combined with (A) HDL, (B), LDL and (C) VLDL and high concentration (0.06 mg/mL) of 
the photosensitizers combined with (D) HDL, (E), LDL and (F) VLDL. Curves were fitted 
and constants derived from one site binding equation and are presented in the main text. 
Y axis units are relative fluorescent units per mL of the solution. On graphs (A) and (F) 
trendlines were not presented for some of the data sets because the data did not fit in 
the binding equation. 
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via receptor-mediated endocytosis [180]. Using a spectrophotometry method, the 
binding of lipoprotein with Ce6 and Ce6-PVP has been studied to understand the 
influence of PVP on the distribution of Ce6 with various lipoproteins. Non-specific 
binding was measured by incubating Ce6 and Ce6-PVP with various 
concentration of human lipoproteins. The affinity association of Ce6 and Ce6-
PVP is analyzed by plotting the emission peaks against increasing 
concentrations of HDL, LDL and VLDL (Figure 5.5). Data analysis was performed 
using one site binding equation: 
    Y = Bmax*X 
                 (Kd+X) 
 
 
This equation describes the binding of a photosensitizer to a lipoprotein receptor 
following the law of mass action. ‘Y’ in the above equation is the fluorescence 
intensity of the photosensitizer, which is assumed to be linearly proportional to 
the concentration of the photosensitizer, ‘Bmax‘ is the maximal binding (binding 
capacity). ‘X’ is the concentration of the lipoprotein, and ‘Kd’ is the concentration 
of photosensitizer required to reach half-maximal binding (binding affinity). The 
absorbance level of Ce6 was measured to confirm that all the photosensitizer 
concentrations used for this experiment were consistent with one another. A 
preliminary binding affinity of different lipoproteins to both Ce6 and Ce6-PVP 
were calculated and presented in Table 5.1. In general, when the concentration 
of the lipoproteins increased, the fluorescence intensity of both Ce6 and Ce6-
PVP increased until a plateau was reached (Figure 5.5). The plateau occurred 
because the free binding sites of the lipoproteins were no longer free to interact 
with Ce6. It was observed that the Bmax of all three lipoproteins binding with Ce6-
PVP was slightly higher compared to that of Ce6, at the photosensitizer 
concentration of 0.01mg/mL. When the binding capacity for various lipoproteins 
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was measured in the presence of high Ce6 concentration (i.e. 0.06 mg/mL), the 
Bmax of the HDL increased by 1.7 fold, the Bmax of the LDL increased by 1.2 fold 
and the Bmax of VLDL decreased by 2.6 fold in comparison to the values 
obtained for the low Ce6 concentration. For the high concentration of Ce6-PVP, 
the Bmax of HDL, LDL and VLDL increased by 3.3, 2.1 and 3.0 fold, respectively 
compared to the values obtained for the low concentration of Ce6-PVP. If these 
preliminary results could be further confirmed, it may have important indication 
that the binding capacity of Ce6 to the lipoproteins is influenced by PVP as well 
as by the concentration levels of the photosensitizer. 
 
Table 5.1 The influence of different concentrations of three lipoproteins on the protein 




It is well established that porphyrins have a high affinity for  human serum 
proteins, albumin, HDL, LDL, and VLDL .However, this selective mechanism is 
yet to be elucidated [173]. It is possible that an over expression of LDL receptors 
on the tumor cell surface or on neovascular endothelial cells may result in the 
enhanced uptake of LDL-bound photosensitizer by receptor-mediated 
endocytosis [181]. Since LDL is the main component of lipoprotein in the blood, it 
is the most likely lipoprotein to interact with photosensitizer. It has been shown 
Photosensitizer Ce6 Ce6-PVP 
Lipoproteins HDL LDL VLDL HDL LDL VLDL 
Low concentration 
(0.01 mg/mL) 1.66 1.84 3.10 1.68 2.23 3.13 
High concentration 
(0.06 mg/mL) 2.74 2.23 1.19 5.71 4.58 9.53 
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that lypophilic photosensitizers have a high affinity for LDL and VLDL whereas 
amphiphilic photosensitizers have a higher affinity for HDL. In contrast, a very 
hydrophilic photosensitizer has been reported to have a high affinity for albumin 
[175]. However, in this experiment, it was observed that low concentrations (i.e. 
0.01 mg/mL) of Ce6 and Ce6-PVP had high binding affinities for LDL and VLDL, 
while only a low binding affinity was observed with HDL. This suggests that the 
LDL and VLDL are the principal carriers for Ce6, which supports the existing 
literatures demonstrating the role of LDL receptors as carrier molecules to Ce6 
and thereby improving the photodynamic therapy [182]. Thus, hydrophilic Ce6-
PVP bound to LDL may preferentially accumulate in proliferating endothelial cells 
through the LDL receptor-mediated endocytosis pathway.  
 
A significant increase in fluorescence yield was observed when low concentration 
of Ce6-PVP was bound with VLDL. The fluorescence yield increased even higher 
at high concentration of Ce6-PVP. However, no association of VLDL was 
observed for high concentration of Ce6 alone (Figure 5.5). This suggests that 
Ce6 could be aggregated at high concentrations thereby blocking it from binding 
to the lipoproteins. The tissue distribution of VLDL receptor (VLDLR) has been 
studied in adult humans and in various animals. Expression of VLDLR was found 
in several tissues, including heart, skeletal muscle, adipose tissue, kidney, 
placenta, and brain (Montel et al., 2007). The presence of VLDLR was also 
demonstrated in gastric adenocarcinoma cells [183] and breast carcinomas 
[184]. This inevitably suggests a possible uptake of Ce6-PVP in cancer cells via 
VLDLR. 
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Published literature has shown that by increasing the lipophilicity of Ce6 its 
binding affinity to LDL also increased, thus potentially enhancing its tumor-
localizing ability [105]. In one study using the murine model, it was demonstrated 
that a relatively hydrophilic compound N-aspartyl chlorin e6 (NPe6) was bound 
predominantly to albumin and HDL, while only 1% to 2% of the compound was 
bound to LDL [185]. The generalization that hydrophobic compounds are 
transported in vivo via lipoproteins appears to be true for the photosensitizer 
family of benzoporphyrin derivatives (BPDs). Preclinical studies of 
benzoporphyrin derivative monoacid ring A (BPD-MA) biodistribution showed that 
the majority of the BPD-MA is associated with LDL [186]. It is possible that this 
factor may not be a problem for cellular uptake of Ce6 by the tumor tissues, as 
the photosensitizers in serum are probably in a dynamic state as they are 
transferred between various protein fractions within the same serum.  
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5.4.5 Subcellular localization 
In vitro experiments were conducted to compare the cellular uptake of Ce6 and 
Ce6-PVP. MGH human bladder cancer cells were incubated with 10 µM Ce6 or 
Ce6-PVP for 30 min and subsequently observed the fluorescence by confocal 
laser scan microscopy equipped with a 63x, numerical aperture 1.3 oil immersion 
objective (Figure 5.6). The fluorescence images were displayed in pseudo colors 
for organelle markers and photosensitizer, respectively. Cellular uptake of Ce6-
PVP was significantly higher compared to Ce6 (0.182 ± 0.065 and 0.043 ± 0.008 
intensity (a.u.)/area, respectively, p = 0.0015) (Figure 5.7). The colocalization 
study indicated that intracellular deposition of both Ce6 and Ce6-PVP was 
localized in cytoplasma and nucleus. The precise step involving the transfer of 
Ce6 from PVP carriers to cellular membranes is still unknown. Therefore, PVP 
was labeled with FITC to study the uptake dynamics of PVP into cells. 




















































Figure 5.6 MGH cells were incubated with PVP-FITC (green) for 30 min and co-stained 
(A) rhodamine-phalloidin (red) and, (B) DAPI (blue). Cells were also incubated with (C) 
Ce6 (red) and (D) Ce6-PVP (red) for 30 min and and co-stained with rhodamine-























Figure 5.7 Determination of Ce6 and Ce6-PVP fluorescence intensities distribution in 
MGH cells by image analysis. Each bar represents average intensities of 10 cells divided 
by the area of the cell. Error bars represent the standard error of the mean. 
 
 
with no nuclear colocalization, indicating the transport of PVP across cellular 
membrane. This result is in good agreement with the intracellular transport of 125I-
labeled PVP in isolated rat hepatocytes 187 (England et al., 1986). Another study 
also demonstrated drug co-precipitate with PVP were transported across 
membrane in high energy amorphous phase (Corrigan et al., 1980). Another 
hypothesis proposed that lipophilic photosensitizer (i.e. hypericin) is bound to the 
hydrophilic PVP carrier with weak hydrogen bonds and that the photosensitizer is 
able to cross the cellular membranes after being released from the PVP carrier 
molecule [83].  Hence, in the current study, the cellular uptake of Ce6-PVP in 
MGH cells was observed to be higher compared to that of Ce6. This implies that 
PVP may increase the rate of membrane transport of Ce6 in the cells. We also 
hypothesize that because of the presence of numerous lipoprotein receptors on 



























p = 0.0015 
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than in non tumor cells. As a whole, the data presented here indicate that the 
critical determinant of differences in phototoxicity between Ce6 and Ce6-PVP 
was that the presence of PVP enhanced the rate of cellular accumulation as well 
as solubility in aqueous media. 
 
5.7 Conclusion 
Ce6-PVP was found to be stable in a protein environment. A decrease in pH from 
7 to 6 caused the partition coefficient of both Ce6 and Ce6-PVP to become more 
lipophilic. However, Ce6-PVP was slightly less lipophilic than Ce6. The cellular 
internalization of Ce6-PVP was higher than Ce6, and fluorescence microscopy 
revealed the penetration of PVP into the intracellular compartment of the cells. 
This supported the hypothesis that PVP improves the permeation and solubility 
of Ce6 through biological membranes in cells. The fluorescence intensity of Ce6-
PVP, when bound with HDL, LDL and VLDL, was significantly higher compared 
to Ce6 alone. This indicated that PVP affects the level of association of Ce6 with 
lipoproteins, which would also be expected to influence the intracellular 
distribution of Ce6. This further supports the hypothesis that the externally added 
macromolecule PVP improves the uptake of Ce6 in cells. In particular, Ce6-PVP 
was found to interact more with VLDL, suggesting a role for the VLDL-receptor 
pathway with regard to Ce6-PVP biodistribution. 
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CHAPTER 6 
 
Evaluation of clinical response of chlorin e6 – polyvinylpyrrolidone mediated 
fluorescence diagnosis and photodynamic therapy  
 
6.1 Summary 
Photodynamic therapy (PDT) using a chlorin e6 – polyvinylpyrrolidone (Ce6-
PVP) was investigated as a treatment for refractory superficial bladder cancer 
that had failed the usual treatment options. Two patients with biopsy proven 
carcinoma of the bladder were treated with intravenous or intravesical instillation 
of Ce6-PVP. Five hours after intravenous administration and 3.5 h after 
intravesical administration of Ce6-PVP, both patients were exposed to a laser 
light at 665 nm. Patients were followed for 6 months for safety, efficacy, 
recurrence, and palliative response. Serum and urine samples at various 
intervals were collected for spectrometric quantification of photosensitizer level. 
The levels of inflammatory cytokines before and after post PDT were also 
determined. After PDT with Ce6-PVP, complete response was observed in both 
patients, with no evidence of recurrence at any treated site at the 1-month follow-
up. However, urinary bladder smooth muscle contraction was observed for 
patient that received intravenous Ce6-PVP mediated PDT. Patient that received 
intravesical PDT was disease-free 6 months after PDT. Intravesical treament of 
Ce6-PVP mediated PDT seemed to be safe and effective for the clinical 
treatment of bladder cancer. Expressions of IL-1a, IL-1β, IL-8, IL-10, IL-12, IFN-γ 
and TNF-α were not observed in patient given intravesical Ce6-PVP – PDT at 24 
h post treatment. However, there was decreased expression of the cytokines 
from its baseline level in patient treated with intravenous Ce6-PVP – PDT. IL-6 
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was observed to be upregulated in both patients at post PDT.. Upregulation of IL-
6 suggested that a systemic immunologic response might have occurred 
following PDT. This finding however requires further study to confirm this 
hypothesis. In a different cohort of patients, fluorescence imaging was performed 
on 3 patients with histologically confirmed angiosarcoma and 6 bladder cancer 
patients were instilled with Ce6-PVP. A dose of 2 – 4 mg/kg of Ce6-PVP was 
administered intravenously for the angiosarcoma patients while a dose of 0.0625 
mg/mL were topically instilled to the bladder cancer patients.  The resultant 
macroscopic and microscopic fluorescence intensities were imaged and 
quantified to explore possible mechanisms of penetration and distribution of the 
photosensitizer. It was noted that Ce6-PVP enhanced the image contrast 
between the diseased lesion and surrounding normal tissue in the fluorescence 
image. In clinical biopsies of bladder tumors, fluorescence intensity increased 
with the stage of disease indicating its potential use as a diagnostic fluorescent 
marker. The depth of topical penetration into bladder tumor tissue was found to 
range from 100 – 200 µm. The findings in this chapter highlighted the distinct 
advantage of Ce6-PVP as a diagnostic and therapeutic agent for photodynamic 
therapy of bladder cancer and as a fluorophore for fluorescence imaging of 
angiosarcoma. 
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6.2 Introduction 
Transitional cell carcinoma (TCC) accounts for 90% of all bladder tumors, of 
which 70% are low or medium grade and superficial. Carcinoma in situ (CIS) is 
an aggressive form with a variable and often unpredictable natural history that is 
frequently associated with disease progression. In the USA, the incidence of 
bladder cancer is three-times higher in men than in women and it is the fourth 
most common cancer in men after prostate, lung and colorectal cancer [189].  In 
Singapore, bladder carcinoma is the tenth most common cancer affecting men 
and the disease-free survival after radical cystectomies was 64%, 35% and 32% 
at 1, 3 and 5 years, respectively [190]. Recent development of new diagnostic 
and therapeutic photodynamic applications in combination with optical delivery 
and imaging systems holds promise as an alternative, minimally invasive and 
potentially curative treatment for bladder cancer [191, 192]. Photodynamic 
therapy (PDT) is primarily suggested for the therapy of papillary transitional cell 
carcinoma (TCC) and refractory CIS, and prophylaxis of recurrent superficial 
TCC in those patients who have failed intravesical chemotherapy or 
immunotherapy [193]. Additional approaches, such as PDT with different 
photosensitizers and thermotherapy in combination with intravesical 
chemotherapy, have been evaluated in Phase III clinical studies [194]. This 
chapter compares 2 cases of study to evaluate the safety and effectiveness of 
Ce6-PVP administered intravenously versus intravesically in the treatment of 
refractory bladder carcinoma. This study also examines the fluorescence 
distribution of Ce6–PVP in angiosarcoma lesions and normal skin in patients. 
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6.3 Materials and methodology 
6.3.1 Angiosarcoma patients 
The clinical study was approved by the Clinical Ethics Committee, National 
Cancer Centre Singapore. Fluorescence imaging was performed on patients with 
histologically confirmed angiosarcoma that underwent PDT. All were male with a 
median age of 61 years. Patients were administered intravenously with 2 – 4 
mg/kg of 75% Ce6-PVP prepared in 0.9% NaCl by a clinician from the National 
Cancer Centre of Singapore. The solution was injected intravenously over 10 
minutes by infusion. Fluorescence imaging was performed on various parts of the 
lesion and normal skin from 1 – 3 h post drug administration (before PDT) and 5, 
6 and 48 h post drug administration (post PDT). Fluorescence intensity was 
tabulated as follows: 
                                 INt = IRt  / IBt                         
 
with INt = normalized fluorescence intensity after time, t; IRt = intensity of red 
channel at time t; IBt = intensity of blue channel at time t; t = time in hours after 
drug administration. The spectral measurement was also performed on the lesion 
and normal skin at 1 and 3 h post Ce6-PVP administration using a fiber optics-
based fluorescence spectrometer (Spex SkinSkan, JY Inc., Edison, NJ, USA) 
(decribed in 2.3.5). All patients had to remain under minimum ambient light 
conditions for 48 h. 
 
6.3.2 Bladder cancer patients 
Patients with rapidly recurring, multi-focal, BCG-refractory superficial bladder 
transitional cell carcinoma (pTcis, pTa, pT1) would be selected. Patients who had 
undergone exhausted conventional therapies and were candidates for either 
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radical cystectomy or radiotherapy were suitable for this study. Study exclusion 
criteria included porphyria, gravidity, breast feeding, psychotic disease, invasive 
stage pT2 or greater bladder cancer or metastatic disease, non-urothelial bladder 
tumors, ASA (American Society of Anaesthesiologist) score 4 or greater, major 
renal or liver failure, leukopenia with less than 3500 white blood cells per 109 µL 
and thrombocytopenia with fewer than 100,000 platelets per 109 µL. Patients 
with prior intravesical chemotherapy or immunotherapy were not be excluded. 
  
6.3.2.1 Clinical history for patient received intravenous administration of Ce6-PVP 
The first patient is a 78-year-old Chinese lady who had a medical history of rectal 
prolapse treated with a rectopexy and uterine fibroids treated with a total 
hysterectomy with bilateral salpingo-oophrectomy. She was first seen in 1997 for 
lower urinary tract symptoms especially urge incontinence. Urodynamic studies 
showed detrusor instability. She was treated with oral medications, showed good 
response and discharged subsequently. Her lower urinary tract symptoms 
recurred in August 2001. A flexible cystoscopy was performed to further 
investigate her condition, and it showed cystitis on the posterior wall and bilateral 
walls of the bladder. Urine cytology was taken and it showed high-grade 
urothelial carcinoma. In view of such findings, she underwent a rigid cystoscopy 
and bilateral retrograde pyelogram. Biopsy of the ‘cystitis’ area showed 
carcinoma-in-situ, and she received 6 doses of intravesical BCG. She was put on 
regular follow-up to monitor her disease progress. Repeated cystoscopy did not 
show any recurrence till December 2003. In December 2003, rigid cystoscopy 
and biopsy showed carcinoma-in-situ. As patient was not keen for surgical 
intervention, she received another 6 doses of intravesical BCG.  CT scan of the 
abdomen and pelvis, did not detect any bladder wall thickening, extravesical 
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extension of tumor, enlarged regional lymph nodes or intra-abdominal 
metastases. She was well till October 2004, when a repeat cystoscopy showed 
suspicious lesions on the posterior and left lateral wall of the bladder. Biopsy of 
these areas showed recurrence of carcinoma-in-situ. As this is the third 
recurrence of carcinoma-in-situ after 2 cycles of intravesical BCG previously, the 
option of intravenous administration of Ce6-PVP mediated photodynamic therapy 
(PDT) was offered to the patient. Ce6-PVP was dissolved with 0.9% NaCl. 
Patient weight was 45 kg at the time of treatment. 100 mL of Ce6-PVP solution 
that constituted a dose of 2.5 mg/kg body weight was syringed out into the 
infusion bag and protected from light. A sterile drip infusion i.v. set was also 
provided. 100 mL of Ce6-PVP solution (0.9% NaCl) that constituted a dose of 2.5 
mg/kg body weight was syringed out into a sterile drip infusion i.v. set and 
protected from light was also provided. The solution was injected intravenously 
over 10 minutes of infusion. Drug administration was performed in a dim 
environment and patient’s eye and skin were protected from intense light using 
eye goggle and blanket.  
 
6.3.2.2 Clinical history for patient received intravesical administration of Ce6-PVP 
The second patient is a 78 Chinese year old woman who has multiple co-
morbidities including hypertension, diabetes mellitus on diet control, previous 
cerebrovascular accident with good functional recovery, bilateral cataracts, 
glaucoma of the right eye, Meniere’s disease, previous total thyroidectomy for 
multinodular goiter and Hashimoto’s thyroiditis and total hysterectomy and 
bilateral salpingo-oopherectomy (THBSO).  She first presented with 
asymptomatic microscopic haematuria to the Department of Urology, Singapore 
General Hospital. This was not associated with any weight loss or loss of 
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appetite.  She had earlier been investigated at Changi General Hospital, 
Singapore for the same problem with an intravenous urography which was 
normal and a urine cytology which showed atypical urothelial cells suspicious for 
malignancy.  A bedside ultrasound done showed possible bladder lesions which 
was confirmed on flexible cystoscopy.  A flexible cystoscopy on 23rd Feb 2007 
showed a 1cm solid lesion at the right trigone.  She underwent a TURBT and 
excision of umbilical nodule on 9th March 2007.  Intraoperative findings revealed 
a solid 1.5 cm tumor at the right side of the trigone not involving both the ureteric 
orifices. Bladder capacity at that time was measured at 400 mL.  Histology of the 
tumor revealed a lymphoepithelioma-like high grade undifferentiated carcinoma 
which was noted to be different from the CIS and high grade papillary urothelial 
carcinoma previously. This was noted to be invading the lamina propria, while 
muscularis propria involvement cannot be absolutely excluded. Her case was 
discussed at the Uropathological Conference and she was recommended for 
intravesical administration of Ce6-PVP mediated photodynamic therapy (PDT). 
After discussion with the patient regarding her options and alternative treatment 
such as radical cystectomy, she was agreeable for PDT.  
 
6.3.4 Light source and fiber positioning 
A medical-grade Biolitec Ceralas PDT laser was used to deliver light at 665 nm. 
The laser light was delivered via a spherical light diffuser fiber (model: SD) 
obtained from Medlight S.A, Switzerland. The fiber was sterilized using gas 
plasma sterilization method. Trans-abdominal ultrasonography was used to 
position the fiber in the central region of the bladder through a constant flow 
cystoscope using a 5 Fr ureteral catheter marked at cm intervals with the help of 
ultrasound imaging. The ureteral catheter was inserted through the 
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catheterisation slide and the tip was placed against the bladder wall farthest from 
the entry point. The bulb-shaped fibre tip was then placed halfway along the 
catheter. Anteroposterior and lateral positioning of the fibre tip was controlled by 
endoscopy. The cystoscope was fixed to a mounting device. Continuous 
irrigation with isotonic saline solution was maintained during the entire irradiation. 
 
6.3.5 Light irradiation 
Light dose was simulated and calculated ex-vivo before the actual irradiation. 
Once the simulation once confirmed, a schematic diagram was prepared (Figure 
6.1) for the clinician. All light irradiation, drug administration and other clinical 
procedures were performed by a clinician from the Department of Urology at the 
Singapore General Hospital. 
 
6.3.5.1 Intravenous drug administration 
Light irradiation of the bladder was performed 5 h post drug administration. The 
bladder was distended with saline until the bladder reached a diameter of 7 cm to 
smooth mucosal folds. This corresponded with a bladder volume of 
approximately 180 cm3, which was maintained constant throughout the 
procedure. Irradiation was delivered in 3 fractions with each irradiation lasting for 
20 minutes followed by dark intervals of 5 minutes. A total light dose of 24 J/cm2 
was delivered to the bladder wall at a fluence rate of 6.7 mW/cm2 (Table 6.1). 
 
6.3.5.2 Intravesical drug administration 
A total volume of 40 mL of Ce6-PVP with a concentration of 0.0625 mg/mL was 
prepared in PBS. The solution was filtered with 0.22 µm acetate filter and 
administered intravesically to the patients. Light irradiation of the bladder was 
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performed 3.5 h after the completion of intravesical instillation. The bladder was 
distended with saline until the bladder reached a diameter of 6.6 cm to smooth 
mucosal folds. This corresponded with a bladder volume of approximately 150 
cm3, which was maintained constant throughout the procedure. Irradiation was 
delivered in 3 fractions with each irradiation lasting for 5 minutes followed by dark 
intervals of 5 minutes. A total light dose of 10 J/cm2 was delivered to the bladder 
wall at a fluence rate of 11 mW/cm2 (Table 6.1). PDT was done using laser 665 
nm for 15 minutes and a total of 10 Joules was delivered.  Bladder volume was 
kept constant at 150 mL by transabdominal sonography. 
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Figure 6.1 (A) Ultrasound image of the position of the fiber tip (white arrow) and balloon 
(red arrow) in the bladder (red circle). (B) Schematic diagram of the intensity output of 
the fiber for various bladder volumes was prepared for the clinician. 
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6.3.6 Laser confocal fluorescence microscopy studies 
A total of 6 patients with recurrent bladder cancers were selected for this study. 
The patients were administered intravesically with a volume of 40 mL of 0.0625 
mg/mL of Ce6-PVP prepared in PBS. Approximately 1 – 2 h of incubation, the 
bladder was inspected carefully by a urologist. Multiple biopsies were taken so 
that they could be assessed for routine pathology examination. Each tissue was 
sectioned and examined under the laser confocal scanning fluorescence 
microscope and documented before obtaining the pathology report for 
correlation. A 5 – 10 µm thick sections were stained for haemotoxylin and eosin 
while the 15 – 20 µm thick sections were prepared for confocal fluorescence 
imaging. A 488 nm Argon laser was used to excite Ce6-PVP. Fluorescence 
emissions in the wavelength range of 665-670 nm was split by a dichroic filter 
and detected through a band pass filter. Voltage gain, PMT voltage and 
sensitivity (contrast, brightness, and filters) were fixed for all fields and slides 
imaged. 
 
6.3.7 Analysis of serum and urine uptake 
For analysis of serum and urine, the patient was administered intravenously with 
2.5 mg/kg of Ce6-PVP. The solution was injected intravenously over 10 minutes 
of infusion. Photosensitizer levels in serum and urine were assayed using 
fluorescence spectrofluorimetry. Urine samples were collected at 1, 2, 24 and 48 
h post drug administration. Samples were then centrifuged and the supernatant 
were assayed immediately. Blood samples were collected at 1, 3, 4, 6.5, 24 and 
48 h post drug administration. Serum was isolated from blood by centrifugation, 
and samples were kept at -70°C until assayed. Serum concentrations of Ce6-
PVP were determined by admixture with SolvableTM (Packard Bioscience) and 
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heating at 50°C for 12 h followed by analysis of fluorescence emission spectra. 
Fluorescence emission was measured from 665 to 670 nm upon excitation at 
400 nm using a spectrofluorophotometer RF-5301 PC (Shidmadzu). All samples 
were protected from exposure to surrounding light.  
 
6.3.8 ELISA detection of human inflammatory cytokines 
Human inflammatory cytokines analysis (IL-1a, IL-1b, IL-6, IL-8, IL-10, IL-12, 
IFN-γ and TNF-α) was performed using the commercial enzyme-linked 
immunosorbent assay (ELISA) kit purchased from SuperArray, USA (Cat. No. 
MEH-002A). Serum samples were thawed to room temperature, and assayed in 
duplicates with a standardised laboratory technique according to the 
manufacturer’s protocol. Absorbance was read in an ELISA plate at 450 nm with 
corrections at 570 nm. 
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6.4 Results and discussions 
6.4.1 Fluorescence imaging of angiosarcoma lesions in patients  
Patients with angiosarcoma were given 2 – 4 mg/kg of Ce6-PVP through 
intravenous administration. The accumulation of Ce6-PVP in the angiosarcoma 
lesion was visualized through its typical red fluorescence after blue light 
excitation (Figure 6.2 B). Clear demarcation of the lesion was observed in the 
fluorescence image indicating excellent selectivity of the Ce6-PVP. Fluorescence 
in the lesion was more intense compared to the fluorescence in the normal skin. 















Figure 6.2  White light image (A) and its corresponding fluorescence image (B) of 
angiosarcoma lesion and the surrounding normal skin at 3 h post intravenous 
administration of Ce6-PVP. Spectra kinetic of Ce6-PVP intensity at 1 hr (C) and 3 hr (D)  
in normal skin and angiosarcoma lesions from patient. The fluorescence spectra from 
the cancerous lesion were found to be higher than the surrounding normal skin. 
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Figure 6.3 Scatter plot of red-to-blue intensities in normal skin and angiosarcoma 
lesions plotted against time from 3 patients after intravenous administration of Ce6–PVP. 
Red fluorescence from the cancerous lesion was found to be higher than the 
surrounding normal skin.  
 
Spectra measurement from the cancerous lesion areas showed a distinct Ce6-
PVP induced fluorescence spectrum that discriminate between the cancerous 
lesion and normal skin, with the lesion showing higher fluorescence emission 
intensity compared to normal tissue (Figure 6.2 C, D). These results confirmed 
that fluorescence imaging clearly captured the fluorescence in angiosarcoma and 
good correlation was found between fluorescence imaging and spectral 
measurement in the patient. This is in agreement with other reports, that 
fluorescence ratio imaging in combination with relative spectral measurement of 
the photosensitizer might be a viable method for the optical diagnosis of cancer 
[200]. Furthermore, in vivo and real-time determination of the time course of 
photosensitizer’s fluorescence could potentially be a crucial pre-irradiation 
screening tool to determine the exact location and extent of the tumor before 
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photodynamic therapy. The appreciable red fluorescence emission of Ce6-PVP 
captured using a CCD camera system together with digital imaging, could be 
utilized either for a directed biopsy or for preoperative planning to demarcate 
tumor margins. The routine employment of such systems is being assessed in 
studies with other photosensitizers in various oncologic and non-oncologic 
applications of the skin [195]. 
 
When the measurement of red-to-blue intensities were plotted against time, the 
intensities in the lesions increased rapidly over the first 3 h (Figure 6.3). 
Fluorescence intensities were always lower in the normal skin compared to the 
lesions. The loss of fluorescence at 5 h could be attributed to the photobleaching 
effect of Ce6-PVP immediately after PDT. Interestingly, the red fluorescence 
recovered at 6 h post drug administration, suggesting that the circulating Ce6-
PVP in the serum seemed to be redistributed into the lesions after PDT. At 48 h 
post injection, the fluorescence was lower but still sustained in the lesions.. 
However, PDT efficacy at 48 h drug-light interval might not be good due to an 
overall decrease in the photosensitizer level in the lesions, which may cause a 
decrease in tumor response due to the photosensitizer threshold that is needed 
for a good response. It was reported that PDT performed at 3 h drug-light interval 
was effective in achieving local control of the angiosarcoma lesions for up to 14 
months [196]. This is in agreement with other clinical PDT protocols using 
another hydrophilic Ce6 derivative (Npe6), where light irradiation was performed 
around 3 – 8 h post drug administration with minimal systemic photosensitization 
[94, 95]. This study also further confirms that Ce6-PVP has a faster elimination 
rate in the normal human skin compared to other porphyrin-based 
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photosensitizers [197], indicating that Ce6-PVP may not cause prolonged 
substantial skin photosensitization in human. 
 
6.4.2 Ce6-PVP mediated PDT response for refractory bladder carcinoma patients  
Soon after intravenous mediated PDT was completed, patient had nausea and 
vomited. Patient also experienced pain after the treatment and needed to be 
administered with morphine.  Haematuria was observed in the urine 24 h post 
treatment (Figure 6.4). Patient was evaluated about 2 months after PDT. A rigid 
cystoscopy and bilateral retrograde pyelogram were performed and it showed a 
small fibrotic bladder (130cc) with mucosal sloughing and bilateral hydroureter 
secondary to reflux. Bladder biopsy showed necrotic tissue with no viable tumor 
and urine cytology did not show any malignant cell. Similarly, patients given 
intravenous administration of Photofrin, an FDA approved photosentisitizer for 
the treatment of bladder cancer was also reported experienced bladder 
contracture [201]. 
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Figure 6.4 Urine sample collected before and after PDT from patient given intravenous 
administration of Ce6-PVP. Blood was observed after 24 h post treatment. There was no 
blood detected at 48 h post treatment 
 
 
Intravesical instillation of 50 mL of Ce6-PVP was performed for 1 h. Rigid 
cystoscopy and biopsy was performed under fluorescence imaging. No gross 
tumor was noted and the bladder capacity was noted to be 600 mL. The patient 
tolerated the procedure well and was discharged on the 2nd post operative day. 
A rigid cystoscopy and biopsy was done on 4 month post PDT. Bladder capacity 
was noted to be 630 mL. Histology of the biopsies from the right lateral wall, left 
lateral wall, dome and posterior wall did not reveal any malignancy. Urine 
cytology was reported as atypical cells, which were probably reactive. A 
subsequent flexible cystoscopy performed on 7 month post PDT did not reveal 
any recurrences. Bladder capacity was noted to be more than 500 mL and a 
uroflow performed at that time showed a Qmax of 17.1 with a voided volume of 
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494 mL. Recent preclinical study using orthotopic rat model has demonstrated 
that intravesical was better than intravenous aminolaevulinic acid (ALA)-induced 
protoporphyrin IX as a photosensitizer in eradicating bladder carcinoma with PDT 
[202]. Likewise, in clinical studies, intravesical PDT of the bladder was shown to 
be more effective with lesser side effects [203]. 
 
6.4.3 Analysis of serum and urine uptake of Ce6-PVP  
The kinetics of Ce6-PVP in serum for both patients was analyzed using cuvette 
based spectrophotometric method. Figure 6.5 shows the detectable 
concentration of Ce6-PVP in serum for patient given intravenous administration 
of the photosensitizer. Intravesical administration did not show any detectable 
Ce6-PVP in patient’s serum. Figure 6.6 shows the injected dose of 2.5 mg/kg as 
a function of time after injection in serum and urine. The pharmacokinetic 
parameters obtained using non-linear regression analyses of one phase 
exponential decay are summarized in Table 6.2. Plasma concentration declined 
rapidly in the first 24 h. The photosensitizer concentration continued to decrease 
to a level near baseline at 48 h post injection. The t1/2 of Ce6-PVP in serum was 
calculated to be 9.9 h.  This is in accordance with Kessel’s t1/2 measurement of 
NPe6 in serum of cancer patients [204].  In clinical practice, it would take just 
over 4.7 times the half-life for a drug's serum concentration to reach steady state 
after regular dosing. Effectively, this meant that administration of Ce6-PVP could 
be repeated as soon as 50 h after the initial dosing for repeated PDT treatment. 
Rapid elimination of Ce6 was also observed from the urine of patients after 
intravenous administration of Ce6-PVP and t1/2 was calculated to be 24.6 h, 
which is 2.5 times longer compared to the t1/2 in serum. The longer t1/2 was 
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expected in the urine because of the water-soluble nature of the Ce6-PVP, 
suggesting that one of the elimination routes was through the kidneys. 
 
Table 6.2 Comparison of span, rate constant decay (K) and half-life (t1/2) of Ce6-PVP in 
serum and urine sample from clinical patients. 
 
Best-fit values Serum Urine 
Span 12.02 ± 0.19 1.36 ± 0.13 
95% CI for Span 11.63 to 12.42 1.09 to 1.63 
K 0.07 ± 0.003 0.03 ± 0.01 
95% CI for K 0.06 to 0.08 0.01 to 0.05 
t1/2 (hours) 9.9 h 24.6 h 
95% CI for t1/2 9.04 to 11.0 h 14.9 to 69.6 h 
Goodness of fit, R² 0.9924 0.5824 
 
The Plateau was fixed to 0.0, and non-linear regression was performed to fit only the 
span and K. Values are denoted ± standard error of the mean. R2 is the goodness of fit; 
CI is the confidence interval. 












Figure 6.5 Emission spectra of Ce6-PVP in serum at 1 h post drug administration, 
recorded with a spectrophotometer after excitation at 400 nm. Ce6-PVP was not 
detected in the serum of patient that received intravesical administration (red line), 















Figure 6.6 Uptake kinetic of Ce6-PVP in serum (A) and urine (B) from patient after 
intravenous administration as determined using spectrofluorimetry. Fluorescence 
emission was measured from 665 nm – 670 nm (λex = 400 nm). For urine, triplicates 
sample/time point was analysed for each data point while for serum, 4 replicates/time 
point for each data point were analysed. 
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6.4.4 Fluorescence imaging and laser confocal microscopy study of refractory 
bladder carcinoma patients 
Ce6-PVP mediated fluorescence cystoscopy was well tolerated by the patients 
and no adverse effects were noted. The preliminary result presented here 
showed that Ce6-PVP mediated fluorescence cystoscopy enabled the 
visualization of tumors and suspicious areas in the bladder urothelium that could 
not be clearly seen by white light cystoscopy (Figure 6.7). To date several 
photosensitizers have been used in the diagnosis of bladder cancer. Various 
studies have reported on 5-aminolevulinic acid (ALA) and its derivative hexyl-
ALA induced porphyrin mediated fluorescence detection of bladder cancer with a 
sensitivity ranging from 89% to 96% [37, 205, 206]. However, current 
formulations of ALA are unstable and require preparation immediately before use 
[85]. Besides, the systemic use of porphyrins is normally associated with 
prolonged skin photosensitivity and bladder damage [207]. Recently, hypericin 
with PVP was proposed as light stable photosensitizer with tumor selective 
properties and sensitivity similar to those of ALA and derivatives [208]. Hence, 
the results here demonstrated that the formulation of Ce6-PVP might similarly be 
effective in the fluorescence diagnosis of other malignancies in hollow organs. 
 
Confocal microscopy examination revealed that there was an increased in Ce6-
PVP induced fluorescence with the stages of the disease (Figure 6.8). The 
degree of fluorescence intensity as revealed by confocal laser microscopy was in 
the following order:  acute and chronic inflammation < low grade papillary 
urothelial carcinoma < high grade papillary transitional cell carcinoma. For this 
reason the degree of Ce6-PVP induced fluorescence could be used as an 
indicator for determining the invasiveness of bladder malignancies. This 
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increased in the selective uptake of Ce6-PVP in higher grade tumor cells 
compared to lower grade tumor cells could be ascribed to the fast metabolic 
activity of higher grade cells compared to the lower grade tumor cells. 
Furthermore, it was suggested that modifications in the adhesion properties of 
neoplastic cells, by alteration of expression of transmembrane glycoproteins that 
mediate the cell-to-cell and the cell-to-extracellular matrix adhesion, such as 
catherins and integrins, may play a pivotal role in the development and 
progression of bladder cancer that are responsible for the selective penetration 














Figure 6.7 Representative images of optical detection of human bladder carcinoma 
using Ce6-PVP as a fluorescent marker. (A) Normal bladder under white light 
illumination and (B) its corresponding image taken using blue light excitation. (C) 
Carcinoma of the bladder under while light illumination and (D) its corresponding image 













Figure 6.8 Laser confocal microscopy and histopathology of cross section of biopsy 
sample of bladder wall. Laser confocal microscopy of cryo-section of bladder biopsy; 
images show Ce6 fluorescence for acute and chronic inflammation (A), low grade 
papillary urothelial carcinoma (B) and high grade papillary transitional cell carcinoma C). 













Figure 6.9 Measurement of fluorescence kinetics of different histopathological grades of 
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Figure 6.10 Cross section of fluorescence image (A, B) and corresponding hematoxylin–
eosin-stained image (C, D) and measurement of fluorescence intensity and depth of 
penetration of Ce6-PVP  (E, F) in bladder tumor biopsy tissue at 2 h after oral 
administration of Ce6-PVP. 
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In Figure 6.10, the penetration of Ce6-PVP after intravesical administration is 
seen in the urothelium of the bladder. The depth of topical penetration of Ce6-
PVP into bladder tumor tissue was found to range from 80 – 180 µm. Because 
the penetration of 665 nm light at treatment power can approach up to 5 mm in 
certain tissue, it is of utmost importance that the photosensitizer does not 
penetrate deeper into the muscle layer of the bladder because whole bladder 
PDT could potentially cause severe bladder contraction. This result 
demonstrated that topical application of Ce6-PVP was a convenient and safe 
method of specifically directing Ce6-PVP to bladder tumors, avoiding the 
widespread distribution in the muscle layers that would have occured following 
intravenous administration.  
 
6.4.5 Analysis of cytokines at post PDT 
The cytokines investigated in this study were divided into 3 categories: (1) IL-12 
and IFN-γ which are generally secreted by lymphocytes and macrophages 
involved in the proinflammatory, neutrophil activating, granulomatous response; 
(2) IL-10 associated with a humoral immune response that may inhibit 
proinflammatory cytokines; and (3) TNF-α, IL-6, and IL-8, which are released by 
macrophages and monocytes and primarily activate other cells, including T 
lymphocytes and neutrophils. The results of inflammatory cytokine released into 
the serum before and after intravenous mediated PDT are shown in Figures 6.11. 
The patient given intravenous administration of Ce6-PVP had significantly higher 
baseline levels IL-1b, IL-6, IL-8, IL-10, IL-12, IFN- γ and TNF-α whereas patient 
given intravesical instillation of Ce6-PVP did not have quantifiable cytokines in 
serum. There was decreased expression of IL-1a, IL-1b, IL-8, IL-10, IL-12, IFN-γ 
and TNF-α from its baseline level in patient treated with intravenous Ce6-PVP – 
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PDT. The expression of these cytokines also could not be detected in patient 
given intravesical Ce6-PVP – PDT at 24 h post treatment. Only IL-6 was 
observed to be upregulated in both patients at post PDT (Figure 6.11).  As the 
measurement of cytokine at post PDT was only performed with 2 patients, it 
wasn’t clear as to why these cytokines were downrequlated in the bladder cancer 
patient given intravenous administration of Ce6-PVP-PDT. However, the 
hypothesis that PDT light and drug dose might have an immune modulatory 
effect remains to be further investigated. Recently, photodynamic therapy - 
activated immune response against distant untreated tumors in recurrent 
angiosarcoma  was reported [196]. High dose PDT carried out at a high fluence 
rate resulted in local control of the disease for up to a year; however, the disease 
recurred and PDT had to be repeated [199]. Other studies have shown that the 
secretion of a large array of proinflammatory cytokines in the serum of treated 
patients following mycobacterial stimulation suggesting the involvement of 
systemic immune responses of the antitumor effect [210, 211]. Another 
preliminary study showed that quantifiable concentrations of interleukin 1-beta, 
interleukin 2, and TNF-alpha were detected in urine samples from the PDT 
patients with the highest light energies, while no urinary cytokines were found in 
the PDT patient who received the lowest light energy nor in any of the control 
subjects, suggesting that a local immunologic response may occur following PDT 
for bladder cancer [212]. The results further suggest that the increased 
expression of IL-6 serum after PDT might have a possible correlation to systemic 
immunological responses. Cytokines, such as IL-6, produced by the tumor cells 
could attract immunocompetent cells such as macrophages and lymphocytes to 
the tumor sites and stimulate them [213]. Although it has not been demonstrated 
whether secreted cytokines can inhibit or stimulate the growth of bladder cancer 
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cells, patients with invasive bladder cancer that expressed variant IL-6 was 
















Figure 6.11 Serum cytokines (IL-1 β, IL-8, IL-10, IL-12, IFN-γ and TNF-α) levels after 
PDT. Serum samples were obtained before PDT and 24 h post PDT for patient treated 



















Figure 6.12 Comparison of IL-6 for patient treated with intravenous or intravesical Ce6-
PVP mediated PDT. Results are presented as average of duplicate experiments. 
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6.5 Conclusion 
 
Review of the above cases suggested that intravesical mediated PDT with Ce6-
PVP was a safe and well-tolerated procedure that could be an effective therapy 
for the refractory bladder carcinoma. The selective responses seen in the patient 
given intravesical administration of Ce6-PVP indicated that photosensitizer 
exhibited the same preferential retention within tumor tissues as seen in other 
porphyrin or ALA compounds. It was suggested that with further refinement in the 
methodology, intravesical mediated PDT may be feasible as an outpatient 
treatment for superficial bladder TCC under local anaesthetic [215]. It should be 
cautioned that the finding of a negative association between major inflammatory 
cytokines (i.e. IL-1a, IL-1b, IL-8, IL-10, IL-12, IFN-γ and TNF-α) and the 
upregulation of IL-6 at post Ce6-PVP – PDT treatment is based on a relatively 
short period of follow-up. Long-term follow-up will be needed to validate these 
findings. The use of PVP had led to a high solubility of an injectable aqueous 
formulation of Ce6 that is safe for use in patients and have observed selective 
uptake in angiosarcoma lesions compared to normal skin. Further studies 
involving larger numbers of patients are required to confirm the efficacy of Ce6-
PVP mediated PDT in the management of refractory bladder carcinoma and 
fluorescence diagnosis of angiosarcoma. 
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CHAPTER 7 
 
Conclusion and future perspective  
7.1 Conclusion 
The overall aim of this work was to study the photophysical, photochemical and 
pharmacokinetic properties of the photosensitizer Ce6 formulated with PVP so as 
to gain a better understanding of the efficacy and mechanisms of Ce6-PVP 
induced fluorescence imaging and photodynamic therapy of cancer. The 
chlorophyll derivative, Ce6 was obtained by a chemical treatment of a chlorin-
containing substance extracted from the biomass of Spirulina algae. The 
polyvinylpyrrolidone used for the preparation of Ce6-PVP was a water-soluble 
grade polymer. PVP in the final formulation ensured a higher bioavailability of 
Ce6 in tumor tissue compared to suspended chlorin. This thesis has contributed 
to the optimization and expansion of PDT field and is decribed in the following 
paragraphs: 
 
In chapter 2, pharmacokinetic studies were performed in animal implanted with 
human nasopharyngeal (CNE2) and bladder tumor (MGH) by means of light-
induced fluorescence ratiometric imaging, fiber optics-based fluorescence 
spectrometric measurement, chemical extraction and confocal fluorescence 
microscopy after intravenous administration of Ce6-PVP. Good red fluorescence 
image and emission signal with a peak at about 665 nm was recorded in the 
malignant tissue, indicating highly selective accumulation compared to the 
surrounding normal tissue. Selective accumulation in the tumor tissue, which was 
approximately 2 to 5-fold higher than with Ce6 only, was observed in the model 
of CNE2 and MGH tumor xenografts. Its bioavailability peaked shortly after 
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parenteral administration (up to 2 hours) in the blood compartment and the tissue 
it targeted, consistent with the critical time window within which PDT was 
effective. Biodistribution data exhibited fast clearance rate of Ce6-PVP from 
normal tissue with no significant prolong accumulation in normal skin. Compared 
to porphyrins, Ce6-PVP was eliminated from the body very quickly, within 10 – 
12 h after parenteral administration. After 24 h, less than 4 – 6% of the 
administered Ce6-PVP was detected in the body tissues and serum of mice. This 
improves the risk to benefit ratio in favour of Ce6-PVP as there was no prolong 
skin accumulation of the photosensitizer. The photosensitizing effect of Ce6-PVP 
and the subsequent necrosis was higher than Ce6 itself. The frequency of 
complete tumor necrosis could be achieved with Ce6-PVP. Ce6–PVP was found 
to have less acute toxicity compared to Ce6 only in tumor-bearing nude mice. 
After illumination at 665 nm, Ce6-PVP elicited no acute phototoxicity for at 3 h 
drug-light interval at drug dose of 2.5 – 5 mg/kg and light dose of 50 – 300 J/cm2. 
On the other hand, Ce6 elicited acute toxicity at the light dose of 100 J/cm2 at 1 h 
drug-light interval which resulted in normal tissue damage. These results 
indicated that Ce6-PVP was a safe PDT agent, exhibiting negligible effects in 
normal tissue.  
 
In chapter 3, a highly purified version of Ce6-PVP was synthesized and it was 
demonstrated that this new formulation showed improved selectivity and 
specificity for fluorescence diagnostic imaging and PDT of human cancer 
compared to Ce6 or Ce6 delivered using DMSO. 
 
In chapter 4, Ce6-PVP preferential uptake by tumor versus normal tissue was 
confirmed in the CAM model, demonstrating the feasibility of this formulation to 
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visualize and demarcate cancer. The effect of PVP on the transport of Ce6 
across live membrane was evaluated on the CAM model. The highly purified 
Ce6-PVP was transported across the membrane twice as much compared to 
Ce6 alone. Thus, PVP was proven to enhance membrane permeability of Ce6. 
The sensitivity and specificity Ce6-PVP for tumor detection was also increased 
compared to the formulation with a lower purity level of Ce6-PVP. Using 
irradiation at a low light dose of 10 J/cm2, apoptotic cell deaths were detected in 
tumor cells implanted on the CAM after treated with Ce6-PVP. 
  
In chapter 5, the interactions of Ce6 and Ce6-PVP with lipoproteins were 
investigated using steady-state fluorescence measurements. Upon increasing 
Ce6-PVP concentration, the fluorescence increased drastically, suggesting that 
PVP effectively prevent the agglomeration of Ce6, which could have important 
implications for the successful outcome of fluorescence diagnosis and PDT. It is 
concluded that Ce6-PVP at high concentration bound considerably with VLDL 
indicating that VLDL was its principal carriers. In vitro studies have shown that 
PVP localized in the cell cytoplasma and Ce6-PVP was internalized more 
efficiently compared to Ce6 only.  
 
In chapter 6, preliminary results on the clinical study of refractory bladder cancer 
and angiosarcoma patients treated with Ce6-PVP mediated fluorescence 
imaging and PDT were presented. Fluorescence imaging and spectroscopy data 
showed a significant accumulation of Ce6-PVP in angiosacorma lesions, showing 
that Ce6-PVP could provide a useful tool for demarcation of tumor lesions. There 
was a significant reduction of tumor after intravesical administration Ce6-PVP at 
post PDT for refractory bladder cancer patients. However, patient given 
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intravenous Ce6-PVP experienced severe side effect while patient given 
intravesical administration of Ce6-PV exhibited no adverse reactions. In bladder 
cancer biopsies, microscopic fluorescence intensity was found to increase with 
higher grades of cancer. These preliminary results suggested that intravesically 
administered Ce6-PVP mediated PDT was of value in the management of 
refractory bladder cancer.  
 
In conclusion, this thesis has presented evidence that the Ce6-PVP formulation 
had improved bioavailability, selectivity and photosensitizing properties towards 
malignant tissue. This formulation was found to have several advantageous 
effects such as providing a novel photosensitizer of a high chemical and 
photochemical stability, good solubility both in water and in biological fluids, high 
affinity to the target region or the surface of the body or a tissue, large depth of 
necrosis, efficient generation of the active species that cause destruction of the 
pathologically changed tissue, low phototoxicity as well as to provide a method of 
preparation of such photosensitizer. Ce6-PVP has a high stability in proteinous 
environment, without loosing efficacy of Ce6 as a photosensitizer. The 
association ensures also a deep penetration of irradiation into biological tissues, 
a high degree of pathological tissues necrosis and strong inhibition of neoplasm 
growth at post PDT. These findings were of important relevance for future 
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7.2 Future perspective 
As the work progressed, both here and elsewhere in the field of photobiology, the 
role of PVP in the photosensitizer formulation has been questioned. The results 
presented in this thesis specifically indicated that PVP enhanced 
pharmacokinetic enrichment of Ce6 in the final PVP-containing formulation, 
exhibiting a more pronounced antitumor activity with respect to the extent of 
tumor necrosis, the inhibition of tumor proliferation and the prolongation of 
survival time at post Ce6-PVP mediated PDT. Ce6-PVP was formulated in the 
form of a lyophilized composition for easy reconstitution prior to use in a liquid 
aqueous carrier for injections. The work performed here had laid a promising 
foundation for the use of Ce6-PVP formulation in photodynamic therapy and 
fluorescence diagnosis. Several avenues for future work could be directed 
towards developing the composition in the form of a preparation for external use, 
for instance in the form of a solution or a lotion in appropriate solvent, or an 
ointment, gel or cream in a typical vehicle, to be applied on the skin or mucosal 
tissue such as in the oral or bladder cavity. It is also possible to prepare the 
invention in a semisolid pharmaceutical formulation for the topical application is 
desirable specifically for local efficacy. The clinical study suggested that topically 
applied Ce6-PVP could be efficacious for bladder cancer and perhaps other 
dermal malignancies, such as basal cell carcinoma, as well as non-malignant 
conditions of the skin, such as psoriasis. Ce6-PVP had shown a good efficacy on 
skin making it possible to treat skin diseases (i.e. angiosarcoma), as a preventive 
measure or as a therapy.  
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